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The importance of the role of oxidative stress in aging and numerous age-related diseases has 
become undeniable due to enormous weight of supporting evidence from the field of free radical 
biology. One of the most prominent oxidative modifications of proteins is the introduction of 
carbonyl groups. As with oxidative stress, protein carbonylation has been correlated with various 
disease states and natural aging. While protein carbonyls are relatively stable, reproducible 
detection and modification site localization are still challenging. This thesis details attempts to 
improve the analytical methodology used for the identification and quantitation of carbonylated 
proteins. We have studied the impact of exogenous and endogenous methods for increasing the 
flux of the progenitor reactive oxygen species, the superoxide radical anion, in Drosophila 
xvii 
  
melanogaster using protein carbonylation measurements. Furthermore, we have applied the same 
methodology to plasma and serum obtained from trauma patients. 
Superoxide flux was manipulated first by administering Paraquat to increase generation rates 
throughout the cell and second through RNA interference knockdown of Mn or mitochondrial 
superoxide dismutase (Sod2) to decrease destruction rates in mitochondria. Protein carbonylation 
was measured since carbonyls are not present in the twenty canonical amino acids and are 
amenable to labeling and enrichment strategies (biotin hydrazide was used for labeling and 
streptavidin bead-immobilization for enrichment). On-bead digestion was used to release 
carbonylated protein peptides, which were then subjected to the iTRAQ mass spectrometry-
based proteomics approach to obtain Paraquat-exposed and Sod2 knockdown versus control 
carbonylated protein relative abundance ratios. Western blotting and biotin quantitation assay 
approaches were also investigated. Considering the whole set of detected carbonylated proteins, 
lipid droplet and mitochondrial proteins were found to be particularly prevalent. By both western 
blotting and proteomics, Paraquat exposure resulted in a greater global increase in carbonylation 
than Sod2 knockdown. However, the Sod2 knockdown dataset included an interesting outlier, 
cytochrome c oxidase subunit Vb, which could shed light on the mechanism of superoxide 
generation or the Sod2 knockdown phenotype. 
An alternative to the iTRAQ quantitation approach, the label-free  “Spectral counting” technique 
was also investigated, using the Paraquat-exposed versus control Drosophila melanogaster 
samples. Thus, we investigated the correlation between spectral count and iTRAQ-based 
quantitation. We observed good reproducibility for the iTRAQ approach but not for spectral 
counting. Comparing mitochondrial relative protein abundances, we found only a weak positive 
correlation between these two approaches. 
xviii 
  
Discovery proteomics approaches that aim to identify biomarkers or signaling pathways 
associated with human diseases have gained much attention in recent years. Due to the 
minimally invasive nature of collecting blood, plasma proteomics has become a common means 
of studying the entire human proteome, even though cellular proteins leaking into the circulatory 
system are present at very low concentrations. Severe blunt trauma produces significant changes 
in leukocyte mRNA levels, corresponding to changes in expression for >80% of human genes. 
Thus, the early leukocyte genomic response involves simultaneously increasing expression of 
genes involved in the systemic inflammatory, innate immune, and compensatory anti-
inflammatory responses, as well as with suppressing genes involved in adaptive immunity. 
Inflammation and oxidative stress are often correlated. Thus we analyzed the carbonylated 
protein proteome at multiple time points in the blood of patients that had endured traumatic 
injuries. First, temporal changes in carbonylated protein concentrations were measured. Second, 
the ProteoMiner affinity-ligand strategy was added to the procedure to increase proteome 
coverage through the depletion of high-abundance plasma proteins. This improved method 
resulted in the identification of greater numbers of low-abundance proteins. Since the sample 
size (n=2) was very small, no biological conclusion could be drawn; however, we have shown 
that measurements of changes in the carbonylated protein proteome over time are possible by 
this method. The hope is that protein carbonylation biomarkers could someday aid in predicting 
patient outcomes in clinical settings. 
 
 
 
1 
  
CHAPTER 1 
 
 
 
 
 
INTRODUCTION 
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1.1 Introduction 
1.1.1 Oxygen paradox and oxidative stress 
Evolution of complex life forms began when life switched from anaerobic to aerobic respiration 
and without oxygen higher eukaryotic aerobic organisms cannot exist. Oxygen evolution is the 
fundamental process by which oxygen is released into the atmosphere by light dependent 
photosynthesis reactions in cyanobacteria, green algae’s chloroplasts and in plants.1 This 
increase in oxygen in the atmosphere provided more energy for various metabolic pathways in 
single cell organisms and pushed them to evolve into more complex multicellular life forms. 
Though the process appears straightforward, it involved key changes in biological processes. It 
took millions of years for these anaerobic species to adapt to an oxygen rich environment due to 
the chemical nature of oxygen.  
The atomic form of oxygen exists as a free radical (O
.
) and when combined with another oxygen 
atom to form molecular oxygen (O2), its outer valence electrons do not spin-pair and remain as 
two unpaired electrons, a diradical. Concerted tetravalent reduction of oxygen into water by 
electron transport chain enzymes in mitochondria is considered to be a relatively efficient 
process and utilizes more than 95% of oxygen in mitochondria, conserving the free energy 
potential of the reduction  in the form of ATP.
2–5
 In non-enzymatic pathways oxygen can 
undergo four successive one-electron reductions due to its radical nature.
6
 The first one-electron 
reduction gives rise to a radical anion (O2
•−
) also known as superoxide. The next addition of an 
electron, along with two protons,
 
produces hydrogen peroxide (H2O2). The third addition of an 
electron splits H2O2 and generates the highly reactive hydroxyl radical (·OH) and releases a 
hydroxide ion (OH
−
). The fourth and final addition of an electron generates another hydroxide, 
which is at the oxidation level of H2O.  Each product formed here except the water molecule 
3 
  
possesses  varying degrees of adverse reactivity toward  biological macromolecules, hence the 
“oxygen paradox”.7 These reactive intermediates are also known as reactive oxygen species 
(ROS). 
             
   
Figure 1.1. Univalent and tetravalent reduction of molecular oxygen. 
Oxidative stress can be defined as a disturbance in the balance between the production of pro- 
oxidants and the antioxidant defense system.
8
 Pro-oxidants are mainly reactive oxygen species 
(ROS) and reactive nitrogen species (RNS). The imbalance is governed by the following factors : 
1) increased pro-oxidant generation, 2) decreased anti-oxidant protection, 3) both 1 & 2 and 4) 
failure to repair oxidative damage.
9
  Pro-oxidants are classified as radicals or non-radicals. The 
radical compounds contain at least one unpaired electron.
10
 The unpaired electron makes these 
compounds highly reactive with a strong driving force to donate or obtain another electron to 
attain a closed electron shell and stability. Though the life spans of most ROS species are short 
and often dependent on the environment, a relatively long life span for an ROS might lead to a 
4 
  
greater toxicity because adequate time is available to reach a biological target and cause damage 
far from the site of production.
11
 
Scheme 1.1. Examples for ROS & RNS species. 
i) Radicals (contains at least one unpaired electron) : superoxide radical anion (O2
•−
), 
Hydroxyl radical (
•
OH), peroxyl radical (ROO
•.
), Oxygen (O2), Nitric oxide radical 
(NO
•
) 
ii) Non-radicals – hydrogen peroxide (H2O2), organic peroxide (ROOH), peroxynitrite 
(ONOO
−
), ozone (O3), singlet oxygen( O2*) and hypochlorous acid (HOCl)  
ROS and RNS generation can occur in response to diverse stimuli, which can come from both 
exogenous and endogenous sources.
12
 Exposure to ionizing and non-ionizing radiation such as 
ultra violet (UV light ) and γ radiation, exposure to xenobiotic and chemical pollutants, various 
environmental pollutants such as cigarette smoke and industrial contaminants, are major 
exogenous sources.
13–16
 Also drugs, food, bacteria and viruses are also major exogenous sources 
of ROS and RNS.
17–20
 Endogenous sources are mainly mitochondria, peroxisomes, 
lipooxygenases, NADPH oxidase and cytochrome P450.
21–24
 Proteins, lipids, carbohydrates and 
nucleic acids have all been studied for sensitivity to oxidative modification by a wide variety of 
free radicals and reactive species.
25–28
 Superoxide radicals in the presence of transition metal 
prosthetic groups will react with proteins impacting in protein/enzyme activity, for example, 
bacterial aconitase loses its activity after exposure to O2
•−
.
29
. Hydrogen peroxide can also readily 
react with biological molecules, especially those containing sulfhydryl groups, iron-sulfur 
clusters, heme moieties, and copper prosthetic groups.
30–33
 The hydroxyl radical is the most 
reactive of all oxygen radicals and will readily cause the oxidation of proteins, lipids, 
5 
  
carbohydrates, DNA, and RNA.
34–38
 Another oxygen-based species involved in oxidative stress 
is hypochlorous acid. Phagocytic cells use this acid to kill invading organisms such as bacteria. 
In this process, it can generate secondary oxidants such as chloramines, which can travel far 
from the site of production and cause multiple effects
39
. Nitric oxide (NO
•.
) , nitrogen dioxide 
(NOO
•
), ozone (O3) , and peroxynitrite (NOO
−
) are also known to cause various deleterious 
oxidative modifications to biological molecules.
40–42
 
1.1.2 Free radical theory of aging (FRTA) 
The deleterious effect of oxygen radicals were first observed by two American scientists, 
Rebecca Gershmann and Dan Gilbert, when they found that high levels of oxygen led to 
blindness in premature babies.43 Based on this observation, Denham Harman formally proposed 
the free radical theory of aging in 1956, which suggested that free radicals produced during 
aerobic respiration cause cumulative oxidative damage resulting in aging and death44. Even 
though the presence of free radicals in the biological system was highly questionable at that 
time, it provided a general mechanism for the rate-of-living theory45. Generation of free radicals 
during mitochondrial electron transport was later confirmed by the identification of the enzyme 
superoxide dismutase (SOD), which is the body’s first defense mechanism against superoxide 
free radicals46. The role of mitochondria as a source for ATP and the location of oxidative 
damage were heavily supported by these two theories. According to Harman, oxygen radicals 
produced during normal respiration accumulate over time and cause cumulative damage which 
will eventually lead to loss of function and death. 
In 1972, Harman modified his original theory to accommodate growing evidence of 
mitochondrial oxidative damage in cells and recasts it as the mitochondrial free radical theory of 
6 
  
aging (MFRTA).
47
 This theory proposes that reactive oxygen species that are produced in the 
mitochondria cause damage to certain macromolecules including lipids, proteins and most 
importantly, mitochondrial DNA. This damage then causes mutations, which leads to an 
increase in ROS production and greatly enhances the accumulation of free radicals within cells. 
A major role for the mitochondrial theory of aging has become more widely accepted due to the 
following observations: (i) mitochondrial function is gradually lost during aging, (ii) inhibition 
of mitochondrial function can enhance ROS production and, (iii) several age-dependent diseases 
are associated with severe oxidative stress. 
Understanding the production of ROS in mitochondria requires a detailed look into the role of 
the electron transport chain (ETC).  The electron transport chain, illustrated schematically in 
Figure 1.2. consists of four different enzyme complexes, numbered complex I through complex 
IV.  The generation of superoxide radicals mainly happens in complexes I and III. The chain 
obtains electrons from NADH and succinate through complexes I and II, respectively, and 
transfers these electrons to complex III using quinol and subsequently to complex IV, using a 
reduced form of cytochrome c, where oxygen is reduced to water. In addition to electron 
transfer, protons are pumped from the mitochondrial matrix to the intermembrane space through 
complexes I, III, and IV, creating a proton gradient which drives ATP synthase (sometimes 
referred as complex V) to catalyze the conversion of ADP in to ATP.48 The impact of ROS 
generation has both negative and positive effects on cells; however it is evident that ROS and 
oxidative stress play a major role in aging and age-related diseases. ROS readily react with 
different cell components such as lipids, proteins, and DNA. This can lead to alterations in 
various biological functions such as mitochondrial dysfunction,49 oncogenes activation,50 
damage to DNA,51 damage to the cell membrane,52 and apoptosis.53 
7 
  
       
 
 
 
 
                                                                                                                       
             
             
             
             
             
                              
Figure 1.2. Mitochondrial electron transport chain (ETC). 
The peroxidation of lipids ( also known as the ROS-activated deterioration of unsaturated fatty 
acid, phospholipids, glycolipids, and cholesterol) generally follows a free radical chain reaction 
mechanism.
54
 In the presence of transition-metal ions, lipid hydroperoxides (LOOH), generated 
by a free radical chain reactions produce highly reactive lipid alkoxy radicals (LO
•
), which 
generate  various secondary peroxidation products such as malondialdehyde (MDA), 4-oxo-2-
nonenal (ONE), and 4-hydroxy-2-nonenal (HNE). Damage to DNA was first reported by 
Frenkel et al. when he observed the presence thymidine glycol in mouse live nuclear DNA 
(nDNA).
55
 Richter et al. detected another important oxidative by product, 8-oxo-2-
deoxyguanosine (oxo8dG) in rat liver mitochondrial DNA (mtDNA), also reporting that 
oxidation damge was 16-fold greater  in mtDNA than in nDNA.
56
 ROS damage to proteins leads 
to oxidation products that are excellent biomarkers for oxidative damage and has been observed 
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in many diseases including Parkinson’s disease,57 Alzheimer’s disease,58 liver59 and heart 
disease,
60
 and aging.
61
 
1.1.3 Antioxidant defense 
Antioxidants are types of molecules that can neutralize free radicals by accepting or donating 
electrons to eliminate the unpaired condition of the radical. Antioxidant molecules directly react 
with reactive radicals and destroy them, sometimes becoming new free radicals which are less 
active, longer-lived or less dangerous than those radicals they have neutralized. The byproducts 
may be neutralized by other antioxidants or other mechanisms to terminate their radical 
character. Antioxidants can be classified into two types:  i) small molecule antioxidants and ii) 
antioxidant enzymes.  Examples of small molecule antioxidants are lipophilic scavengers such 
as tocopherols and flavonoids, and hydrophilic radical scavengers such as ascorbate, urate, and 
glutathione.
62–64
 Antioxidant enzymes provide additional cellular defense against oxidative 
stress and their actions are diverse in nature. Examples of such enzymes are superoxide 
dismutase (SOD),
65
 catalase,
66
 glutathione peroxidase (GPX),
67
 and glutathione reductase 
(GSH).
68
 Also, synthetic antioxidants such as tert-butylhydroxyl-toluene, tert-
butylhydroxyanisole, and tert-butylhydroquinone have been widely used in the food industry.
69
  
In Figure 1.3. the location of various organelles within the cell and their respective antioxidant 
molecules are shown.  
The level of oxidative stress is determined by the balance between pro-oxidants and anti-
oxidants. This balance is crucial in maintaining the physiological homeostasis needed for normal 
growth and metabolism. Recent evidence suggests that ROS are necessary for specific cell 
signaling processes. For example ROS generation by phagocytic cells constitutes an essential 
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host defense mechanism necessary to combat infection. Likewise, cytosolic ROS produced in 
response to stimulation by growth factors are involved in regulating the proliferative response 
under certain situations of metabolic stress and even mitochondria derived oxidants seem to 
function as signaling molecules.
70
 
  
 
 
 
 
 
 
 
Figure 1.3. Antioxidants acting on various cell organelles. 
Regardless of their origin, a rise in intracellular oxidant levels has two potentially important 
effects: damage to various cell components and activation of specific signaling pathways. Both 
of these effects can influence numerous cellular processes linked to aging and the development 
of age-related diseases. Figure 1-4 graphically represents this balance act and the deleterious 
effect of an imbalance on physiological functions. 
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Figure 1.4. Oxidative stress and ROS caused interference to the balance in biological system. 
(adopted from Finkel and Holbrook)
71
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1.1.4 Protein Oxidation 
Proteins are major components of biological systems and play an important role in signal 
transduction, mitosis, cellular transport systems, and chaperone activity.72 Concentrations of 
oxidatively modified proteins have been shown to increase as a function of age.73 Due to their 
varied biological functions, oxidative stress on proteins induces a variety of effects. Protein 
oxidation is defined here as the covalent modification of a protein induced either directly by 
reactive oxygen species or indirectly by reaction with secondary byproducts of oxidative stress. 
Agents that lead to protein oxidation include oxidants such as H2O2 and HOCl, xenobiotics such 
as Paraquat, γ irradiation, UV light, ozone, oxidoreductase enzymes, and byproducts of lipid and 
free amino acid oxidation. Since so many mechanisms are involved in the induction of protein 
oxidation and  amino acid side chains can become oxidatively modified, there are numerous 
types of protein oxidative modification. In Table 1.1. some these modifications are listed. 
Table 1.1. Oxidative modifications of protein74 
Modifications Amino acid involved Oxidizing agent 
Disulfides,  Glutathiolation Cys MCO, γ radiation , HOCl, Ozone, 
1O2 
Methionine sulfoxide Met MCO, γ radiation, HOCl, Ozone, 
1O2 
Carbonyl (aldehydes, ketones) Lys, Arg, Pro, Thr MCO, γ radiation, HOCl, Ozone, 
1O2 
Nitro tyrosine Tyr ONOO- 
Lipid peroxidation Lys, Cys, His γ radiation, MCO 
Glucoxidation adducts Lys Glucose 
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A potent mode of direct oxidative attack on a protein is site-specific metal-catalyzed oxidation 
(MCO), in which a protein-bound transition metal (e.g., Fe2+, Cu+) reduces H2O2 to form a 
reactive intermediate (e.g., 
.
OH) in the immediate proximity of vulnerable amino acids.75 Metal- 
catalyzed oxidation (MCO) is one of the major contributors to oxidative damage to proteins76. 
The mechanism of MCO follows Fenton chemistry (see below), in which the hydroxyl radical 
(
.
OH) can lead to chain reactions, polypeptide bond breakage, and lipid peroxidation. The 
resulting lipid peroxidation products acts as secondary oxidation products; for example, acrolein 
(2-propenal) is a lipid peroxidation-derived aldehyde that can readily modify surrounding 
biomolecules via Michael addition.76-77 
Scheme 1.2. MCO oxidation mechanism 
Fe (II)       +      H2O2        Fe (III) +   
.
OH + OH
-
 (Fenton reaction)     Eq (1) 
 Fe (III)      +     O2
.
                  Fe (II)    +     O2                                  Eq (2) 
 
 Combining Eq (1) and Eq (2), 
 O2
.
           +    H2O2              
.
OH        + OH
-
     + O2    Eq (3) 
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Scheme 1.3.  Lipid Peroxidation Pathway 
 
 
 
 
1.2 Project Design 
1.2.1 Protein Carbonylation 
Protein carbonylation is a form of protein oxidation that post-translationally introduces an 
aldehyde or ketone moiety onto nucleophilic amino acid residues and these modifications alter 
protein properties, and function. They also strongly correlate with the onset and progression of 
various age-associated phenotypes, including type II diabetes, cancer, neurodegenerative 
disorders, and the aging process.
78-79
 Among the amino acid residues, proline, arginine, lysine 
and threonine have been found to be the most susceptible to carbonylation through direct 
oxidation (see Figure 1.5. for structures and products). Protein carbonyls can also be introduced 
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through oxidative cleavage of the protein backbone, either through the α-amidation pathway 
(Figure 1.6.) or via oxidation of the glutamyl acid residue side chain (Figure 1.7.). Protein 
carbonylation has been proposed to be an effective biomarker for oxidative stress. Studies in 
various organisms, including insects, rodents, and humans have shown an exponential increase in 
protein carbonylation with age and age-related diseases. Aldehydes formed by lipid peroxidation 
will also react with cysteine, histidine, and lysine residues to give secondary products, mainly 
protein carbonyls (Figure 1.8.). 
 
         Lysine         α-aminoadipic semialdehyde 
 
     Arginine                 Glutamic semialdehyde 
 
Proline               Glutamic semialdehyde 
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Threonine      2-amino 3-keto butyrate 
 Figure 1.5. Direct oxidation of amino acid side chain.
81
 
 
 
 
Figure 1.6. α-amidation pathway.82 
 
 
 
Figure 1.7. Oxidation of glutamyl side chains.
83
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Figure 1.8. Michael addition of 4-hydroxy-2-nonenal.
84–86
 
1.2.2 Measurement of Protein Carbonyls 
Protein carbonyls, in aggregate, were first measured by spectrophotometric methods using 2,4- 
dinitro phenylhydrazine (DNPH) labeling. First developed by Levine et al., the method involves 
derivatizing protein carbonyls by reaction with DNPH to form a hydrazone that has an 
absorbance at 370 nm.
87
 To gain more information with greater sensitivity, the DNPH labelling 
can be followed by western blotting with anti-DNPH antibodies
88
. This approach is the basis of 
the commercially available OxyBlot system.
89
 OxyBlot kit includes primary anti-DNPH primary 
antibodies and fluorescent secondary antibodies for imaging purpose. In addition, protein 
carbonyl content can be measured using an enzyme linked immunosorbent assay (ELISA).
90
 
17 
  
Finally, tritiated sodium borohydride (NaBT4) can be used to reduce protein carbonyls to the 
corresponding alcohols, thus facilitating assessment of the amount of carbonylation through 
scintillation counter measurements.
91
 
However, the anti-DNPH antibody-based methods suffer from severe limitations when applied to 
tissue extracts from mammalian sources due to the presence of contaminating 
immunoglobulins.
92
 Inevitably, the secondary antibodies that typically are used to detect DNP 
moiety:anti-DNP complexes will detect nonspecific IgGs present in the mammalian tissue. If 
serum is present, this problem can be rather severe, even when a “species-specific” secondary 
IgG is employed. A high degree of non-specific binding by these contaminant antibodies has 
been observed in control samples when DNPH labeling was omitted. These problems can be 
circumvented somewhat by modifying the classic reductive hydrazide-labeling chemistry to 
employ biotin hydrazide in place of DNPH. Reaction of biotin hydrazide with a protein carbonyl 
yields a stable hydrazone derivative. The biotin-tagged protein carbonyl can then be visualized 
by standard detection methods such as chemiluminescent detection of derivatized proteins on 
western blots using horseradish peroxidase-conjugated streptavidin (HRP-streptavidin).
93
 This 
method employs the known specificity of streptavidin and is not sensitive to endogenous 
immunoglobulin. In our laboratory, using mass spectrometry, the performance of biotin 
hydrazide and a number of similar labels has been investigated using oxidatively modified 
human serum albumin (HSA)  as source of protein carbonyls. 
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Scheme 1.4. Biotin hydrazide reaction scheme. 
 
Alternatively, biotinylated protein carbonyls can be quantified in aggregate through their 
displacement from avidin of 4’-hydroxyazobenzene-2-carboxylic acid (HABA).94 When 
complexed with avidin, HABA has a strong absorbance at 500 nm, whereas free HABA has an 
absorbance peak at 348 nm. Due to the difference in binding affinities (biotin-avidin binding 
affinity Kd =1×10
−15
 versus HABA-avidin binding affinity Kd =5.8×10
−6
), HABA bound to 
avidin can be easily displaced by biotin, resulting in a decrease in absorbance of the mixture at 
500 nm. Additional options are provided by fluorescein -5-thiosemicarbazide (FTC)
95
 and Alexa 
488 fluorescence hydroxylamine (FHA)
96
,  two visible wavelength fluorescence labels reported 
in the literature to react with protein carbonyls. 
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1.2.3 Mass spectrometry based proteomics  
The proteome is the protein equivalent of the genome. The term "proteomics" is used to refer to 
large-scale, comprehensive studies of  specific proteomes, including collecting information on 
protein abundances, post-translational modifications, protein-protein interactions, and networks, 
in order to understand cellular processes. In general, proteomics deals with the large-scale 
determination of gene and cellular function directly at the protein level. In comparison with the 
genome, which is static in nature, the proteome is much more complex and dynamic. Proteomics 
and functional genomics (e.g., microarrays) are complementary and are often combined by 
bioinformaticians to produce systems biology approaches. Since there is not reliable correlation 
between gene and protein expression, it is very important to explain the dynamic nature of the 
proteome. Protein diversity can be explained by differences in stability and turnover between 
mRNA and proteins, alternative mRNA splicing resulting in a variety of protein products, and 
post-translational modifications. To understand the biological complexity of a cell it is necessary 
to examine the entire proteome in addition to the  static genome. Most proteins undergo chemical 
modifications known as post-translational modifications (PTMs).  PTMs play a crucial role in 
generating heterogeneity, allowing protein variants identical at the primary sequence level to 
have different functions in different cell types. Understanding the extent and the motif of the 
many PTMs in cells will shed  light on the function and dynamics of proteomes.
97,98
 Recently, 
mass spectrometry-based proteomics techniques have  become the preferred method of analysis 
for complex protein samples. 
Mass spectrometry-based proteomics can be divided into two distinct categories- (i) top-down 
and (ii) bottom-up proteomics. Top-down proteomics refers to the analysis of intact proteins. 
Fragmentation in the mass spectrometer is used to generate a series of ions indicative of  amino 
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acid sequence. Such information can be derived from difference in the m/z values of fragment 
ions. Top-down is especially well-suited to the detection of degradation products, sequence 
variants, and combinations of PTMs.
99
 However, the approach requires very high mass accuracy 
and often is unable to provide detailed information about large portions of the protein sequence . 
Furthermore, problems in sample handling related to solubility and the need for highly sensitive 
instruments pushes many researchers away from the top-down approach.
100
 The bottom-up 
approach is characterized by the digestion of proteins to small peptides using a sequence- 
specific proteolytic enzyme. The resulting peptides are separated by liquid chromatography and 
analyzed by  tandem mass spectrometry (MS/MS).
100,101
 We used the bottom-up approach for all 
proteomics studies reported in this work.  
Mass spectrometry is the most widely used analytical tool in proteomics. Usually, mass 
spectrometers are composed of three basic components: an ion source, a mass analyzer, and an 
ion detector. In principle, mass spectrometry consists of ionizing chemical compounds to 
generate charged molecules or molecule fragments followed by measurement of their m/z ratios. 
Mass spectrometry measurements can only be made for ionized analytes in the gas phase. 
Therefore, the transfer of molecules from solution or the solid phase to the gas phase is a critical 
step in the procedure. The discovery of soft ionization techniques such as electrospray ionization 
(ESI)
102
 and matrix-assisted laser desorption ionization (MALDI)
103
 has opened a new era in 
proteomics research.
 
These are the most commonly used ionization techniques. Both MALDI 
and ESI generate ions with very low internal energies that undergo little fragmentation. After 
ionization, ions reach the mass analyzer, which separates them by their m/z ratios. Ion motion 
can be manipulated by electric or magnetic fields in the mass analyzer to direct ions to a detector, 
which estimates the number of ions at each individual m/z value. Mass analyzers can be divided 
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into five categories.  (a) magnetic sector, 
104
 (b) ion trap,
105–109
 (c) quadrupole,
110–113
 (d) ion 
cyclotron resonance,
114,115
 and (e) time-of-flight mass analyzers.
116–119
 Each one has different 
characteristics in terms of sensitivity, resolution, mass accuracy, and the ability to fragment 
peptide ions. ESI is commonly coupled with ion traps. (three-dimensional, linear) and hybrid 
instruments like quadrupole/time-of-flight (Q/TOF). Ion trap instruments are well-suited to 
proteomics experiments because they combine robustness and economy with flexible MS/MS 
capabilities. Ions with specific m/z ratios can be captured in the trap for fragmentation induced 
by collision with an inert gas, usually helium. This process is called collision-induced 
dissociation (CID).
120
  Other fragmentation techniques like electron capture dissociation 
(ECD)
121
 and  electron transfer dissociation (ETD)
122
 are also used in proteomics workflows. 
Each technique results in a distinct peptide fragmentation pattern. CID normally gives b- and y-
ions, while ECD and ETD generates c- and z-ions. Compared with CID, ECD gives more 
extensive fragmentation, and better sequence coverage. While ECD can only be performed in ion 
cyclotron resonance mass spectrometers, ETD is compatible with ion traps. In the ETD 
technique, electrons are transferred from radical anions with low electron affinities to multiply-
protonated peptides, thus resulting in fragmentation. ETD gives superior sequence coverage and 
can be a good complement to traditional CID. Fragments are only detected if they carry at least 
one charge. If this charge is retained by the N-terminal fragment, the ion is classified as 
either a, b or c, as illustrated in Figure 1.9. If the charge is retained on the C-terminal fragment, 
the ion is classified as either x, y or z (See Figure 1.9.). A subscript number is used to complete 
the fragment name and to indicate the number of residues in the fragment. Peptides are identified 
from MS/MS spectra using programs such as SEQUEST or MASCOT,
123,124
 which search 
protein sequence databases. Programs that associate peptide identifications with tandem mass 
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spectra provide scores that indicate the quality of the match. Determining a threshold to separate 
accepted from rejected identifications can be assisted by including proteins in the search that 
could not be present in the sample; identifications of such proteins must clearly be incorrect. 
Such decoy proteins must have similar characteristics to the anticipated proteins, for example, 
similar lengths and amino acid compositions. One of the simplest means to achieve these criteria 
is to reverse the protein sequences present in the database. With the development of high-
resolution mass spectrometers such as the Orbitrap
125
 and  FT-ICR in conjunction with the 
availability of complete genome sequences and new bioinformatics tools, mass spectrometry has 
positioned itself as an indispensable tool in proteomics.  
23 
  
 
Figure 1.9. Peptide fragment classifications.
126
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1.2.4 Quantitative proteomics 
Advances in MS have enabled the identification of thousands of proteins in a single LC-MS/MS 
run. However, since these methods have typically provided only qualitative information, there is 
also a need for quantitative proteomics. For example, the distinction between normal and 
stimulated/disease states may be in protein concentration rather than in the presence or absence 
of certain proteins. In order to address this issue, many methodologies have been introduced to 
enable absolute and relative quantitation in MS based proteomics.
126,127
 In absolute quantitation 
methods an internal standard is introduced to permit calibration. In complex matrices, such as 
those often analyzed in proteomics experiments, due to ion suppression, the only effective 
internal standard is a stable isotope (
2
H, 
13
C, 
15
N and 
18
O )-labeled version of the peptide targeted 
for quantitation. This method is also known as isotope dilution or absolute quantitation 
(AQUA).
128
 However, since labeled peptides are expensive, this approach can only be used in 
experiments targeting a relatively modest numbers of proteins. Nevertheless, while absolute 
concentration measurements are clearly valuable, often relative abundance levels between 
control and disease state states can provide sufficient information . First reported by Gygi et al. 
isotope coded affinity tags (ICAT)
129
 are designed to allow relative concentrations between 
control and condition states to be determined for all proteins present in a sample. ICAT labels 
undergo cysteine-specific reactions for incorporation into proteins. The ratio between  peaks for 
the heavy and light isotopically labeled peptides gives the relative quantities of a protein between 
two different samples. In vivo labeling such as stable isotopic labeling in cell culture (SILAC),
130
 
and in vitro labeling like enzymatic 
18
O labeling,
131
 and iTRAQ
132
 are also used in relative 
quantitation. In SILAC, stable isotope-labeled amino acids are incorporated from the growth 
medium during cell culture, resulting in labeled proteins that can then be compared with proteins 
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from cells grown in normal medium. The main disadvantage of SILAC is that it is practical only 
in cell culture studies, excluding higher organisms. With enzymatic labeling, 
18
O atoms are 
incorporated into the C-terminus of every proteolytic peptide by trypsin or another protease 
during or after digestion. One half of the comparison is digested in H2
18
O, whereas the other 
control is digested in H2
16
O, resulting in 2-4 Da mass shifts due to incorporation of one or two 
18
O atoms. Incomplete labeling and back exchange are major issues with the enzymatic labeling 
method. Introduced in the last decade, the isobaric tags for relative and absolute quantitation 
(iTRAQ) approach has been used in our work to quantitate relative abundance changes in 
carbonylated proteins. The iTRAQ reagents react with primary amino groups in peptides such as 
the peptide N-terminus and the lysine side chain. As with the ICAT approach, isotopically 
distinct labels are added to peptides in each sample to be compared. However, unlike the ICAT 
approach, the labels are isobaric. Quantitative information is only obtained on fragmentation, 
which reveals reporter ions. Label-free quantitation techniques have also gained importance due 
to limitations in label-based techniques such as high cost, and complicated and time-consuming 
sample preparation procedures. Label-free protein quantification133 is usually achieved through 
one of two strategies. In the first measurements, peptide peak areas are used for quantitation, 
requiring exceptional reproducibility in all aspects of sample preparation and analysis.
134
 The 
second is based simply on counting the number of MS/MS spectra supporting each protein 
identification.
140-141
 Peptide peak intensity or MS/MS spectrum counts are measured for 
individual LC-MS/MS or LC/LC-MS/MS runs, with changes in protein abundance calculated via 
direct comparisons between different analyses. 
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1.3. Fruit fly model for aging and age-related studies 
Model organisms such as C. elegans, D. melanogaster and mice have been studied extensively in 
aging and age-related disease research. However, Drosophila have several features that make 
them especially well-suited for applications in the age-related disease field. Most genes in 
Drosophila have homologs in mammals and the physiology between flies and mammals is 
generally conserved. Therefore, the molecular-genetic mechanisms associated with aging and 
age-related diseases are likely to be conserved between flies and vertebrates.
137
 Furthermore, 
there are no cells in adult fruit flies that undergo mitosis (thus, all cells in the adult fly are the 
same age). This is important for aging studies because there is evidence that functional 
senescence is due to the inability to maintain homeostasis in existing cells. In addition, a 
relatively short lifespan, rapid age-related declines in locomotion, and the availability of 
powerful genetic strategies to manipulate the genome
138
 are features that are beneficial for 
studying aging and age-related disease. Fruit fly model system has been used in the study of  
age-related functional declines
139
 and diseases. Flies have been used to study many age-related 
diseases including cancer, heart failure, diabetes, and neurodegenerative diseases.
140–145
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CHAPTER 2 
 
 
 
 
Affinity enrichment and mass spectrometric 
quantitation of protein carbonyls in Paraquat-exposed 
Drosophila melanogaster  
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2. 1. Abstract 
Protein post-translational modifications are often analyzed using mass spectrometry-based 
quantitative methods. In this chapter, protein carbonylation, a class of post-translational 
modification resulting from oxidative stress by a superoxide radical anion (O2
•−
) generator, 
Paraquat, is measured. Labeling of carbonylated proteins was achieved using hydrazide 
chemistry and enrichment was carried out with streptavidin beads. On-bead digestion followed 
by subsequent labeling with iTRAQ reagents resulted in the detection of 249 carbonylated 
proteins. Western blotting and biotin quantitation assay approaches were also investigated. By 
both western blotting and proteomics, Paraquat exposure resulted in increased carbonylated 
protein relative abundance. For Paraquat exposure versus control, the median carbonylated 
protein relative abundance ratio (1.53) determined using MS-based proteomics was in good 
agreement with that obtained using the biotin quantitation kit (1.36). Functional analysis, using 
DAVID (Database for Annotation, Visualization, and Integrated Discovery), was used to search 
for system biology connections between the entire set of carbonylated proteins. Significant 
changes in relative abundance were noted in many proteins associated with various cellular 
functions. Of these, mitochondrial proteins were found to be a major target for Paraquat- induced 
oxidative stress. Some major mitochondrial components, such as electron transport chain (ETC) 
complexes, citric acid cycle proteins, and anti-oxidant enzymes, were found to be differentially 
abundant when compared with control flies. 
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2. 2. Introduction 
Oxidative stress occurs due to an imbalance between ROS production and destruction by the 
cellular anti-oxidant defenses and it can impact various cell components such as proteins, lipids, 
DNA, and carbohydrates.
25–28
 In the case of proteins, this damage due to ROS sometimes leads 
to structural changes in proteins, often accompanied with partial or total loss of protein 
function.
146
 Proteins may undergo reversible or irreversible damage upon oxidative stress.
87,147,148
 
Reversible changes occur mostly in the cysteine and methionine residues. Cysteine oxidation can 
be repaired by specific enzymes such as glutaredoxin or thioredoxin.
149
 Methionine oxidation is 
repaired by methionine sulfoxide reductase.
150
 On the other hand, irreversible modifications, 
such as protein carbonylation and tyrosine nitration, have been used as biomarkers for 
assessment of oxidative stress in aging and diseases.
152–156
 
Furthermore, the damage caused by endogenous reactive oxygen species is closely associated 
with aging, diabetes, cancer, cardiovascular disease, and neurodegenerative disease.
157–160
 
Mitochondria are an important source and target of ROS mediated damage.
161–163
 Of the many 
possible oxidant generation sites, much attention has been focused on electron transport chain 
(ETC) complexes due to the presence of various redox centers with trace metals such as iron and 
copper.
164
 Generally, the mitochondrial electron transport chain (ETC) is regarded as the chief 
source of the progenitor ROS, superoxide, O2
•−
. Superoxide (O2
•−
) toxicity in the membrane 
environment is likely to proceed through protonation of O2
•−
 to produce HO2
•
, a powerful lipid 
peroxidation agent,
165
 while in aqueous environments the exceptionally reactive species HO
•
 can 
be produced in the iron-catalyzed reaction of O2
•−
 with H2O2.
166
  Superoxide dismutases reduce 
the toxicity by catalyzing the disproportionation of O2
•−
 to H2O2 and O2.
4
 While O2
•−
 will 
undergo spontaneous disproportionation at a lower rate in the absence of superoxide dismutases, 
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the importance of rapid destruction and low steady-state concentrations of O2
•−
 is highlighted by 
the inactivation of catalase by O2
•−
.
167
  Many types of oxidative damage can lead to protein 
carbonylation. Direct oxidation by ROS or addition of lipid peroxidation products to nucleophilic 
residues are the two most common ways of introducing carbonyls. Increase in protein 
carbonylation have been observed with aging and during age-related conditions such as 
Alzheimer’s disease, diabetes, kidney disease, and Parkinson’s disease.168 The present study is 
based on our working hypothesis that protein carbonylation is not a random process, but is 
localized at sites with features such as metal binding sites that can catalyze HO
•
 generation or 
hydrophobic pockets that can promote interactions with lipid peroxidation products. In this work, 
using Drosophila melanogaster as a model system, we have investigated the impact on protein 
carbonylation levels of exogenous oxidative stress induced by Paraquat (methyl viologen; 1,1’-
dimethyl-4,4’-bipyridinium dichloride). Paraquat is a redox cycling agent capable of producing 
O2
•−
 when linked to a suitable electron donor (typically an oxidoreductase enzyme that uses 
NADH or NADPH as electron donor). 
Hydrazide-based chemistry is a common way of labelling carbonylated proteins due to the ease 
of Schiff base formation with this functional group and subsequent stabilization by reduction 
with sodium cyanoborohydride. Using biotin hydrazide, biotin-avidin affinity chromatography 
and related approaches have been successfully used for the enrichment of carbonylated proteins 
in various studies. Soreghan et al. used streptavidin affinity-based enrichment in high-throughput 
proteomic identification of protein carbonyls in mouse brain.
169
 In this study we used 
streptavidin that had been covalently immobilized to acrylamide beads (Pierce's UltraLink 
Resin). Streptavidin was used instead of avidin due to its reduced non-specific binding (the 
bacterial protein is not glycosylated).  
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Figure 2.1. Streptavidin affinity enrichment strategy. 
 
Enriched biotinylated proteins were digested on the beads and the resulting free peptides were 
labeled with iTRAQ reagents to allow relative carbonylated protein abundances to be obtained. 
In this exogenous oxidative stress system, we were able to collect abundance ratios that were in 
close agreement across full biological replicates, suggesting the robustness and reproducibility of 
our analytical method. 
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2. 3. Experimental procedures 
2.3.1. Materials 
Biotin hydrazide, calcium chloride, iodoacetamide, sodium cyanoborohydride, SDS, and 
triethylammonium bicarbonate were purchased from Sigma (St. Louis, MO). Ammonium 
bicarbonate was supplied by J.T. Baker (Phillipsburg, NJ) and DMSO, DTT, and HPLC-grade 
water and methanol were obtained from Fisher Scientific (Pittsburgh, PA). Sequencing-grade 
modified trypsin was from Promega (Madison, WI) and iTRAQ reagent kits were purchased 
from AB SCIEX (Framingham, MA). 
2.3.2. Paraquat exposure and initial preparation 
Flies for all experiments were reared under standard conditions.
170
 As animal models,  w
1118
 flies 
(Stock Number 5905; Drosophila Stock Center; Bloomington, IN) were used in Paraquat-
exposure studies, which were performed essentially as described by Goddeeris et al.
171
 Mixed 
populations of males and females were grown to adulthood, collected under brief CO2 
anesthesia, placed into food vials (25 flies per vial), allowed to recover overnight, and then 
exposed to Paraquat until ~50% were dead. Age-matched populations of control flies were 
handled in parallel. Batches of ~500 living flies per group were frozen at −20°C overnight and 
then homogenized with 15 strokes of a Dounce homogenizer in 5 mL ice-cold buffer (100 mM 
sucrose, 100 mM KCl, 50 mM Tris-HCl, 1 mM KH2PO4, 0.1 mM EGTA, adjusted to pH 7.3) 
containing the protease inhibitors aprotinin, leupeptin, and pepstatin A at 500 ng/mL. 
Homogenates were centrifuged at 300 × g for 20 min at 4°C to remove large debris. Supernatants 
were stored at −20°C until further processing could be performed. Protein concentrations in the 
homogenates were determined using the Lowry protein assay (DC Protein Assay; Bio-Rad; 
Hercules, CA). 
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2.3.3. Biotinylation of protein carbonyls 
Biotin hydrazide was added to Paraquat-exposed and associated control fly homogenates (500-
µg total protein aliquots) to 5 mM. Samples were then incubated for 1 h at room temperature 
with gentle shaking before SDS was added to 2% (w/v). The labeling reaction was allowed to 
proceed for a further 2 h after a second biotin hydrazide addition had been made. Parallel 
experiments where biotin hydrazide addition was omitted were performed to allow assessment of 
non-specific binding. Hydrazone-bond reduction was achieved by adding sodium 
cyanoborohydride to 15 mM and then incubating at 4°C for 1 h (see Fig.2.2.) Samples were then 
desalted using PD midiTrap G-25 columns (GE Healthcare; Piscataway, NJ) and protein 
concentrations were determined using the bicinchoninic acid (BCA) assay (Pierce 
Biotechnology; Rockford, IL). 
 
 
 
 
 
 
 
 
 
Figure 2.2. Biotinylation of protein carbonyls. 
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2.3.4. Western blotting for protein carbonyls 
Beginning with unlabeled homogenates, OxyBlot kits (Millipore; Billerica, MA) were used as 
recommended by the manufacturer to visualize protein carbonyls through derivitization with 2,4-
dinitrophenylhydrazine (DNPH) followed by western blotting with an antibody specific for the 
dinitrophenyl group. Enhanced chemiluminescence kits (GE Healthcare; Piscataway, NJ) were 
used for visualization. Alternatively, starting with homogenates labeled with biotin hydrazide as 
described above, western blotting with HRP-conjugated streptavidin (Pierce Biotechnology), 
with visualization achieved using TMB substrate (Promega) was investigated. 
2.3.5. Peptide biotin quantitation assay 
Urea and DTT were added to biotinylated protein samples (and parallel samples where biotin 
hydrazide addition had been omitted) to achieve final concentrations of 8 M and 10 mM, 
respectively. Denaturation and reduction was allowed to proceed for 1 h at 37°C. Cysteines were 
capped by adding iodoacetamide to 55 mM and then continuing incubation at room temperature 
in the dark for 1 h. Samples were prepared for digestion by diluting 10-fold in PBS and then 
adding calcium chloride to 1 mM and trypsin to achieve a circa 1:50 trypsin: protein ratio. 
Digestion was allowed to proceed for 16 h at 37°C and then terminated by acidification with 
10% (v/v) TFA (aq). The resulting peptide solutions were desalted using reversed-phase, C18 
SPE cartridges (Sep-Pak; Waters; Milford, MA) and then dried by centrifugal evaporation. To 
determine aggregate biotinylation levels, the amount of peptide-bound biotin was measured 
using a biotin quantitation kit (Pierce Biotechnology), based on the displacement of 4’-
hydroxyazobenzene-2-carboxylic acid (HABA) from avidin, as recommended by the 
manufacturer. 
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2.3.6. Enrichment of biotinylated proteins and on-bead tryptic 
digestion 
Biotinylated protein samples were added to streptavidin UltraLink resin (Pierce Biotechnology), 
which had previously been washed three times with PBS, and incubated at room temperature 
overnight. Unbound proteins were removed by washing the resin three times with PBS followed 
by washing once with 8 M urea and 10 mM DTT in PBS. Bound proteins were denatured and 
reduced by incubating with 8 M urea and 10 mM DTT in PBS for 1 h at 37°C. Cysteines were 
then alkylated by adding iodoacetamide to 55 mM and continuing the incubation for a further 1 h 
at room temperature in the dark. Excess reagents were removed prior to digestion by washing 
three times with 50 mM ammonium bicarbonate. Digestion with trypsin (1:50, trypsin: protein 
ratio; calcium chloride added to 1 mM) was allowed to proceed for 16 h at 37°C before being 
terminated by acidification with 10% (v/v) TFA (aq). Peptides were recovered by extensive 
washing of the beads with 50 mM ammonium bicarbonate followed by SPE (same method as 
biotin quantitation assay) and centrifugal evaporation. 
2.3.7. iTRAQ labeling of peptides 
The iTRAQ (isobaric tags for relative and absolute quantitation) approach exploits an N-
hydroxysuccinimide (NHS) ester derivative to modify primary amino groups by linking a mass 
balance group (carbonyl group) and a reporter group (based on N-methylpiperazine) to 
proteolytic peptides via the formation of an amide bond. Because the iTRAQ reagents are 
isobaric, differentially labeled peptides will appear as a single peak in MS scans. Upon 
fragmentation, the mass balancing carbonyl moiety will be released as a neutral fragment, 
thereby liberating the isotopically-labeled reporter ion to provide relative quantitation 
information. In Fig 2.3. the structures of the iTRAQ labels are shown. The advantage of the 
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iTRAQ approach is that peptides from different sources and labeled with different iTRAQ 
reagents will have identical masses, but when fragmented will give unique mass ions (114-117) 
for quantification as well as peptide fragments for structural identification of the peptide. 
Recently 8-plexed iTRAQ labels were introduced which can be used to label 8 different peptide 
samples with reporter ions having  m/z of 113-119 and 121 Da.  
 
 
  
 
 
 
 
 
 
 
Figure 2.3. A) iTRAQ structure, B) iTRAQ isotopic distribution, and C) iTRAQ workflow. 
Prior to labeling, entire dried peptide samples were dissolved in 30 µL of iTRAQ dissolution 
buffer (0.5 M triethylammonium bicarbonate, pH 8.5). Here, two iTRAQ 4-plex reagents were 
required. Parallel experiments where duplicate aliquots not labeled with biotin hydrazide were 
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prepared required all four iTRAQ 4-plex reagents. After allowing the labeling reaction to 
proceed for 2 h at room temperature, samples to be compared were combined and then dried in a 
centrifugal evaporator. Prior to LC–MS/MS analysis, the combined peptide samples were 
suspended in 20 µL of 0.1% formic acid (aq). 
2.3.8. LC–MS/MS 
Combined, iTRAQ-labeled samples were analyzed using an LTQ Orbitrap Velos mass 
spectrometer (Thermo Scientific; San Jose, CA) interfaced with a Waters nanoACQUITY UPLC 
system. The injection volume all cases was 2 µL, with a nanoACQUITY trapping column being 
used to reduce loading time. Labeled peptides were separated with a RP, C18 nanoACQUITY 
capillary analytical column (1.7 µm particles, 100 µm × 100 mm). Elution was achieved using a 
gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in water (A) at a flow 
rate of 0.4 µL min
−1
. Beginning with an equilibration mobile phase of 1% B, the linear gradient 
initially ran to 15% B over 25 min, then to 25% B over 35 min, then to 35% B over 40 min, and 
finally to 85% B over 20 min. Eluting peptides flowed into a nano-scale ESI source that was 
operated at 3.5 kV. Full scan mass spectra (m/z = 400–2000), which were collected at 60,000 
resolution in the Orbitrap, were followed by ten data-dependent MS/MS spectra, using higher-
energy C-trap dissociation (HCD)
172
 to access iTRAQ reporter ions. HCD parameters included 
normalized collision energy set to 40 and activation time at 0.1 ms. Ions selected twice for 
fragmentation within a 30 s window were excluded for 180 s. 
2.3.9. Data processing and analysis 
Peptides were identified using the X! Tandem code fork included with version 4.6.3 of the 
Trans-Proteomic Pipeline (TPP) software package (Institute for Systems Biology; Seattle, WA). 
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The protein sequence database used was generated from the whole D. melanogaster proteome 
(FlyBase version R5.35, FB2011_03; 23361 proteins), 112 common contaminant proteins 
(Global Proteome Machine; Common Repository of Adventitious Proteins; downloaded on April 
8, 2011), and reversed versions of these sequences included for false positive rate estimation. 
Search parameters included a precursor ion mass tolerance of ±15 ppm, a requirement for at least 
one trypsin-conforming peptide terminus, and a maximum of one missed cleavage. Fixed mass 
shifts were applied for alkylation with iodoacetamide at cysteine (+57.021464 Da) and addition 
of 4-plex iTRAQ labels at lysine and the peptide N-terminus (+144.102063 Da). Differential 
mass shifts were included for methionine sulfoxide (+15.994915 Da) and for the 4-plex iTRAQ 
reagents at tyrosine. PeptideProphet,
173
 a component of the TPP software package, was used to 
filter identifications proposed by X! Tandem, with peptide-spectrum matches (PSMs) scoring 
≥ 0.9 being accepted. The PSM false positive rate was estimated as described by Elias and Gygi 
(2 × decoy PSM count/total accepted PSM count).
174
 PSMs were organized into protein groups 
defined by parent gene, rejecting PSMs that indicated more than one gene. Relative abundance 
ratios were calculated for each PSM having no missing reporter ions and then combined to 
produce consensus values for each gene-based protein group by calculating the geometric mean. 
These ratios were corrected independently for each preparation using the ratio observed for 
trypsin autolysis peptides. Only groups supported by at least five measurements were accepted. 
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2. 4. Results & Discussion 
2.4.1. Paraquat-induced oxidative stress in Drosophila melanogaster 
Paraquat (1,1’-dimethyl-4,4’-bipyridinium dichloride), also known as methyl violgen, is a redox 
cycler which stimulates the production of superoxide in mitochondria. Paraquat in its dication 
form (PQ
2+
) accepts an electron from a reductant and forms a monocation radical (PQ
+•
), which 
reacts with O2 to produce superoxide radical (O2
•−
).
175
 Use of Paraquat in generating O2
•−  
in 
mitochondria has been reported extensively in systems such as cultured mammalian cells, 
isolated mitochondria, Drosophila melanogaster, Caenorhabditis elegans and rodents.
176–180 The 
toxicity of Paraquat
 
is due to the generation of the superoxide anion, which can lead to the 
synthesis of more toxic reactive oxygen species (ROS) such as hydroxyl radicals and hydrogen 
peroxide as discussed above. On the other hand, the oxidation of reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) as a consequence of Paraquat administration results in the 
disruption of biochemical processes requiring NADPH.
181
 The proposed Paraquat redox cycling 
mechanism is shown in Scheme 2.1 Paraquat-induced O2
•−
 generation would be expected 
throughout the cell with perhaps greatest flux in mitochondria. Helena et al. showed complex I in 
electron transport chain (ETC) was the major site of mitochondrial superoxide production in 
yeast and mammalian mitochondria exposed to Paraquat.
182
 However, Costella et al. showed in 
rats that mitochondria were a major ROS generator upon intake of PQ
2+
 and identified complex 
III as the most important site of Paraquat action.
183
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Scheme 2.1. Paraquat redox mechanism.
184
 
 
Paraquat has been used extensively in studies of the impact of oxidative stress in Drosophila 
melanogaster.
178
 Paraquat is generally administered by feeding flies with a Paraquat/sucrose 
solution for 24 h. Sucrose is thought to promote feeding. The ease of this administration method 
has led to widespread application; however, a high-sucrose diet, even in the short term, may have 
a substantial metabolic effect, possibly confounding or complicating studies of oxidative stress. 
High-sucrose diets in D. melanogaster have been shown to promote oxidative stress and to effect 
live weight, total protein, and the activities of many enzymes.
185,186
  In our current protocol, one-
week-old adult flies with fully developed bodily functions were fed with 20 mM Paraquat in 5% 
sucrose. The effectiveness of Paraquat-induced oxidative stress as a model system was initially 
studied by evaluating the level of carbonylation under oxidative stress at the whole organism 
level using two different western blotting approaches (OxyBlot and HRP-conjugated 
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streptavidin). The approximate time to a 50% death rate was three days for Paraquat exposure. 
Control flies exhibited few (~1%) deaths through the duration of these experiments. 
2.4.2. Visualization of carbonylated proteins by western blotting  
In 1994 Shacter et al. introduced a western blotting-based method for the detection of 
carbonylated proteins.
187
 This method, later commercialized under the name OxyBlot, takes 
advantage of the fact that protein carbonyls (aldehydes and ketones) can be derivatized using 
2,4-dinitrophenylhydrazine (DNPH). We used this methodology to make a general comparison 
between aggregate carbonylation levels in control and Paraquat-exposed fly homogenates. A 
general working protocol is displayed in Scheme 2.2.  
Scheme 2.2. OxyBlot procedure for the detection of protein carbonyls. 
 
OxyBlot results for Paraquat-exposed and control flies are shown in Fig 2.4. Paraquat exposure 
can clearly be seen to result in elevated levels of carbonylation when compared with control 
flies, which exhibit some level of background oxidation. Fig 2.5 gives the picture obtained when 
western blotting with HRP-conjugated streptavidin was applied to Paraquat-exposed and control 
samples that had been labeled with biotin hydrazide. These results also clearly indicate a higher 
degree of protein carbonylation in Paraquat-treated versus control flies.  
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Figure 2.4. OxyBlot results for control versus Paraquat-exposed flies.  
 
In all cases, whole-fly homogenates were analyzed. This system was used to visualize the effects 
of Paraquat exposure, with lanes shown for Paraquat-exposed and control flies along with 
samples processed in parallel where the DNPH label was omitted. 
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Figure 2.5. HRP-conjugated streptavidin approach results for control and Paraquat-exposed flies.  
In all cases, whole-fly homogenates were analyzed. Here, control and Paraquat-exposed fly samples were 
biotinylated. Elevated protein carbonylation levels are clearly visualized for Paraquat exposure with some 
degree of background oxidation in control samples. 
2.4.3. Biotin quantitation assay 
Biotinylated protein carbonyls can be quantified using the color change associated with the 
displacement of weakly bound 4’-hydroxyazobenzene-2-carboxylic acid (HABA) from avidin.49, 
50
  HABA complexed with avidin, HABA has a strong absorbance maximum at 500 nm, whereas 
free HABA has an absorbance maximum at 348 nm. Since the biotin-avidin binding affinity (Kd 
=1×10
−15
) is higher than the HABA-avidin binding affinity (Kd =5.8×10
−6
), HABA bound to 
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avidin can be easily displaced by biotin, resulting in a decrease in absorbance of the mixture at 
500 nm (see Fig 2.6). Hence, the amount of HABA released from the HABA-avidin complex is 
equal to the amount of biotin associated with  the biotinylated proteins. 
 
Figure 2.6. HABA-avidin displacement assay for biotin quantitation.(Figure obtained from 
Pierce website) 
We slightly modified this assay due to difficuties in solubilizing D.melanogaster membrane 
proteins in buffers compatible with the assay by switching from protein to peptide level biotin 
quantitation. Control and Paraquat-exposed samples were biotinylated with biotin hydrazide. A 
parallel control sample where biotinalytion step had been omitted was used as negative control. 
Biotinylated proteins were denatured in urea, reduced with DTT, and alkylated by 
iodoacetamide. To determine aggregate biotinylation levels, the amount of peptide-bound biotin 
was measured using a biotin quantitation kit (Pierce Biotechnology), based on the displacement 
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of 4’-hydroxyazobenzene-2-carboxylic acid (HABA) from avidin, as recommended by the 
manufacturer.Using the third full repeat for the Paraquat-exposure system, peptide-bound biotin 
concentrations were then determined. The assay was repeated three times. Expressed as average 
± standard deviation, the results obtained were 2.6 ± 0.7, 32.1 ± 0.5, and 42.7 ± 3.7 pmol biotin 
per µg peptide for non-biotinylated control, biotinylated control, and biotinylated Paraquat-
exposed samples, respectively. Subtracting the background amount from each intentionally 
biotinylated sample, this implies a 36 ± 3.5% increase in protein carbonylation on exposure to 
Paraquat. 
 
Figure 2.7. Biotin quantitation measurments for control versus Paraquat-exposed samples. 
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2.4.4. Non-specific binding estimation by mass spectrometry 
The interaction between (strept)avidin and biotin is non-covalent and highly specific. The biotin-
streptavidin binding interaction has a dissociation constant, Kd, in the order of 4×10
−14
 M, the 
strongest known in nature thus far. The strength and specificity of the interaction has led it to 
become one of the most used affinity pairs in molecular, immunological, and cellular assays. 
Enrichment of carbonylated proteins using biotin-avidin chemistry has been reported by many 
researchers.
190–195
 The major difference between avdin and streptavidin is that avdin, an egg 
protein of 68 kDa is highly glycosylated with basic a pI of 10-10.5, but streptavidin (60 kDa), 
isolated from bacteria, Streptomyces avidinii is non-glycosylated with a neutral pI of 6.8-7.5. 
This strutural difference makes avidin inferior to streptavidn in terms of  non-specific binding.
57, 
58
 Nevertheless, retention of non-biotinylated proteins on streptavidin beads is still  a concern in 
our experiments. Therefore, the degree of non-specific binding was estimated by creating 
duplicate samples that were not exposed to the labeling reagent, biotin hydrazide. This 
comparison was performed for the Paraquat-exposure system with three replicate LC–MS/MS 
runs performed for a single sample preparation. In the case of extensive non-specific binding, 
many proteins would be expected to have non-biotinylated to biotinylated ratios of close to one 
for both the Paraquat-exposed and control pairs.i.e., equal affinity for biotinylated and non-
biotinylated forms. After filtering, the dataset consisted of 6373 peptide spectrum matches 
(PSMs), four of which indicated decoy proteins (implying a PSM false positive rate of 0.13% , 
that is, an acceptably low error rate). Processing into gene-based protein groups resulted in 101 
groups. The distribution of observed ratios is provided in  Figure 2.8., with ratios provided 
separately for each protein group in Appendix Table A1. Median non-biotinylated versus 
biotinylated ratios for control and Paraquat-exposed samples were 0.23 and 0.18, respectively, 
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indicating some level of non-specific binding. For the control comparison, ratios greater than 0.5 
were found for nine protein groups, while for the Paraquat comparison, three groups exceeded 
0.5 (two of these overlapped with the nine from the controls). These ten protein groups were 
excluded from further analysis due their demonstrated propensity for non-specific binding. 
Interestingly, two protein groups had non-biotinylated to biotinylated ratios in excess of one for 
both the control and Paraquat-exposed samples. Acetyl-CoA carboxylase (FBgn0033246) gave 
non-biotinylated to biotinylated ratios of 3.36 for the control and 4.12 for the Paraquat-exposed 
comparison while CG1516 (FBgn0027580) gave 2.12 for the control and 2.00 for the Paraquat-
exposed samples. 
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Figure.2.8. Non-specific binding to the streptavidin beads 
Here to assess non-specific binding to the streptavidin beads used in this work, parallel samples 
where the biotinylation step was omitted were prepared. The Paraquat-exposure system was 
used, resulting in four samples (Paraquat-exposed biotinylated and non-biotinylated; control 
biotinylated and non-biotinylated) that were compared in a single iTRAQ experiment. Since 
Paraquat exposure would be expected to produce changes in carbonylation, non-specific binding 
was assessed by comparing the non-biotinylated to biotinylated samples. This figure gives the 
observed non-biotinylated to biotinylated abundance ratio distribution for the Paraquat-exposed 
and control comparisons. Non-specific binding is observed, but at a moderate level. 
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2.4.5. Mass spectrometry quantitation of Paraquat-induced changes 
in protein carbonylation 
While correlation between protein carbonylation and various disease states has been established  
by numerous authors, there are still many uncertainties involved in identification and 
quantitation of carbonylated proteins.
12, 59, 60
 DNPH-derivitization of carbonyl groups is a well-
known analytical method in organic chemistry. A modified version of this derivitization strategy 
is used by many researchers to isolate, identify, and quantify carbonylated proteins.
199
 
Previously, Butterfield and coworkers used DNPH-specific antibodies to isolate protein 
carbonyls and used mass spectrometry for subsequent identification.
200
 Biotin hydrazide 
chemistry is used extensively in carbonylated protein-identification due to the effectiveness of 
enrichment using avidin or streptavidin. Regnier and coworkers have used biotin hydrazide-
monomeric avidin enrichment strategies in rat plasma, human plasma, and yeast for 
carbonylation site identification.
201–203
 In a separate study, Soreghan and coworkers used a 
streptavidin affinity pull down method for isolation of rat brain carbonylated proteins, 
identifying 100 proteins.
169
 For our analysis we used streptavidin UltraLink resin. Streptavidin is 
a purified recombinant protein with tetrameric biotin-binding sites and is covalently immobilized 
onto an azlactone-activated polyacrylamide support in our system; this material is known to have 
less non-specific binding when compared with similar products based on avidin. Our working 
hypothesis for this project was that mitochondria under Paraquat treatment will experience 
oxidative damage, particularly in ETC proteins. 
 Briefly, 500 µg of control and Paraquat-treated fly homogenate was solubilized in 1% SDS prior 
to the addition of the biotin hydrazide label, to increase the solubility of mitochondrial 
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membrane proteins. After biotinylation, the resulting hydrazone bonds were reduced with 
sodium cyanoborohydride; enrichment of carbonylated proteins then proceeded using UltraLink 
streptavidin resin. The proteins were digested on the beads and the subsequently recovered 
peptides were labeled with the iTRAQ reagents. For iTRAQ quantitation MS we used an LTQ-
Orbitrap Velos instrument in which higher energy C-trap dissociation (HCD) was used for the 
efficient fragmentation of iTRAQ-labeled peptides. Protein group relative abundance ratios were 
calculated by combining iTRAQ ratios for  all MS/MS supporting each identified protein. 
Peptides that indicated multiple protein that were products of multiple genes were rejected and 
accepted proteins were grouped by gene. We used trypsin autolysis peptides as an internal 
standard to correct iTRAQ ratios. Relative abundance ratios were combined for each protein 
group by calculating geometric means. 
Paraquat exposure was expected to result in a significant increase in protein carbonylation levels 
over those found in the control. Three replicate LC–MS/MS runs were recorded for each sample 
preparation and the entire experiment was repeated three times, which resulted in 25621 PSMs 
after filtering. Only twelve of these indicated decoy proteins, giving an estimated PSM false 
positive rate of 0.09%. Quantitative information was obtained for 249 protein groups after 
removal of non-specific binding proteins. The full list of quantified carbonylated proteins is 
provided with combined ratios for all repeats as Appendix Table A2 and with separate ratios for 
each repeat as Appendix Table A3. Those proteins found to exhibit at least a doubling of 
carbonylation levels over the control on exposure to Paraquat are shown in Table 2.1. 
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Table 2.1. List of carbonylated proteins found in an MS-based proteomics study in D. 
melanogaster to be at least doubled in relative abundance on exposure to Paraquat. 
FlyBase gene 
ID used for 
protein-group 
construction  
Associated 
FlyBase gene 
symbol 
Associated FlyBase gene 
name 
PSM 
count 
Paraquat-
exposed versus 
control 
carbonylated 
protein relative 
abundance ratio 
FBgn0010516 wal walrus 16 2.75 
FBgn0010213 Sod2 superoxide dismutase 2 (Mn) 25 2.73 
FBgn0031801 CG9498  5 2.53 
FBgn0024289 Sodh-1 sorbitol dehydrogenase 1 6 2.52 
FBgn0003067 Pepck 
phosphoenolpyruvate 
carboxykinase 
9 2.45 
FBgn0019957 ND42 
NADH:ubiquinone reductase 
42kD subunit precursor 
37 2.42 
FBgn0020653 Trxr-1 thioredoxin reductase-1 14 2.38 
FBgn0000556 Ef1α48D elongation factor 1α48D 42 2.36 
FBgn0029823 CG3011  23 2.30 
FBgn0261014 TER94 TER94 76 2.27 
FBgn0020513 ade5 ade5 86 2.26 
FBgn0010482 l(2)01289 lethal (2) 01289 17 2.25 
FBgn0000052 ade2 adenosine 2 5 2.22 
FBgn0000319 Chc clathrin heavy chain 17 2.21 
FBgn0036044 CG14168  11 2.20 
FBgn0260439 Pp2A-29B protein phosphatase 2A at 29B 49 2.16 
FBgn0037607 CG8036  48 2.16 
FBgn0001219 Hsc70-4 heat shock protein cognate 4 31 2.14 
FBgn0040349 CG3699  28 2.13 
FBgn0003887 βTub56D β-tubulin at 56D 15 2.09 
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FBgn0004047 Yp3 yolk protein 3 842 2.09 
FBgn0004419 me31B maternal expression at 31B 10 2.07 
FBgn0003676 T-cp1 Tcp1-like 17 2.07 
FBgn0000261 Cat catalase 82 2.06 
FBgn0039737 CG7920  153 2.04 
FBgn0012036 Aldh aldehyde dehydrogenase 43 2.01 
FBgn0262559 Mdh2 malate dehydrogenase 2 637 2.01 
FBgn0019830 colt congested-like trachea 9 2.01 
 
 
Of the 28 carbonylated proteins found to be at least doubled in relative abundance on exposure to 
Paraquat, SOD2, thioredoxin reductase-1, and catalase stand out as key antioxidant enzymes. Six 
proteins showed Paraquat-exposed to control ratios of less than one (not shown in Table 2.1). 
While it would seem unlikely that the degree of carbonylation for any protein would fall on 
exposure to Paraquat, proteins falling in overall relative abundance in response to Paraquat 
treatment is certainly possible. For the whole set, the median Paraquat-exposed to control ratio 
was 1.53. A histogram illustrating the ratio distribution is provided as Figure 2.9. Functional 
analysis, using the DAVID
204
 (Database for Annotation, Visualization, and Integrated 
Discovery) Bioinformatics Database (Release 6.7; http://david.abcc.ncifcrf.gov), was used to 
search for connections between the entire set of 249 carbonylated proteins. This group is best 
viewed as a list of background carbonylated proteins. Since functional analysis tools usually 
manipulate gene lists only, the practice of defining protein groups by parent genes was 
beneficial.  
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Figure 2.9. Distribution of relative abundance ratios obtained when an MS-based proteomics 
approach was used to measure changes in carbonylated protein levels in response to Paraquat 
exposure. 
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All 249 genes were recognized by the DAVID system, although FlyBase secondary identifiers 
were required in some cases. Using the whole D. melanogaster proteome as a background, 
strong associations were seen with the lipid particle (86 out of 249 genes were associated with 
GO:0005811; p = 1.5 × 10
−61
) and mitochondrion (81 out of 249 genes were associated with 
GO:0005739; p = 2.6 × 10
−26
) gene ontology cellular component classifications. (37 proteins 
were annotated to both GO:0005811 and GO:0005739) 
Lipid particles or lipid droplets, which are also known as adiposomes, consist of a neutral lipid 
core surrounded by a phospholipid monolayer with numerous associated proteins.
67, 68 Lipid 
droplets (LDs) are present during all developmental stages in Drosophila. As with higher 
organisms, triacylglycerols (TGs) are the dominant lipid type present in fly LDs. Drosophila 
development is characterized by alternating TG synthesis and mobilization phases, which cause, 
for example, a dramatic increase in body fat content during larval development followed by a 
threefold reduction during metamorphosis. Furthermore, during larval development Drosophila 
accumulate large amounts of storage lipids in an organ called the fat body, which corresponds to 
adipose tissue and possesses some liver-like functions.
207
 Moreover, Cermelli et al. found the 
lipid droplet proteome in D. melanogaster to be unexpectedly complicated and proposed a role 
for the droplets in storage or sequestration of excess or incorrectly folded proteins.
208
 In this 
work, the carbonylated proteins associated with the lipid particle annotation clearly include both 
mitochondrial and ribosomal proteins. Rather than actually being in storage, mitochondrial 
proteins might be present in lipid droplet preparations as impurities; however, association 
between lipid droplets and RNA has been observed, thus indicating ribosomal localization is 
conceivable.
209
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 In contrast to the uncertain association with lipid particles, the connection to mitochondria 
seems obvious. Many ETC and citric acid cycle proteins were found to be carbonylated, with 
SOD2 found to be the second most highly carbonylated with respect to the control in the 
Paraquat-exposure study. 
FlyBase (using the more recent FB2014_01 version) and DAVID annotations were combined 
with MitoDrome (http://mitodrome.ba.itb.cnr.it) functional classifications to investigate the 
distribution of carbonylated mitochondrial proteins. Combining these information sources 
increased the total number of protein groups associated with mitochondria to 85. The distribution 
of these carbonylated mitochondrial proteins among MitoDrome classes is illustrated in Figure 
2.10. Briefly, twelve genes were associated with ETC Complex I (GO:0005747), two with 
Complex II (GO:0005749), six with Complex III (GO:0005750), five with Complex IV 
(GO:0005751), and ten with ATP synthase (GO:0005753). Similarly, fifteen genes were 
associated with the citric acid cycle (GO:0006099), although in this case there was significant 
overlap with other functional classifications. Of these gene-organized protein groups, three were 
found at double or greater relative abundance in the Paraquat-exposed versus control samples (all 
three repeats combined): NADH:ubiquinone reductase 42kD subunit precursor (FBgn0019957) 
at a ratio of 2.42, Tcp1-like (ATP Synthase; FBgn0003676) at 2.07, and malate dehydrogenase 2 
(FBgn0262559) at 2.01. Finally, three mitochondrial genes were associated in MitoDrome with 
cell  rescue, defense, and death classification (this category includes antioxidant enzymes). Of 
these, the two that exceeded our  significance threshold are SOD2 (FBgn0010213) at a ratio of 
2.73 and thioredoxin reductase-1 (FBgn0020653) at 2.38. 
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Figure 2.10. Distribution of MitoDrome functional classifications for the entire set of 
mitochondrial proteins from the Paraquat-exposure study. 
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2.5. Conclusion 
In conclusion, in vivo oxidative stress induced by Paraquat in D. melanogaster resulted in a 
broad-based increase in the level protein carbonylation that included the mitochondrial electron 
transport chain complexes. A notable increase in oxidation was also seen in a number of 
antioxidant enzymes. From our crude fly preparations using the biotin-streptavidin enrichment 
strategy, we could identify and quantitate large numbers of carbonylated proteins. Although the 
association of carbonylated proteins with lipid particles in conjunction with a proposed role for 
the lipid particle in sequestration of damaged proteins is interesting, it would indicate that many 
of the identified carbonylated proteins are merely awaiting destruction. In contrast, the 
association of carbonylated proteins with the mitochondria is important and anticipated. Paraquat 
was expected to result in widespread O2
•−
 generation and the general increase observed in 
carbonylated protein relative abundance is consistent with this expectation. Western blotting 
results (OxyBlot and HRP-conjugated streptavidin) showed a clear increase in protein 
carbonylation, which was supported by both the biotin quantitation assay and the distribution of 
observed iTRAQ ratios. Antioxidant enzymes were prominent in the set of most highly 
carbonylated proteins (Paraquat-exposed to control ratio > 2), but no particular protein stands out 
as being specifically damaged. 
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CHAPTER 3 
 
 
 
 
 
Protein relative abundance quantitation: Comparative 
study between spectral counting and isobaric tag 
labeling 
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3. 1. Abstract 
Determining difference in protein abundance levels between biological samples is known as 
comparative proteomics. Isotopic labeling strategies like iTRAQ, ICAT, and SILAC are widely 
used in quantitative proteomics techniques but label-free methods such as spectral counting are 
also gaining popularity. Here, we have compared label-free spectral counting with iTRAQ 
labeling for control and Paraquat-treated D.melanogaster mitochondrial samples. Our working 
hypothesis is that the model system will respond to oxidative stress by altering the levels of 
proteins associated with antioxidant defense. The iTRAQ method was associated with greater 
counts of detected proteins and with good quantitative reproducibility across the sample set. 
Though spectral counting data is reproducible between different samples, high complexity and 
the presence of various other non-mitochondrial proteins hindered identification and 
quantitation. By direct comparison we established a weak correlation in protein abundance levels 
between these two methods.  
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3. 2. Introduction 
Mass spectrometry-based shotgun proteomics (the analysis of many proteins in the same 
experiment with some degree of random sampling) is one of the most frequently used analytical 
tools for protein identification and quantification.210 Many isotopic label-based quantitation 
methods such as isotope coded affinity tags (ICAT)129, stable isotope labeling with amino acids 
in cell culture (SILAC)130, and iTRAQ132 are currently used; however intrinsic limitations, which 
include requirements for higher amounts of starting materials, increased complexity of 
experimental protocols, and the high costs of reagents, hinders the effectiveness of these 
methods. As a result, there has been increased interest in label-free approaches.133 The most 
widely used label-free approach requires extremely reproducible chromatography to ensure that 
peptides in separate LC/MS/MS runs are experiencing the same environment during the 
electrospray ionization process and to allow raw mass spectrum peak area to be used for relative 
abundance measurements. In practice, daunting computational effort is required to cope with 
data imperfection due to factors such as drift in chromatographic retention times and variations 
in the sample background matrix.  Therefore such methods are not viable for many laboratories. 
Spectral counting (SpC) provides a more accessible label-free strategy.211 In this approach, 
relative protein abundance measurements are achieved by comparing counts of MS/MS spectra 
supporting each protein from separate LC-MS/MS datasets.   
The advantage is that chromatograms do not need to be aligned and therefore quantification 
becomes a part of the normal protein identification workflow. The logic is that the probability 
that a peptide peak is selected for an MS/MS scan is closely related to its concentration (there is 
competition with other peptides in the selection process; higher concentration peptides are 
selected more often). Given a steady background of co-eluting peptides, an increase in the 
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concentration of a particular peptide would be expected to lead to a higher probability of that 
peptide being selected for fragmentation.  Therefore, the number of spectral counts tracks 
relative abundances. Liu et al.  reported a strong linear correlation (r2= 0.9997) between spectral 
count and relative protein abundance, with a dynamic range of over two orders of magnitude212. 
Zybailov et al. using an S.cerevisiae sample confirmed the reproducibility and large dynamic 
range of spectral counting213. Relative quantification by spectral counting has been applied 
widely, including searches for biomarkers of type-2 diabetes in human saliva, the comparison of 
relative protein abundance in yeast and mammalian cells under different culture conditions, and 
the screening of phosphotyrosine-binding proteins in mammalian cells214–217. Normalization of 
spectral count data is required here since SpC data is count data which is not distributed to infer 
significant difference in abundance. Various statistical tests, including Fisher’s exact test, 
student’s t-test, and the goodness-of-fit test (G-test) have been used to evaluate the significance 
of measurements made by spectrum counting.218–221 iTRAQ labeling was performed using the 
scheme described in chapter 2. Direct comparison of these two methods showed a weak 
correlation in protein abundance levels. 
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3. 3.Experimental procedures 
3.3.1 Materials 
Iodoacetamide, dithiothreitol, SDS, urea, calcium chloride and 10× PBS concentrate were 
purchased from Sigma-Aldrich (St. Louis, MO). Sequencing grade modified trypsin was 
purchased from Promega (Madison, WI). Bicinchoninic acid (BCA) Protein Assay kits were 
purchased from Pierce (Rockford, IL) and iTRAQ reagent kits were obtained from Applied 
Biosystems (Foster City, CA). The Oxyblot
TM
 protein oxidation detection kit was purchased 
from Millipore (Billerica, MA). HPLC-grade water and methanol were obtained from Fisher 
Scientific (Pittsburgh, PA). 
3.3.2 Isolation of Paraquat-exposed D. melanogaster mitochondria 
Adult flies for all experiments were reared under standard conditions.
222
 Mixed populations of 
males and females were grown to adulthood, collected under brief CO2 anesthesia, placed into 
food vials (25 flies per vial), allowed to recover overnight, and then exposed to Paraquat until 
~50% of the flies were dead. Age-matched populations of control flies were handled in parallel. 
Control flies exhibited few (~1%) deaths through the duration of these experiments. Flies (Stock 
Number 5905; Drosophila Stock Center; Bloomington, IN) were used in Paraquat exposure 
studies, which were performed essentially as described by Goddeeris et al.
223
   
 Briefly, flies were treated by adding 200 µl of 20 mM Paraquat in 5% sucrose to each vial; 
control flies were exposed to 5% sucrose alone. The approximate time to a 50% death rate was 
three days for Paraquat-exposed flies. When the number of dead flies reached 50% 
(approximately 500 flies), the remaining live flies were sacrificed, homogenized, and then 
subjected to differential centrifugation for mitochondria isolation. A similar set of 500 flies that 
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were exposed only to the 5% sucrose solution constituted the control sample. All mitochondrial 
samples were stored at      −80°C until used. 
3.3.3 Identification of mitochondrial carbonylation using the 
OxyBlot
TM
 approach 
The OxyBlot detection procedure was taken directly from the manufacturer’s protocol. Briefly, 
fresh, isolated control and Paraquat-treated mitochondrial samples (5 µg) were denatured by 
adding 12% SDS to a final concentration of 6% SDS, and then were derivatized using 10 µl 2,4-
dinitrophenylhydrazine in 2M HCl solution for not more than 15 minutes at room temperature. 
Samples were neutralized by adding 7.5 µl of neutralizing solution (2M Tris base/ 30% glycerol) 
and reduced by adding 1 µl of 5% v/v 2-mercaptoethanol. Mixtures were loaded on 4-20% 
gradient polyacrylamide gels, and then transferred to a PVDF membrane by electrobloting. The 
membrane was blocked with 5% fatty acid-free BSA in 1×-PBST solution for 1 hour and 
incubated with 1:150 primary goat anti-DNP antibody suspended in 1% BSA/PBST for 1 hour. 
The membrane was then washed with 1×-PBST and then incubated with secondary HRP- 
conjugated goat anti-rabbit in 1% BSA solution (1:300 dilutions) for 1 hour at room temperature. 
Following washing with 1×-PBST, the membrane was developed with ECL detection reagents. 
 
3.3.4 Enzymatic digestion 
Briefly, 500 µg of control and Paraquat fly mitochondria were first dissolved by adding 10% 
SDS to a final concentration of 1%. Solid urea is then added to bring the final concentration of 
urea to 8M. Both protein samples were reduced with 10 mM DTT for 1 hour at 37°C, followed 
by alkylation with 40 mM IAM for 1 hour at 37°C. Excess IAM is removed by treating the 
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samples with 50 mM DTT for an hour at 37°C. After diluting the samples ten-fold to reduce the 
SDS concentration to < 0.05%, sequencing grade trypsin (enzyme to substrate ratio 1:40) was 
added and the mixture incubated for 16 hours at 37°C. Digestion was terminated by adding 10% 
formic acid. Digested peptides were recovered using Oasis MCX cartridges supplied by Waters 
(Milford, MA) and then evaporated to dryness by centrifugal evaporation. 
3.3.5 iTRAQ labeling 
Peptide concentrations were measured using the BCA protein assay. For labeling, approximately 
100 µg of peptides were dissolved in 30 µL of iTRAQ dissolution buffer (0.5 M 
triethylammonium bicarbonate, pH 8.5). For the Paraquat-exposure study, where a single control 
was used, two iTRAQ 4-plex reagents were used. The iTRAQ reagents (114-117) were dissolved 
in 70 µl of ethanol and added to the respective samples. After allowing the labeling reaction to 
proceed for 2 h at room temperature, samples to be compared were combined and then purified 
using Waters Oasis MCX solid phase extraction cartridges. The final sample was dried using a 
centrifugal evaporator and then re-suspended with 20 µL of 0.1% formic acid (aq.) 
3.3.6 LC–MS/MS 
For spectral counting, LC/ESI-MS/MS analysis of digested peptide samples was performed using 
a capillary HPLC system (Thermo Finnigan, San Jose, CA) connected to an LTQ linear ion trap 
mass spectrometer (Thermo Finnigan, CA) with a nanospray source. Tryptic peptides were 
separated by reverse-phase chromatography on a C18 column (100×0.18 mm; Thermo, 5 um 
particle size) with a split-flow system used to speed up sample loading. The split is 
approximately 100:1, with a master flow rate of 50 μL/min (thus ~0.5 μL/min in the analytical 
column). The digested peptides were eluted from the column using two mobile phases, A (0.1% 
formic acid in water) and B (0.1% formic acid in methanol). The gradient started from 2% B, 
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then increased to 15% B over 5 min, then increased to 80% B over 70 min, and finally increased 
to 95% B over 25 min. The eluted peptides (singly, doubly, or triply charged ions) were analyzed 
using a data-dependent scan procedure. To prevent the redundant processing of a few dominant 
ions in the MS/MS analyses, a dynamic exclusion feature was used that only allows a particular 
m/z value to be processed twice in a 2 min time window. 
Combined iTRAQ-labeled samples were analyzed using an LTQ Orbitrap Velos mass 
spectrometer (Thermo Scientific) interfaced with a Waters nanoACQUITY UPLC system. 
Labeled peptides were separated with a reversed-phase, C18 nanoACQUITY capillary analytical 
column (1.7 µm particles, 100 µm × 100 mm). Elution was achieved using a gradient of 0.1% 
formic acid in acetonitrile (B) versus 0.1% formic acid in water (A) at a flow rate of 
0.4 µL min
−1
. Beginning with an equilibration mobile phase of 1% B, the linear gradient initially 
ran to 15% B over 25 min, then to 25% B over 35 min, then to 35% B over 40 min, and finally to 
85% B over 20 min. Eluting peptides flowed into a nano-scale electrospray ion source that was 
operated at 3.5 kV. Full scan mass spectra (m/z = 400–2000), which were collected in profile 
mode at 60,000 resolution in the Orbitrap, were followed by ten data-dependent MS/MS spectra, 
using high-energy C-trap dissociation (HCD) to access iTRAQ reporter ions. HCD parameters 
included normalized collision energy set to 40 and an activation time at 0.1 ms. Ions selected 
twice for fragmentation within a 30 s window were excluded for 180 s. 
3.3.7 Database searching 
For spectral counting analysis, peptide sequences were identified using the BioWorks version 
3.3.1, SP1 implementation of Sequest (Thermo). The acquired MS/MS spectra were then 
searched against the FlyBase D.melanogaster protein database (FlyBase version R5.35, 
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FB2011_03; 23361 proteins).  Reversed versions of all sequences were also included to permit 
false discovery rate estimation. The database searching was set to only consider peptides within 
the mass range 500–4000 Da. Up to two missed cleavage sites were allowed, and 
carbamidomethylation at cysteine (which results from acetylation using iodoacetamide) was 
treated as a fixed modification (+57 Da), and methionine oxidation (+16 Da) was an optional 
modification (modified and unmodified methionine considered). For iTRAQ labeled peptides, a 
fixed mass shift of +144 Da was added to the peptide N-terminus and lysine residues. Sequest 
results were refined using Scaffold 3.0 (Proteome Software; Portland, OR) software. 
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3. 4. Results & Discussion 
3.4.1. Detection of protein carbonyls by western blots 
Fully developed, one week-old adult flies were fed with 5% (w/v) aqueous sucrose solution 
containing 20 mM Paraquat. Once a mortality rate of 50% had been achieved, the remaining live 
flies were collected and then sacrificed. Mitochondria were isolated using differential 
centrifugation, in Dr. Grotewiel’s lab. OxyBlot results for Paraquat-exposed and control flies are 
shown in Figure 3.1. Paraquat exposure can clearly be seen to result in elevated levels of 
carbonylation in treated when compared with control flies, which exhibit some level of 
background oxidation. 
 
          
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.1. OxyBlot results of control versus Paraquat-exposed fly mitochondria. 
 
3.4.2. Spectral counting analysis 
We used Scaffold 3.0 software for refinement of Sequest output and for statistical analysis of our 
data. The numbers of proteins identified in both conditions of Batches 1 and 2 were 110 and 187 
(see Figure 3.2) respectively (each sample was injected in triplicate into the LTQ-XL mass 
1. Control fly mitochondria—DNPH labeled 
2. Control fly mitochondria—No DNPH control 
3. Paraquat exposed fly mitochondria—DNPH 
labeled 
4. Paraquat exposed fly mitochondria—No DNPH 
control 
5. Standard ladder 
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spectrometer). The large difference is attributed to difficulties in our in-house mitochondrial 
isolation protocol. Protein identification acceptance required two distinct peptides 99% 
ProteinProphet protein probability, and a 0.2% false discovery rate (FDR) at the protein level 
were required (only peptides assigned a 95% PeptideProphet probability were used). 
 
 
 
 
 
 
 
Figure 3.2. Venn diagrams illustrating the number of proteins identified in Batches 1 and 2 using 
spectral counting and the overlap in identifications between the control and Paraquat-exposed 
samples. 
 
 
Since large proteins tend to contribute more peptides/spectra than small ones, a 
normalized spectral abundance factor (NSAF)
224
 was defined to account for the effect of 
protein length on spectral count. NSAF is calculated as the number of spectral counts 
(SpC) identifying a protein, divided by the protein’s length (L), divided by the sum of 
SpC/L for all proteins in the experiment. NSAF allows the comparison of abundance of 
individual proteins in multiple independent samples and has been applied to quantify 
changes in various complexes.
20,21
 
Batch_1 
 
Batch 2 
 
69 
  
Table 3.1. Counts of peptides and proteins identified using the spectral counting method. 
 
Sample Name       Proteins           Unique peptides         Total spectrum counts 
Batch 1 
Control   119   427         2024 
Paraquat   115   338         1661 
Batch 2 
Control   199   708         3405 
Paraquat   191   752         3988 
 
We observed considerable variation in number unique peptide and total spectrum counts (see 
Table 3.1). The percentages of unique peptides shared between control and Paraquat-treated 
samples in Batch 1 and Batch 2 was 54.8% and 56.4%. Similarly, for the spectral counts, the 
overlaps were 52.4% and 54%, respectively. The top 15 proteins in terms of spectral counts 
account for nearly 60% of total spectral counts in Batch 1 and 50% in Batch 2. 
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Figure 3.3. Histogram of the total number of spectral counts for the top 15 proteins in Batch1 
and Batch 2 control and Paraquat samples. 
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A comparison of relative abundances for the 15 most abundant proteins in the Batch 1 and Batch 
2 samples, as determined by spectral counts (SpC), is illustrated in Figure 3.3. The 10 most 
abundant proteins are well characterized mitochondrial proteins from FlyBase such as 
ATPsynthase-beta chain, bellwether, ATP:ADP antiporter activity protein (sesB-PA), 
ATPsynthase-gamma chain, A Na pump α subunit (Atpalpha-PB), Porin, Aconitase, cytochrome 
c oxidase subunit Vb, mitochondrial electron transport protein from ubiquinol to cytochrome c 
(CG4769-PA), and ubiquinol-cytochrome-c reductase activity (CG4169-PA). 
In both batches, most protein ratios lie in the range from 0.8 to 1.4, making the change in 
abundance less likely to be statistically significant. Recent studies have indicated that the spectral 
counting technique is very accurate at measuring large changes between conditions, but accuracy 
drops dramatically when smaller changes are estimated (see Appendix Table A4). From our 
analysis, it’s clear that identified proteins associated with few spectral counts tend to vary greatly 
in terms of relative abundance ratio between two batches. In order to be confident in our results, 
we introduced an additional requirement for a minimum combined spectral count of 20 for both 
control and Paraquat samples and only considered as significant those proteins displaying 
relative abundance ratios ≤ 0.7 or ≥ 1.5 in either or both batches. Protein relative abundance 
ratios obtained after applying this policy are displayed in Table 3.2 
 Only 13 proteins were acceptable according to the above criteria. Of these, 10 proteins were 
annotated as mitochondrial by FlyBase. Proteins like porin and cytochrome c oxidase subunit Va 
showed contradictory values between batches. Inconsistent results might be attributed to 
differences between the in biological replicates. 
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Table 3.2. List of proteins found, using the spectrum counting approach, to differ significantly 
(relative abundance ratio ≥ 1.5 or ≤ 0.7) between the Paraquat-exposed and control fly 
mitochondria samples in at least one of the two batches 
Protein 
Name 
FlyBase ID Batch1 Ratio Batch2 Ratio 
Geo_ 
Mean 
Role 
Mhc-PG FBpp0080452 0.2 0.1 0.1 ATP Binding 
Atpalpha-PB FBpp0088503 1.6 1.2 1.4 
cation transmembrane 
transporter activity 
Ca-P60A-PE FBpp0072121 0.7 0.6 0.6 
calcium-transporting 
ATPase activity 
CG11015-PA FBpp0078918 0.7 0.8 0.7 
cytochrome-c oxidase 
activity 
Acon-PB FBpp0081002 0.6 0.8 0.7 
aconitate hydratase 
activity 
CG3192-PA FBpp0070950 0.5 0.6 0.5 
NADH dehydrogenase 
(ubiquinone) activity 
porin-PA FBpp0079771 1.1 2.3 1.6 
voltage-gated anion 
channel activity 
Act57B-PA FBpp0071448 0.8 0.4 0.6 
structural constituent of 
cytoskeleton 
CoVa-PA FBpp0081947 0.6 1.5 0.9 
cytochrome-c oxidase 
activity 
Pdsw-PA FBpp0077209 1.1 0.7 0.9 
NADH dehydrogenase 
(ubiquinone) activity 
Gpo-1-PC FBpp0086442 1 1.5 1.2 
glycerol-3-phosphate 
dehydrogenase activity 
ATPsyn-d-PB FBpp0083141 1.1 1.9 1.4 
hydrogen-exporting 
ATPase activity, 
phosphorylative 
mechanism 
CG9140-PA FBpp0078847 0.4 0.6 0.5 
4 iron, 4 sulfur cluster 
binding 
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3.4.3. iTRAQ quantitative analysis 
In our iTRAQ analyses, peptides were initially identified using the Sequest algorithm, which in 
the case was controlled using ProteomeDiscoverer (Thermo) software. Protein inference was 
performed using Scaffold 3.0 software, which combines the PeptideProphet and ProteinProphet 
algorithms with an intuitive graphical user interface. The principal output of Scaffold  is a list of 
accepted, identified proteins ranked by identification confidence. The threshold for protein 
identification acceptance is 99.0% ProteinProphet protein probability; the threshold for the 
peptide identifications used to support the protein identification is a 0.2% false discovery rate 
(FDR) and a 95% PeptideProphet peptide probability. Fig. 3.4 provides protein identification 
counts for both biological preparations and also indicates the observed overlap using a Venn 
diagram.    
 
 
Fig. 3.4. Number of proteins identified in two entirely separate iTRAQ labeling biological 
replicates.                                                                                                                                                   
 
An MS/MS spectrum for a typical iTRAQ labeled peptide is shown below in Fig.3.5. Here the 
control sample was labeled with iTRAQ-114 and the Paraquat-exposed sample was labeled with 
iTRAQ-116.   
Batch 
Number 
Count of 
Accepted 
Proteins 
1 165 
2 177 
74 
  
Figure 3.5. MS/MS of peptide KGYSPFGTK, which originates from FlyBase mitochondrial 
protein CG9172-PB 
The lower trace provides the whole spectrum while the upper trace is an exploded view of the 
lower m/z ratio region that provides a better view of the iTRAQ reporter ion peaks. Additional 
filtering criteria were required when working with iTRAQ quantitative data. For a combined 
protein ratio to be accepted, a minimum of two contributing peptide ratios were required. Based 
on our initial analysis, there were 87 proteins for which relative abundance ratios were available 
for both samples (refer Appendix Table A5). The number of proteins for which a ratio could be 
obtained from only one of the biological replicates was 3 and 12 for Batches 1 and 2, 
respectively. Out of 87 quantifiable and comparable proteins, 84% of them were classified as 
mitochondrial. This implies effective isolation of mitochondria, but does suggest the potential for 
additional mitochondrial enrichment. Presenting data as Log2 transformed Paraquat-exposed 
versus control ratios, it can be seen that the majority of the transformed ratios lie between −0.19 
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and +0.20 (Fig.3.6). Given the observed experimental uncertainty, these proteins must be classed 
as unchanged by Paraquat treatment. Proteins with ratios outside this range are most interesting. 
With our initial protocol, the 20 mM Paraquat treatment was carried out for 12-14 hours to 
establish a 50% mortality rate. We feel that varying this exposure time could provide interesting 
information related to the systematic response to differing levels of oxidative stress and 
potentially shift the distribution seen in Fig. 3.6. Table 3.3 shows the list of proteins that were 
significantly lower in abundance in the Paraquat-exposed flies when compared with the control 
samples. The criterion for being included was a reduction of at least 20% in relative abundance 
in at least one of the batches.  
  
Figure 3.6. Distribution of Paraquat-Exposed versus Control Protein Relative Abundance Ratios. 
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Table 3.3. Proteins found to be lower in relative abundance in the Paraquat-exposed fly 
mitochondrial samples in either Batch 1 or Batch 2  
FlyBase 
Protein ID Batch 1 Ratio Batch 2 Ratio Protein Role 
FBpp0291928 0.35 0.31 Myosin light chain kinase activity 
FBpp0070039 0.87 0.57 NADH dehydrogenase activity 
FBpp0070094 0.71 0.66 Electron carrier activity 
FBpp0072124 0.62 0.71 calcium-transporting ATPase activity 
FBpp0074481 0.93 0.71 NADH dehydrogenase (ubiquinone) activity 
FBpp0084905 0.71 0.76 hydrogen-exporting ATPase activity 
FBpp0080835 0.62 0.76 cytochrome-c oxidase activity 
FBpp0070950 0.93 0.76 NADH dehydrogenase (ubiquinone) activity 
FBpp0070871 0.71 0.87 citrate (Si)-synthase activity (TCA cycle) 
 
The value of identified proteins found to be lower or higher in relative abundance between 
different conditions can be enhanced by identifying common factors between the listed proteins. 
For example, if a number of proteins could be linked through membership in a common 
pathway, this would clearly be biologically-relevant information. Of the 9 proteins determined to 
be lower in relative abundance in the Paraquat-exposed fly mitochondria (Table 3.3), three are 
subunits of Complex I of the mitochondrial electron transport chain (NADH dehydrogenase). 
Cytochrome P450-4g1(FBpp0070094) and one protein annotated as being cytochrome-c oxidase 
subunit IV (FBpp0080835) also showed notably lower relative abundance. Other important 
proteins that were found to be lower in relative abundance were ATP synthase-γ chain 
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(FBpp0084905), calcium ATPase at 60A (FBpp0072124), and a tricarboxylic acid cycle protein 
(FBpp0070871).  
Table 3.4. Proteins found to be higher in relative abundance in the Paraquat-exposed fly 
mitochondrial samples in either Batch 1 or Batch 2. 
 
Table 3.4 shows a list of proteins that were found to be significantly more abundant in Paraquat-
exposed fly mitochondria in either Batch 1 or Batch 2. Again, a 20% increase in at least one 
batch was required for inclusion in the list. The list of proteins found to be higher in relative 
FlyBase Protein ID 
Batch 1 
Ratio 
Batch 2 
ratio Protein Role 
FBpp0083588 1.23 1.07 
isocitrate dehydrogenase (NAD+) activity (TCA 
cycle) 
FBpp0072135 1.32 1.07 
acetyl-CoA C-acyltransferase activity (ß-
Oxidation) 
FBpp0100178 1.74 1.07 hydrogen-exporting ATPase activity 
FBpp0084901 1.41 1.07 Electron carrier activity 
FBpp0088503 1.32 1.15 
sodium: potassium-exchanging ATPase activity 
(ATPα-PB) 
FBpp0082459 1.15 1.15 ubiquinol cytochrome c reductase activity 
FBpp0086694 1.74 1.15 ATP binding (HSc70-5) 
FBpp0078707 1.52 1.23 cytochrome-c oxidase activity 
FBpp0081370 1.23 1.32 transketolase activity 
FBpp0073277 1.15 1.52 ATP:ADP antiporter activity (SesB) 
FBpp0072246 1.07 1.52 hydrogen-exporting ATPase activity 
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abundance in the Paraquat-exposed fly mitochondrial samples consists mainly of mitochondrial 
electron transport chain components like ATP-alpha-PA (FBpp0088502) and c cyclope 
(Fbpp0078707). Apart from these there was a mix of TCA cycle proteins, heat shock proteins 
(HSc70-5) and a protein involved in the ß-oxidation of fatty acids. Overall, it appears that the 
impact of oxidative stress is more apparent from the changes in protein relative abundance, 
which is also evident in Fig 3.6. Direct comparison of SpC ratios with iTRAQ ratios has been 
shown in Fig 3.7. It is evident that these two quantitation methods has only a weak correlation 
for this set of samples. 
 
 
 
 
 
 
 
Figure 3.7. Scatterplot of spectral count (SpC) versus iTRAQ ratios. 
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3.5. Conclusion 
iTRAQ labeling of complex proteome samples is now routinely used in quantitative proteomic 
applications. In addition, label-free approaches to determine relative protein abundance levels, 
such as spectral counting, are becoming increasingly popular. By analyzing control and 
Paraquat-treated D. melanogaster samples, we investigated the correlation between label-free 
quantitation based on spectral counts and iTRAQ-based isotopic labeling. We showed that, for 
the iTRAQ approach, relative quantitation ratios were similar and reproducibility can be 
achieved between two batches. In contrast, spectral counting was not reproducible in the two 
batches. The number of proteins for both approaches varied from Batch 1 to Batch 2, indicating 
that differences between the biological preparations could have been important. By directly 
comparing protein relative abundance levels obtained by both methods we showed that there is a 
weak positive correlation between these two approaches. However, since the results presented 
here are preliminary, we expect that the correlation will improve with the analysis of additional 
samples. 
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CHAPTER 4 
 
 
 
 
Effect of Mn-Superoxide dismutase2 (Sod2) gene 
knockdown on protein carbonylation in Drosophila 
melanogaster  
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4. 1. Abstract 
Quantitative mass spectrometry methods have been used here to study the effect of 
mitochondrial superoxide dismutase-2 (Sod2) knockdown on the Drosophila melanogaster 
proteome. Using RNA interference, levels of this major mitochondrial antioxidant enzyme were 
diminished, thereby increasing the flux of the superoxide radical anion, a progenitor reactive 
oxygen species. Protein carbonylation, an irreversible post-translational modification, was used 
to assay oxidation because carbonyls are not present in the twenty canonical amino acids and are 
amenable to labeling and enrichment strategies. Labeling of carbonylated proteins was achieved 
using biotin hydrazide and enrichment was carried out using a streptavidin bead-immobilization 
technique. Since efficient elution from beads could not be achieved, on-bead digestion was used 
to release peptides from carbonylated proteins. An iTRAQ mass spectrometry-based proteomics 
approach was then used to quantify the impact of Sod2 knockdown on carbonylation levels. 
Using our on-bead digestion approach, we obtained carbonylation abundance ratios for 276 
gene-based protein groups. Considering the whole set of detected carbonylated proteins, lipid 
droplet and mitochondrial proteins were found to be particularly prevalent. A western blotting 
approach using HRP-conjugated streptavidin was also investigated. By both western blotting and 
proteomics, Sod2 knockdown produced little change in aggregate protein carbonylation levels; 
across all protein groups, the median relative abundance ratio is 1.10. However, some proteins 
were found to be differentially abundant: CG5506 (no functional information) and CG11015 
(cytochrome c oxidase subunit Vb) stood out with increased relative abundance levels. The 
involvement of COX subunit Vb could shed some light on the mechanism of superoxide 
generation or the Sod2 knockdown phenotype. 
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4. 2. Introduction 
Some amount of oxygen is not completely reduced to H2O by the mitochondrial electron 
transport chain, but is instead partially reduced to produce the progenitor reactive oxygen 
species, superoxide radical anion (O2
•−
).
227
 Superoxide radical anion (O2
•−
) is converted into 
oxygen and hydrogen peroxide in the mitochondrial matrix by SOD2.
228
 In the presence of 
transition metals such as iron and copper, hydrogen peroxide can be converted into highly 
reactive hydroxyl radicals (OH
•−
). Other enzymes are responsible for the removal of hydrogen 
peroxide, but many of these are prone to direct inactivation by superoxide. For example, catalase 
inhibition by superoxide has been reported.
229
 As the major source of ROS in the cell, 
mitochondria appear to also be a key target of oxidative damage.
230
 The relative contributions of 
the electron transport chain complexes have been extensively studied, with complex III found to 
produce the majority of observed superoxide under conditions that increase the reduction state of 
the electron transport chain.
231
 Recent research has also indicated that electron leakage at 
complex I (NADH dehydrogenase) may also be responsible for some superoxide production.
232–
234
 Furthermore, the electron transport chain’s terminal complex, cytochrome c oxidase, has been 
shown to release ROS under some conditions.
235
 
 Accumulating evidence suggests that oxidative damage may be a key cause of aging and age-
related diseases in species ranging from Drosophila to C. elegans to humans.
71,228,236,237
 ROS 
such as superoxide, hydrogen peroxide, the hydroxyl radical, and others are produced as toxic 
byproducts of normal cellular metabolism.
238
 Among the most important defenses against 
oxygen radicals are the superoxide dismutase (SOD) enzymes.
4,46
 SOD generally exists in two 
forms inside the eukaryotic cell; Cu/ZnSOD (SOD1) is in the cytoplasm, the outer mitochondrial 
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intermembrane space peroxisomes, lysosomes, and the nucleus,
239
 and MnSOD (SOD2) is 
exclusively in the mitochondrial matrix.
240,241
 In addition, many species have an extracellular 
form Cu/ZnSOD (SOD3).
242,243
 Superoxide generated by the mitochondria and other sources is 
converted to H2O2 and O2 by SOD enzymes.
166
  Catalase then converts H2O2 to H2O and O2.
244
 
The ability of cells to detoxify ROS and replace oxidatively damaged macromolecules can 
become inefficient as the products of such damage accumulate during aging and age-related 
diseases.
245
  
The fruit fly, Drosophila melanogaster, possesses the three major eukaryotic SOD isoforms: 
SOD1, found predominantly in the cytosol; SOD2, in the mitochondrial matrix; and SOD3, in 
the extracellular space.
228
 The localization of SOD2 to the mitochondrial matrix places it in close 
proximity to the ETC, suggesting that this enzyme has an important role in protecting cells from 
the superoxide produced by mitochondrial respiration. The physiological importance of SOD is 
illustrated by the severe pathologies evident in mice genetically engineered to lack these 
enzymes. Mice lacking Sod2 die several days after birth, amid massive oxidative stress.
246
 Mice 
lacking Sod1 develop a wide range of pathologies, including hepatocellular carcinoma, an 
acceleration of age-related muscle mass loss, an earlier incidence of cataracts, and a reduced 
lifespan.
247–251
 Mice lacking Sod3 do not show any obvious defects and exhibit a normal lifespan, 
although they are more sensitive to hyperoxic injury.
252
 All Sod knockout mice are more 
sensitive to the lethal effects of superoxide generating-drugs, such as paraquat and diquat.
253,254
 
In Drosophila, Sod2 knockout has also been shown to severely reduce life span.
255
 Furthermore, 
RNA interference-mediated silencing of Sod2 in fruit flies has been shown to reduce  life span, 
accelerate senescence of locomotor function, and enhance sensitivity to applied oxidative 
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stress.
256–258
 In addition, protein carbonyl and lipid peroxidation, also known to be induced by 
oxidative stress, are significantly increased in Sod2 knockdown rats.
259
 
In this study, we have investigated the impact of Sod2 knockdown by RNA interference on 
protein carbonylation levels using Drosophila melanogaster as a model system. Fruit flies were 
chosen due to their genetic tractability and because the balance of evidence indicates that 
oxidative stress limit their lifespan. Removal of SOD2 would be expected to produce much 
higher steady-state O2
•−
 concentrations in the mitochondrial matrix. In this project, we used 
carbonyl-reactive biotin hydrazide to tag carbonylated proteins. For enrichment of labeled 
proteins, the method developed in chapter II was used (refer to Fig. 2.1). Enriched biotinylated 
proteins were digested off of the beads and the resulting peptides were labeled with iTRAQ 
reagents to allow relative carbonylated protein abundances to be obtained. In this endogenous 
oxidative stress system we were able to collect abundance ratios that were in close agreement 
across full biological replicates. Western blotting experiments using HRP-conjugated 
streptavidin were also performed. Our proteomics and western blotting experiment results were 
in agreement on the aggregate level of protein carbonylation. 
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4. 3. Experimental procedures 
4.3.1. Materials 
Biotin hydrazide, calcium chloride, iodoacetamide, sodium cyanoborohydride, SDS, and 
triethylammonium bicarbonate were purchased from Sigma (St. Louis, MO). Ammonium 
bicarbonate was supplied by J.T. Baker (Phillipsburg, NJ) and DMSO, DTT, and HPLC-grade 
water and methanol were obtained from Fisher Scientific (Pittsburgh, PA). Sequencing-grade 
modified trypsin was from Promega (Madison, WI) and iTRAQ reagent kits were purchased 
from AB SCIEX (Framingham, MA). 
4.3.2. Sod2 knockdown and initial preparation 
Flies were reared to adulthood at 25°C and 55% relative humidity under a 12 hour light–dark 
cycle on a sugar : yeast : cornmeal : agar medium (10% : 2% : 3.3% : 1% w/v) supplemented 
with 0.2% Tegosept (Sigma) and active yeast. Silencing of Sod2 gene expression by RNA 
interference (RNAi) was achieved using the yeast GAL4/UAS system as described by Bhandari 
and coworkers.
258
 Once expressed, GAL4 binds to UAS sequences flanking a Sod2 inverted 
repeat (Sod2IR) transgene, resulting in expression of sense and anti-sense Sod2 cDNA, and 
thereby producing a double-stranded RNA species (via hairpin formation) that elicits RNAi-
mediated knockdown of native Sod2 gene expression. When circa 50% of the Sod2 knockdown 
flies had died, they were frozen at −20°C overnight and then and homogenized in a Dounce 
homogenizer using ice-cold buffer (100 mM sucrose, 100 mM KCl, 50 mM Tris-HCl, 1 mM 
KH2PO4, 0.1 mM EGTA, adjusted to pH 7.3) containing the protease inhibitors aprotinin, 
leupeptin, and pepstatin. Homogenates were centrifuged at 300 × g for 20 min at 4°C to remove 
large debris. Supernatants were stored at −20°C until further processing could be performed. 
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Protein concentrations in the homogenates were determined using the Lowry protein assay (DC 
Protein Assay; Bio-Rad; Hercules, CA). 
4.3.3. Biotinylation of protein carbonyls 
Biotin hydrazide was added to Sod2 knockdown and associated control fly (Gal4 & IR24) 
homogenates (500-µg total protein aliquots) to 5 mM. Samples were then incubated for 1 h at 
room temperature with gentle shaking before SDS was added to 2% (w/v). The labeling reaction 
was allowed to proceed for a further 2 h after a second biotin hydrazide addition had been made. 
Parallel experiments where biotin hydrazide addition was omitted were performed to allow 
assessment of non-specific binding. Hydrazone-bond reduction (thus fixing the label) was 
achieved by adding sodium cyanoborohydride to 15 mM and then incubating at 4°C for 1 h (see 
Fig 2.2.). Samples were then desalted using PD midiTrap G-25 columns (GE Healthcare; 
Piscataway, NJ) and protein concentrations were determined using the bicinchoninic acid (BCA) 
assay (Pierce Biotechnology; Rockford, IL). 
4.3.4. Western blotting for protein carbonyls 
Samples containing equal amounts of protein were separated by SDS-PAGE using Mini-
PROTEAN TGX gels (Bio-Rad, 4-20% gradient) in sample buffer (25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS, pH 8.3) at 100 V. Proteins were transferred to a PVDF membrane in 
transfer buffer (25 mM Tris, 192 mM glycine, 20% MeOH, pH 8.3) at 100 V. The membrane 
was blocked with 5% non-fat dry milk and then incubated with a 1:10000 dilution of HRP-
conjugated streptavidin in 5% BSA in TBS-T buffer (0.1% Tween-20) at 4°C overnight with 
shaking. Next morning, the membrane was washed three times with TBS-T buffer and   
visualization achieved using TMB substrate (Promega). 
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4.3.5. Peptide biotin quantitation assay 
Urea and DTT were added to biotinylated protein samples (and parallel samples where biotin 
hydrazide addition had been omitted) to achieve final concentrations of 8 M and 10 mM, 
respectively. Denaturation and reduction was allowed to proceed for 1 h at 37°C. Cysteines were 
capped by adding iodoacetamide to 55 mM and then continuing incubation at room temperature 
in the dark for 1 h. Samples were prepared for digestion by diluting 10-fold in PBS and then 
adding calcium chloride to 1 mM and trypsin to achieve a circa 1:50 trypsin: protein ratio. 
Digestion was allowed to proceed for 16 h at 37°C and then terminated by acidification with 
10% (v/v) TFA (aq). The resulting peptide solutions were desalted using RP, C18 SPE cartridges 
(Sep-Pak; Waters; Milford, MA) and then dried by centrifugal evaporation. To determine 
aggregate biotinylation levels, the amount of peptide-bound biotin was measured using a biotin 
quantitation kit (Pierce Biotechnology), based on the displacement of 4’-hydroxyazobenzene-2-
carboxylic acid (HABA) from avidin, as recommended by the manufacturer. 
4.3.6. Enrichment of biotinylated proteins and on-bead tryptic 
digestion 
Biotinylated protein samples were added to streptavidin UltraLink resin (Pierce Biotechnology), 
which had previously been washed three times with PBS, and incubated at room temperature 
overnight. Unbound proteins were removed by washing the resin three times with PBS followed 
by washing once with 8 M urea and 10 mM DTT in PBS. Bound proteins were denatured and 
reduced by incubating with 8 M urea and 10 mM DTT in PBS for 1 h at 37°C. Cysteines were 
then alkylated by adding iodoacetamide to 55 mM and continuing the incubation for a further 1 h 
at room temperature in the dark. Excess reagents were removed prior to digestion by washing 
three times with 50 mM ammonium bicarbonate (aq). Digestion with trypsin (1:50, trypsin: 
88 
  
protein ratio; calcium chloride added to 1 mM) was allowed to proceed for 16 h at 37°C before 
being terminated by acidification with 10% (v/v) TFA (aq). Peptides were recovered by 
extensive washing of the beads with 50 mM ammonium bicarbonate (aq) followed by SPE (same 
method as biotin quantitation assay) and centrifugal evaporation. 
4.3.7. iTRAQ labeling of peptides 
Labeling with the iTRAQ reagent proceeded as described in mentioned in Chapter 2 (see section 
2.3.7). Prior to labeling, entire dried peptide samples were dissolved in 30 µL of iTRAQ 
dissolution buffer (0.5 M triethylammonium bicarbonate, pH 8.5). For this study, where two 
controls (Gal4 & IR24) were used, three iTRAQ reagents were required. After allowing the 
labeling reaction to proceed for 2 h at room temperature, samples to be compared were combined 
and then dried in a centrifugal evaporator. Prior to LC–MS/MS analysis, the combined peptide 
samples were suspended in 20 µL of 0.1% formic acid (aq). 
4.3.8. LC–MS/MS 
Combined, iTRAQ-labeled samples were analyzed using an LTQ Orbitrap Velos mass 
spectrometer (Thermo Scientific; Waltham, MA) interfaced with a Waters nanoACQUITY 
UPLC system. The injection volume in each case was 2 µL, with a nanoACQUITY trapping 
column being used to reduce loading time. Labeled peptides were separated with a RP, C18 
nanoACQUITY capillary analytical column (1.7 µm particles, 100 µm × 100 mm). Elution was 
achieved using a gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in 
water (A) at a flow rate of 0.4 µL min
−1
. Beginning with an equilibration mobile phase of 1% B, 
the linear gradient initially ran to 15% B over 25 min, then to 25% B over 35 min, then to 35% B 
over 40 min, and finally to 85% B over 20 min. Eluting peptides flowed into a nano-scale ESI 
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source that was operated at 3.5 kV. Full scan mass spectra (m/z = 400–2000), which were 
collected at 60,000 resolution in the Orbitrap, were followed by ten data-dependent MS/MS 
spectra, using higher-energy C-trap dissociation (HCD) to access iTRAQ reporter ions. HCD 
parameters included normalized collision energy set to 40 and activation time at 0.1 ms. Ions 
selected twice for fragmentation within a 30 s window were excluded for 180 s. 
4.3.9. Data processing and analysis 
Peptides were identified using the X! Tandem code fork included with version 4.6.3 of the 
Trans-Proteomic Pipeline (TPP) software package (Institute for Systems Biology; Seattle, WA). 
The protein sequence database used was generated from the whole D. melanogaster proteome 
(FlyBase version R5.35, FB2011_03; 23361 proteins), 112 common contaminant proteins 
(Global Proteome Machine; Common Repository of Adventitious Proteins; downloaded on April 
8, 2011), and reversed versions of these sequences included for false positive rate estimation. 
Search parameters included a precursor ion mass tolerance of ±15 ppm, a requirement for at least 
one trypsin-conforming peptide terminus, and a maximum of one missed cleavage. Fixed mass 
shifts were applied for alkylation with iodoacetamide at cysteine (+57.021464 Da) and addition 
of 4-plex iTRAQ labels at lysine and the peptide N-terminus (+144.102063 Da). Differential 
mass shifts were included for methionine sulfoxide (+15.994915 Da) and for the 4-plex iTRAQ 
reagents at tyrosine. PeptideProphet,
173
 a component of the TPP software package, was used to 
filter identifications proposed by X! Tandem, with peptide-spectrum matches (PSMs) scoring 
≥ 0.9 being accepted. The PSM false positive rate was estimated as described by Elias and Gygi 
(2 × decoy PSM count/total accepted PSM count).
174
 PSMs were organized into protein groups 
defined by parent gene, rejecting PSMs that indicated more than one gene. Relative abundance 
ratios were calculated for each PSM having no missing reporter ions and then combined to 
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produce consensus values for each gene-based protein group by calculating the geometric mean. 
These ratios were corrected independently for each preparation using the ratio observed for 
trypsin autolysis peptides. Only groups supported by at least five measurements were accepted. 
4. 4. Results & Discussion 
4.4.1. Effect of Sod2 knockdown in Drosophila melanogaster 
Sod2, Sod1, catalase, and glutathione peroxidase are conserved between flies and humans, thus 
making Drosophila a good model system for studies of antioxidant function.
260
 Increased 
concentration of antioxidant enzymes have been shown to result in extension of on lifespan in 
Drosophila.
261,262
 Although overexpression of Sod2 during both development and adulthood does 
not extend lifespan in Drosophila , an extension of mean lifespan by 33% in has been reported 
when this enzyme is overexpressed only during adulthood.
263
 Overexpression of Sod1 alone or 
Sod1 and catalase also extends lifespan in Drosophila.
264
 Mice having a 50% decrease in Sod2 
activity show an increase in oxidative damage and acceleration in Alzheimer's disease-like 
pathology.
265
 Clearly, antioxidant enzymes are very important in protecting against oxidative 
stress. Flies were reared and the required genetic manipulations were performed by members of 
the Grotewiel lab in the VCU Department of Human and Molecular Genetics. RNA interference 
(RNAi) Sod2 knockdown in Drosophila, which was achieved using GAL4 driver to ubiquitously 
express the upstream activator sequence-Sod2-inverted repeat (UAS-Sod2-IR) transgene, 
resulted in a substantial reduction in SOD2 concentration, shortened lifespan, and mitochondrial 
dysfunction consistent with oxidative damage.  Recent work has confirmed that ubiquitous 
GAL4-driven expression of Sod2 knockdown results in decreased lifespan in both males and 
female flies.
266
 In contrast UAS-Sod2-IR expression localized to the Drosophila nervous system 
has only a modest effect on locomotor function and life span. In a similar manner to ubiquitous 
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expression of the Gal4 driver, Sod2 knockdown in the musculature severely curtails lifespan and 
results in accelerated age-related locomotor functional decline in D.melanogaster.
267
 These 
findings clearly indicate the important role that antioxidant enzymes play and provide useful 
insights into the fundamental nature of oxidative stress. Since correlation between protein 
carbonylation and Sod2 knockdown in D. melanogaster has not been established, we investigated 
the system using the methods described in Chapter 2. 
4.4.2 Carbonylated proteins visualization by western blotting 
Streptavidin conjugated poly-HRP was employed to detect biotin-labeled carbonylated proteins 
in Sod2 knockdown and control preparations. Detection is based on the highly specific 
interaction between streptavidin and biotin. Biotin-labeled da-Gal4 driver and UAS-Sod2-IR24 
transgene alone controls along with the Sod2 knockdown sample were subjected to SDS-PAGE 
followed by western blotting. Multiple biotinylated proteins were detected in both of the controls 
and in the Sod2 knockdown samples. An additional gel that was run in parallel to the one used 
for western blotting was Coomassie-stained and is presented as Fig. 4.1. This gel indicates that 
losses of higher mass proteins from all samples might have occurred, but the dynamic range of 
such gels is narrow. The western blotting results, which are displayed as Fig. 4.2, show the same 
intense bands in all three samples and indicate similar levels of protein carbonylation in the Sod2 
knockdown flies when compared with the controls. While we expected a higher level of protein 
carbonylation in Sod2 knockdown flies versus controls, we observed only subtle changes in 
oxidation levels, with background carbonylation in control flies being surprisingly extensive. 
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Figure 4.1. Coomassie-stained SDS-PAGE gel for biotin hydrazide-labeled protein preparations 
from RNA interference Sod2 knockdown (Sod2), da-Gal4 (Gal4) driver-alone control, and UAS-
Sod2-IR24 (IR24) transgene-alone control flies. 
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Figure 4.2. HRP-conjugated streptavidin western blot for biotin hydrazide-labeled protein 
preparations from RNA interference Sod2 knockdown (Sod2), da-Gal4 (Gal4) driver-alone 
control and UAS-Sod2-IR24 (IR24) transgene-alone control flies.     
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4.4.3 Mass spectrometry quantitation of Sod2 knockdown-induced 
changes in protein carbonylation 
Higher protein carbonylation levels were expected for the Sod2 knockdown system. As with 
Paraquat exposure, three replicate LC–MS/MS runs were collected for each of three full repeat 
experiments. Applying a PeptideProphet score acceptance threshold of 0.9, 27910 PSMs were 
obtained, of which 23 were hits to decoy proteins (implying a PSM false positive rate of 0.16%). 
A non-specific binding experiment has been carried out as described in Chapter 2 (refer section 
2.4.5.). Rejecting the non-specifically bound proteins, 276 gene-based protein groups were 
obtained. The whole set is presented with repeat runs combined as Appendix Table A6 and with 
repeat preparations separated as Appendix Table A7. The Sod2 knockdown experiments used 
two different controls: the da-Gal4 driver alone and the UAS-Sod2-IR24 transgene alone. 
Comparing reporter ion ratios between these controls provides a measure of experimental 
precision. Over 24473 measurements (PSMs with a complete set of reporter ions that indicate D. 
melanogaster proteins), the average (geometric mean) da-Gal4 driver alone to UAS-Sod2-IR24 
transgene alone control ratio was 0.92, with a two standard deviation range of 0.61 to 1.40. Thus, 
adding uncertainty due to non-specific binding, it seems sensible to only consider a doubling or 
halving of relative abundance as significant in this work. Using DAVID on the whole set of 276 
carbonylated proteins, results are similar to Paraquat exposure (lipid particle remains the most 
significant term) with the interesting exception of an increase in significance for the ribosome 
Gene Ontology cellular component classification (GO:0005840; 51 proteins/p = 5.73 × 10
−27
). 
Figure 4.3 displays the distribution of carbonylation ratios for Sod2 knockdowns compared to the   
da-Gal4 driver alone and the UAS-Sod2-IR24 transgene alone control ratios.  
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Figure 4.3. Distribution of relative abundance ratios obtained when an MS-based proteomics 
approach was used to measure changes in carbonylated protein levels in response to Sod2 
knockdown in D. melanogaster.  
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In contrast to expectations, Sod2 knockdown produces little or no increase in global protein 
carbonylation levels. Conceivably, this absence of extensive carbonylation could be due to the 
organism’s response to changes in SOD2 concentration or may be due to residual enzyme 
activity. The median relative abundance ratios are 1.13 (versus da-Gal4 driver alone control) and 
1.05 (versus UAS-Sod2-IR24 transgene alone control) and both distributions are similar. Against 
the da-Gal4 driver alone control, three proteins are observed to exceed a doubling in relative 
abundance on Sod2 knockdown; for the UAS-Sod2-IR24 transgene alone control, four proteins 
exceed this threshold. Two proteins exceed doubling in abundance in both control comparisons: 
FBgn0036766 (CG5506) and FBgn0031830 (CG11015). While little information is available for 
FBgn0036766 (protein BLAST provides no functional annotation), FBgn0031830 has been 
annotated as cytochrome c oxidase subunit Vb.  
Considering the complete set of 279 gene-based carbonylated protein groups identified in the 
three Sod2 knockdown repeats, a broadly similar picture is expected to that for Paraquat 
exposure (since the whole set effectively provides a list of background carbonylated proteins). 
Using MitoDrome, FlyBase, and DAVID annotations, 90 of 279 genes were associated with 
mitochondria. Fig. 4.5 provides details of the distribution of these mitochondrial proteins using 
MitoDrome functional classifications. Clearly, the pattern for Sod2 knockdown is very similar to 
that for Paraquat exposure. Considering the mitochondrial ETC complexes, seventeen, one, 
eight, seven, and eleven genes associated with Complex I, II, III, IV, and ATP synthase, 
respectively. Similarly, thirteen genes were associated with the citric acid cycle and two with cell 
rescue, defense, and death (both antioxidant enzymes). In summary Sod2 knockdown does not 
result in widespread increases in carbonylation levels, but does lead to increased carbonylation 
for a small number of proteins. 
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Figure 4.4. Distribution of MitoDrome functional classifications for the entire sets of identified 
carbonylated mitochondrial proteins from Sod2 knockdown experiments. 
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4.4.4 Effect of Sod2 knockdown on cytochrome c oxidase subunit Vb 
Cytochrome c oxidase is the terminal enzyme complex of the mitochondrial electron transport 
chain and catalyzes electron transfer from cytochrome c to molecular oxygen. The mammalian 
form of this enzyme complex has thirteen subunits, of which three subunits are mitochondrially-
encoded components of the catalytic core (the remaining ten are nuclear-encoded). Sohal et al. 
and Ferguson et al. both reported that age-related declines in cytochrome c oxidase activity in 
house flies and D. melanogaster were especially pronounced when compared with other electron 
transport chain components.
268,269
 Sod2-null flies were shown to have high sensitivity to 
oxidative stress, neurodegeneration, DNA strand breakage, and severely reduced lifespan.
256
 
While Sod2 knockdown results in reduced adult lifespan in D. melanogaster, Wicks et al. have 
reported that hypoxia (5% oxygen) can restore normal lifespan.
270
 In this work, using the biotin 
labeling and streptavidin enrichment strategy, carbonylated cytochrome c oxidase subunit Vb 
was found to more than double in concentration in the Sod2 knockdown. This nuclear-encoded 
subunit is necessary for proper regulation and assembly of the complex. Subunit Vb knockouts 
have been shown to lead to reduced complex IV activity and increased ROS production.
271
 
Furthermore, using a proteomics approach, reductions in cytochrome c oxidase subunit Vb 
concentration have been shown to result into reduced Complex IV activity in mitochondria 
obtained from cancer patients.
272
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Figure 4.5. MS/MS spectrum associated with the identification of cytochrome c oxidase subunit 
Vb peptide ENPNLIPSAFDAR.  
The inset shows the region of the spectrum containing the iTRAQ reporter ions: the peak at 114 
represents the da-Gal4 driver alone control, 115 the UAS-Sod2-IR24 transgene alone control and 
116 the Sod2 knockdown sample (117 was not used but some intensity is observed due to 
impurities in the other reporter ions). The observed relative abundance ratio for cytochrome c 
oxidase subunit Vb on Sod2 knockdown is 2.39 versus the da-Gal4 driver alone and 2.26 versus 
the UAS-Sod2-IR24 transgene alone control. The protein group defined by FBgn0031830 
contains a single protein, FBpp0078918, which is supported by a single peptide (35 detections) 
with sequence, ENPNLIPSAFDAR. Since the significance of cytochrome c oxidase subunit Vb 
rests on a single peptide, the MS/MS spectrum is provided as Figure 4..5. Identification is 
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supported by clear, unbroken runs of singly charged b- and y-ions (six consecutive b- and twelve 
consecutive y-ions) in combination with few prominent, unexplained peaks.  
             
             
             
             
             
             
             
             
             
Fig 4.6. Schematic sketch of the topography of constituent subunits of cytochrome c oxidase.
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The X-ray crystallography-derived structure of Complex IV shows that cytochrome c oxidase 
(CcO) subunit Vb is an extra-membrane subunit located on the matrix side of the complex with 
its C-terminus in direct contact with CcO subunit I and its N-terminus in direct contact with CcO 
subunit II.
274
 CcO subunit Vb facilitates the assembly of the holoprotein, enhances the binding 
affinity of subunit II for cytochrome c, and interacts with the regulatory subunit of protein kinase 
A, which modulates CcO activity by a cAMP-dependent mechanism.
275
 Interestingly, 
overexpression of CcO subunits IV or Vb have been shown to elevate CcO holoenzyme activity 
in cultured cell lines.
276
 The localization of the CcO subunit Vb was consistent with the 
expectation that Sod2 knockdown would only increase O2
•−
 concentrations in the mitochondrial 
matrix. The increased concentration of carbonylated CcO subunit Vb could conceivably be due 
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to close proximity to a site of superoxide leakage from Complex IV.  A recent report suggests 
that successful engineering of CcO activity can be achieved through manipulation of  subunit Vb 
and provides experimental support for the development of strategies to further identify electron 
transport chain components that limit mitochondrial function and that can restore respiratory 
capacity during disease or old age.
277
 Thus, the association between increased concentrations of 
carbonylated CcO subunit Vb and Sod2 knockdown is clearly worthy of further investigation. 
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4.5 Conclusion 
In conclusion, oxidative stress induced by Sod2 knockdown was studied in D. melanogaster 
using protein carbonylation as a biomarker of oxidative damage. Despite being an acute 
phenotype, Sod2 knockdown resulted in a little or no increase in aggregate carbonylated protein 
relative abundance. However, significant changes in concentration were observed for some 
carbonylated proteins. The two proteins that were most prominently carbonylated clearly have 
the potential to offer insights into aspects of the O2
•−
 generation process and the Sod2 
knockdown phenotype. Unfortunately, limited information is available for one of these proteins, 
but for the other, cytochrome c oxidase subunit Vb, data exist supporting a role in aging and age-
related disease. Further research targeting these proteins could advance our understanding of the 
role of SOD2 and the mechanistic underpinnings of age-related disorders associated with 
mitochondrial dysfunction. 
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CHAPTER 5 
 
 
 
 
Preliminary study of the effects of traumatic injury on 
the human plasma carbonylated protein proteome 
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5.1. Abstract 
Discovery proteomics approaches that aim to identify biomarkers or signaling pathways 
associated with human diseases have gained much attention in recent years. Due to the 
minimally invasive nature of collecting blood, plasma proteomics has become a common means 
of studying the entire human proteome, even though cellular proteins leaking into the circulatory 
system are present at very low concentrations. In this present study, we analyzed the 
carbonylated protein proteome at multiple time points in the blood of patients that had endured 
traumatic injuries. Initially, western blotting methods were used to study protein carbonylation. 
Labeling of carbonylated proteins was achieved using biotin hydrazide and for mass 
spectrometry-based proteomics, enrichment was carried out using a streptavidin bead-
immobilization technique. The iTRAQ approach was used to obtain carbonylated protein relative 
abundance ratios. In the first sets of samples, we quantified 16 carbonylated proteins in patient A 
and 25 in patient B using the on-bead digestion approach. For both patients, we could quantify 
temporal changes in carbonylation levels. Because plasma proteomics is hampered by the 
presence high-abundance proteins, numerous approaches have been developed to deplete high-
abundance proteins and thus increase proteome coverage. For two additional sets of samples, we 
evaluated the ProteoMiner high-abundance protein depletion system. Using this strategy, we 
successfully quantified a greater number of carbonylated proteins (48 and 38 for patients C and 
D, respectively), thus increasing proteome coverage. 
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5. 2. Introduction 
Each year, traumatic injury accounts for 41 million emergency room visits and 2.3 million 
hospital admissions in the United States; furthermore, trauma is estimated to be responsible for 
30% of all potential life years lost.
278
 Severe blunt trauma produces significant changes in 
leukocyte mRNA levels, corresponding to changes in expression for >80% of human genes.
279
 
Thus, the early leukocyte genomic response involves simultaneously increasing expression of 
genes involved in the systemic inflammatory, innate immune, and compensatory anti-
inflammatory responses, as well as with suppressing genes involved in adaptive immunity.
280
 
Downstream, significant changes in the proteome offer insight into the progression of wound 
healing and into the likelihood of positive outcomes in trauma patients.
281
 Analyzing the plasma 
proteome can potentially provide direct information about the somatic response to trauma, with 
post-translational modifications expected to be an important part of this response. Mass 
spectrometry-based proteomics approaches have recently been used to study the effect of serious 
burns on the proteome.
282,283
 Multiple comprehensive analyses of the trauma patient plasma 
proteome have resulted in the identification of over 3000 proteins, as part of the trauma 
proteome.
284
 
Overwhelming evidence suggests that trauma is associated with increased oxidative stress 
resulting from the inflammatory immune response, which can be especially severe during sepsis 
and acute respiratory distress syndrome.
285–288
 Increased oxidative stress is the consequence of 
increased reactive oxygen species (ROS) concentrations, due either to raised ROS production or 
the depletion of endogenous antioxidants. ROS production pathways mainly originate with the 
release of superoxide (O2
•−
) from the mitochondrial ETC complexes, from NADPH oxidase, and 
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release of redox active transition metals, such as iron and copper, from enzymes.
289
  Oxidative 
stress can lead to many changes in protein behavior. For example, some modifications have been 
shown to impact the coagulation process.
290,291
 Of the many possible oxidative protein 
modifications, protein carbonylation stands out due to being present at relatively high 
concentrations and being suitable for derivitization with affinity tags, thus enabling enrichment 
strategies. As discussed in earlier chapters, protein carbonylation refers to the introduction of a 
reactive carbonyl moiety, either an aldehyde or a ketone functional group, into the protein 
structure. The side chains of the amino acids lysine, arginine, threonine, and proline are most 
prone to direct carbonylation by ROS, while those of cysteine, histidine, and lysine are 
particularly vulnerable to the addition of α,β-unsaturated aldehydes that are among the end 
products of lipid peroxidation. Initial mass spectrometric analyses of samples obtained from 32–
36-year-old human male subjects have shown that numerous oxidized proteins from a wide 
variety of cell types and organs are shed or released into plasma.
292
 Furthermore, in breast cancer 
patients, more than 450 carbonylated proteins have been quantified in plasma.
202
 Butterfield and 
co-workers have also demonstrated that carbonylation related to Alzheimer’s disease can be 
detected in plasma samples.
293
 Plasma protein carbonylation has also been studied in chronic 
uremia and obesity-induced type 2 diabetes mellitus.
294,295
  
In this study, we used the affinity-enrichment strategy detailed in Chapter 2 to study protein 
carbonylation in plasma and serum samples obtained from patients who had suffered severe 
traumatic injuries. First, a series of serum samples from two patients were directly analyzed 
using mass spectrometry-based and western blotting methods. Second, two additional series of 
patient samples were subjected to high-abundance protein depletion prior to the usual sample 
preparation. In recent years, immunoaffinity-based high-abundance protein depletion and related 
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methods have become available and offer the ability to relatively enrich the lower abundance 
proteins, thus greatly expanding the scope of the protein characterization.  This has been 
demonstrated in many studies.
283,284,296
 We used the ProteoMiner (Bio-Rad) system, which is 
described schematically in Fig. 5.1. Briefly, ProteoMiner is designed to provide an equal number 
of binding sites for each protein. Low-abundance proteins will not saturate their binding sites, 
while high-abundance proteins will mostly pass through the cartridge since all available binding 
sites will quickly become occupied; thus, an effective relative enrichment of low-abundance 
proteins is achieved. The iTRAQ approach was used to compare relative carbonylated protein 
abundances between samples collected at different time points (consecutive days). More 
carbonylated proteins were quantified when using the ProteoMiner approach than when 
following the direct analysis procedure used for the first group of sample sets. 
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5. 3. Experimental procedures 
5.3.1. Materials 
Biotin hydrazide, calcium chloride, iodoacetamide, sodium cyanoborohydride, SDS, and 
triethylammonium bicarbonate were purchased from Sigma (St. Louis, MO). ProteoMiner low-
abundance protein enrichment kits were obtained from Bio-Rad (Hercules, CA).  Ammonium 
bicarbonate was supplied by J.T. Baker (Phillipsburg, NJ) and DMSO, DTT, and HPLC-grade 
water and methanol were obtained from Fisher Scientific (Pittsburgh, PA). Sequencing-grade 
modified trypsin was from Promega (Madison, WI) and iTRAQ reagent kits were purchased 
from AB SCIEX (Framingham, MA). 
5.3.2. Blood serum and plasma preparation 
The human blood serum and plasma used in this study were prepared under the direction of Dr. 
Martin Manjino from the Department of Surgery, Medical College of Virginia, Virginia 
Commonwealth University. Blood samples from trauma patients A and B were collected daily, 
post-operation, from Day 1 to Day 8 and from Day 0 to Day 5, respectively [based on labels in 
Figure 5.2]. Blood serum is blood plasma that has undergone clotting to precipitate most 
fibrinogen. Blood samples were collected in 4.5 mL Vacutainer tubes (Becton Dickinson, 
Franklin Lakes, NJ). Tubes were inverted to mix the contents well and then the blood was 
allowed to clot at room temperature for 30 minutes. Cells and the clot were subsequently 
removed by centrifuging at 1,000-2,000 × g for 10 minutes in a refrigerated centrifuge at 4°C. 
The supernatant was collected in polypropylene tubes and stored at −80°C.  Blood was collected 
from patient C daily from Day 1 to Day 7 and from patient D daily from Day 1 to Day 4 and then 
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on Day 7 and Day 11 [collection days from Figure 5.3] for plasma work in 4.5 mL Vacutainer 
tubes containing 3.2% sodium citrate buffer. Cells were removed from the plasma by 
centrifugation for 10 minutes at 1,000-2,000 × g using a refrigerated centrifuge at 4°C. 
Supernatant was collected in polypropylene tubes and stored at −80°C. 
5.3.3. Biotinylation of protein carbonyls 
Plasma and serum samples were removed from storage at −80°C and thawed in an ice bath for 30 
minutes. Biotin hydrazide was added to plasma and serum samples (roughly 3500-µg total 
protein aliquots) to 5 mM. Samples were then incubated for 1 h at room temperature with gentle 
shaking before SDS was added to 1% (w/v). The labeling reaction was allowed to proceed for a 
further 2 h after a second biotin hydrazide addition had been made. Hydrazone-bond reduction 
(thus fixing the label) was achieved by adding sodium cyanoborohydride to 15 mM and then 
incubating at 4°C for 1 h. Following the labeling procedure, the proteins were precipitated with 
10% trichloroacetic acid in an ice bath for 1 h, thus allowing excess reagents to be removed with  
the supernatant. Protein pellets were washed three times with ice cold acetone and then dissolved 
in PBS buffer. 
5.3.4. Western blotting for protein carbonyls 
Samples containing equal amounts of protein (measured by BCA assay)  were separated using 
Mini-PROTEAN TGX gels (Bio-Rad, 4-20% gradient) in sample buffer (25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS, pH 8.3) at 100 V. Proteins were transferred to a PVDF membrane in 
transfer buffer (25 mM Tris, 192 mM glycine, 20% MeOH, pH 8.3) at 100V. The membrane was 
blocked with 5% non-fat dry milk and then incubated with a 1:10000 dilution of HRP-conjugated 
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streptavidin in 5% BSA in TBS-T buffer (TBS buffer with 0.1% Tween-20) at 4°C overnight 
with shaking. Next morning, the membrane was washed three times with TBS-T buffer and 
visualization was then achieved using TMB substrate (Promega). 
5.3.5. ProteoMiner affinity ligand depletion of high-abundance 
proteins 
Plasma samples from patients C and D were subjected to ProteoMiner affinity ligand-based 
depletion of highly abundant proteins. The ProteoMiner protocol began with pre-washing 
ProteoMiner small-capacity spin columns with PBS. 10 mg of plasma proteins were then loaded 
and incubated to promote binding for 2 hours at room temperature. Excess unbound material was 
eluted by passing wash buffer (PBS) through the column three times. Bound proteins were 
subsequently obtained by passing 20 µL elution reagent (8M Urea, 2% CHAPS) through the 
column for three times (60 µL total). Protein biotinylation, reduction, and precipitation were then 
performed as described above. 
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Figure 5.1. Schematic diagram of ProteoMiner work flow 
5.3.6. Enrichment of biotinylated proteins and on-bead tryptic 
digestion 
Biotinylated serum and affinity-depleted plasma samples were added to streptavidin UltraLink 
resin (Pierce Biotechnology), which had previously been washed three times with PBS, and 
incubated at room temperature overnight. Unbound proteins were removed by washing the resin 
three times with PBS followed by washing once with 8 M urea and 10 mM DTT in PBS. Bound 
proteins were denatured and reduced by incubating with 8 M urea and 10 mM DTT in PBS for 
1 h at 37°C. Cysteines were then alkylated by adding iodoacetamide to 55 mM and continuing 
the incubation for a further 1 h at room temperature in the dark. Excess reagents were removed 
prior to digestion by washing three times with 50 mM ammonium bicarbonate (aq). Digestion 
with trypsin (1:50, trypsin: protein ratio; calcium chloride added to 1 mM) was allowed to 
proceed for 16 h at 37°C before being terminated by acidification with 10% (v/v) TFA (aq). 
Peptides were recovered by extensive washing of the beads with 50 mM ammonium bicarbonate 
(aq) followed by SPE using reversed-phase, C18 cartridges as described in Chapter 2) and 
centrifugal evaporation. 
5.3.7. iTRAQ labeling of peptides 
Labeling with the iTRAQ reagents proceeded as described in Chapter 2 (Section 2.3.7). iTRAQ 
8-plex reagents were used in this study. Prior to labeling, entire dried peptide samples were 
dissolved in 30 µL of iTRAQ dissolution buffer (0.5 M triethylammonium bicarbonate, pH 8.5). 
After allowing the labeling reaction to proceed for 2 h at room temperature, samples to be 
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compared were combined and then dried in a centrifugal evaporator. Prior to LC–MS/MS 
analysis, the combined peptide samples were suspended in 20 µL of 0.1% formic acid (aq). 
5.3.8. LC–MS/MS 
Combined, iTRAQ-labeled samples were analyzed using an LTQ Orbitrap Velos mass 
spectrometer (Thermo Scientific; Waltham, MA) interfaced with a Waters nanoACQUITY 
UPLC system. The injection volume in each case was 2 µL, with a nanoACQUITY trapping 
column being used to reduce loading time. Labeled peptides were separated with a RP, C18 
nanoACQUITY capillary analytical column (1.7 µm particles, 100 µm × 100 mm). Elution was 
achieved using a gradient of 0.1% formic acid in acetonitrile (B) versus 0.1% formic acid in 
water (A) at a flow rate of 0.4 µL min
−1
. Beginning with an equilibration mobile phase of 1% B, 
the linear gradient initially ran to 15% B over 25 min, then to 25% B over 35 min, then to 35% B 
over 40 min, and finally to 85% B over 20 min. Eluting peptides flowed into a nano-scale ESI 
source that was operated at 3.5 kV. Full scan mass spectra (m/z = 400–2000), which were 
collected at 60,000 resolution in the Orbitrap, were followed by ten data-dependent MS/MS 
spectra, using higher-energy C-trap dissociation (HCD) to access iTRAQ reporter ions. HCD 
parameters included normalized collision energy set to 40 and activation time at 0.1 ms. Ions 
selected twice for fragmentation within a 30 s window were excluded for 180 s. 
5.3.9. Data processing and analysis 
Peptides were identified using the X! Tandem code fork included with version 4.6.3 of the 
Trans-Proteomic Pipeline (TPP) software package (Institute for Systems Biology; Seattle, WA). 
The protein sequence database used was generated from the whole human proteome                      
113 
  
(NCBI RefSeq version, 35788 proteins), 115 common contaminant proteins (Global Proteome 
Machine; Common Repository of Adventitious Proteins; downloaded on January 15, 2013), and 
reversed versions of these sequences included for false positive rate estimation. Search 
parameters included a precursor ion mass tolerance of ±15 ppm, a requirement for at least one 
trypsin-conforming peptide terminus, and a maximum of one missed cleavage. Fixed mass shifts 
were applied for alkylation with iodoacetamide at cysteine (+57.021464 Da) and addition of 8-
plex iTRAQ labels at lysine and the peptide N-terminus (+304.205360 Da). Differential mass 
shifts were included for methionine sulfoxide (+15.994915 Da). PeptideProphet,
173
 a component 
of the TPP software package, was used to filter identifications proposed by X! Tandem, with 
peptide-spectrum matches (PSMs) scoring ≥ 0.9 being accepted. The PSM false positive rate was 
estimated as described by Elias and Gygi (2 × decoy PSM count/total accepted PSM count). 
Relative abundance ratios were taken as provided in the ProteinProphet output.
174
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5. 4. Results and discussion 
5.4.1. Western blotting-analysis of carbonylated proteins in 
serum/plasma 
Protein carbonyl content is the most general indicator and by far the most commonly used 
biomarker for protein oxidation.
80
 Protein carbonyls are much more stable than other potential 
biomarkers, such as lipid peroxidation products, which is clearly an important advantage.
297
 
Protein carbonyls are reportedly stable in serum for at least four hours.
298
 Therefore, the 
quantification of protein carbonyls can be used to measure the extent of oxidative modification 
on a day-to-day basis. That is, measurements will reflect the previous few hours rather than 
cumulative damage over many days. Recently a number of sensitive biochemical approaches, 
including spectrophotometric, fluorometric, and immunological methods (western blot, enzyme-
linked immunosorbent assay (ELISA)), have been developed for the detection of protein 
carbonylation in human tissues and body fluids.
80
 Here, streptavidin conjugated poly-HRP was 
employed to detect biotin-labeled carbonylated proteins. Detection is based on the highly 
specific interaction between streptavidin and biotin. Biotin-labeled serum samples collected at 
various time points from patients A and B were subjected to SDS-PAGE followed by western 
blotting. Multiple biotinylated proteins were detected in both sets of serum samples. The western 
blotting results, which are displayed as Fig. 5.2, show numerous intense carbonylated protein 
bands across all the lanes. Though, Lanes 2 and 5 for patient A, and Lane 0 for trauma patient B, 
all show unique oxidation patterns, more repeats were needed to prove the changes or it may be 
due to sampling error too. Carbonylated protein western blots for the depleted plasma protein 
obtained from patients C and D are displayed in Fig. 5.3 and show some differences in 
carbonylation between the various lanes. 
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Figure 5.2. HRP-conjugated streptavidin indicate the day count western blot analyses for time 
series samples from trauma patient A and B serum samples.  
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Figure 5.3. HRP-conjugated streptavidin indicate the day count western blot analyses for time 
series samples from trauma patient C and D plasma samples.  
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5.4.2. iTRAQ quantitation of carbonylated proteins in serum from 
patients A and B 
The effectiveness of mass spectrometry-based proteomics methods in the study of serum/plasma 
proteins has been demonstrated in numerous studies, including some related to trauma.
15,26,27
 Our 
hypothesis here is that in the days following a traumatic injury, blood protein oxidation states 
will offer a broad set of easily accessible and reliable markers of the progression of the healing 
process. Preliminary work has been performed with serum sample sets from two patients (A and 
B) in order to gain knowledge about trauma-related protein carbonylation and its quantification. 
A number of studies have been presented that associated increased levels of protein 
carbonylation and lipid peroxidation with life-threatening diseases and severe blunt trauma. Our 
long term goal here is to apply our carbonylated protein-enrichment strategies that were 
described in Chapters 2 and 4 to trauma patient serum samples and attempt to discover 
biomarkers for oxidative injury in the blood samples. For patients A and B, three replicate 
LC/MS/MS runs were collected (the time point samples for each patient were combined after 
iTRAQ labeling, thus resulting in a single sample) . Applying a PeptideProphet score acceptance 
threshold of 0.9, 832 PSMs and 2244 PSMs were obtained for patients A and B, respectively, of 
which 2 and 3 were hits to decoy proteins (implying a PSM false positive rate of 0.5% for A and 
0.3% for B). Rejecting the decoy proteins, a total of 23 and 37 carbonylated proteins were 
detected for patients A and B, respectively. The whole sets are presented as Appendix Table A8 
and A9. Careful analysis of these datasets indicated that acute phase proteins such as 
complement proteins, alpha-1 antitrypsin, serotransferrin and serum amyloid protein often 
showed changes in carbonylation through the time series, which is consistent with an 
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inflammation response. Histograms of serum protein carbonylation levels for patients A and B 
are shown in Figure. 5.4 and Figure 5.5 respectively. 
 
 
Figure 5.4. Patient A serum protein carbonylation levels for the ten most frequently-detected 
proteins. Data are normalized to Day 1. 
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Figure 5.5. Patient B serum protein carbonylation levels for the ten most frequently-detected 
proteins. Data are normalized to Day 1. 
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5.4.3. ProteoMiner depletion and iTRAQ quantitation of 
carbonylated proteins in plasma from patients C and D 
One of the challenges inherent in the analysis of blood plasma and serum is the difficulty of 
detecting low-abundance proteins in the presence of highly abundant proteins such as albumin, 
which is present at tens of µg/µL. In bottom-up mass spectrometry-based proteomic analyses, 
peptides from high-abundance proteins can overshadow those from low-abundance proteins, 
potentially excluding important proteins from the datasets. Since the number of interfering high-
abundance proteins is relatively small, immunoaffinity-based depletion strategies for plasma and 
serum samples have become important.
283,284,299
 Most depletion approaches use immobilized 
antibodies to target a relatively small number of high-abundance proteins; however, the 
ProteoMiner technology used in this work is conceptually different, attempting to impose a 
maximum copy number for each protein present in a sample. ProteoMiner uses hexapeptide 
ligand libraries to mimic the paratrope region of antibodies. If hexapeptide ligands are present 
for every possible sequence (20
6
 peptides) , binding sites for most proteins will be present. Since 
an approximately equal number of copies of each binding site are present, abundant proteins will 
quickly saturate their ligands; thus, high proportions of low-abundance and low proportions of 
high-abundance proteins will be retained, resulting in a relative enrichment of low-abundance 
proteins. Of course, the specificity of the hexapeptide ligands is expected to be inferior to an 
antibody, so many proteins will find multiple binding ligands while some will find none. 
For each of the samples originating from patients C and D, three replicate LC-MS/MS runs were 
collected. Applying a PeptideProphet score acceptance threshold of 0.9, 4051 PSMs and 3443 
PSMs were obtained for C and D, respectively (hits to decoy proteins implied a PSM-level false 
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positive rate of 0.1% for C and 0.2% for D). Rejecting the decoy proteins, a total of 59 and 47 
carbonylated proteins were identified in the samples originating from patients C and D, 
respectively. The whole sets are presented as Appendix Table A10 and A11.  
 
Figure 5.6. Change in protein carbonylation levels over time for the ten proteins in patient C's 
plasma with the greatest temporal change. Data are normalized to Day 1 
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Figure 5.7. Change in protein carbonylation levels over time for the ten proteins in patient D's 
plasma with the greatest temporal change. Data are normalized to Day 1 
 
The trauma suffered by patients C and D resulted from elective surgery, providing a more 
controlled environment than that experienced by patients A and B. Although these patients likely 
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increased considerably. The two proteins that sustained the most oxidative damage were C-
reactive protein and serum amyloid A-2. The C-reactive protein family plays a fundamental role 
in inflammation, an extremely important process in wound healing. It is involved in the warding 
off of bacteria and viruses and in many other key processes critical for survival.
300,301
 The major 
role of serum amyloid A-2, which is an acute phase protein secreted during acute inflammation , 
is the recruitment of immune cells to inflammatory sites.
302 
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5.5. Conclusion 
In conclusion, we successfully applied our affinity-enrichment proteomics and western blotting 
workflow for measuring changes in carbonylated protein relative abundance over time to 
samples originating from human blood. First temporal changes in carbonylated protein 
concentrations were measured in serum originating from patients A and B. Second, the 
ProteoMiner affinity ligand strategy was added to the procedure to increase proteome coverage 
through the depletion of high-abundance plasma proteins. Processing plasma samples originating 
from patients C and D using this improved method resulted in the identification of greater 
numbers of low-abundance proteins. Since the sample size (n=2) was very small, no biological 
conclusion can be drawn; however, we have shown that measurements of changes in the 
carbonylated protein proteome over time are possible by this method. The hope is that protein 
carbonylation biomarkers identified in trauma samples could someday aid in predicting patient 
outcomes in clinical settings. 
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Appendix 
Table A1 
Non-specific binding to the streptavidin beads used in this work for the isolation of carbonylated 
proteins was assessed by preparing parallel samples that were not exposed to the labeling 
reagent, biotin hydrazide. This approach was applied to the Paraquat exposure system to produce 
a four-channel iTRAQ experiment (Paraquat-exposed fly proteins processed as usual with biotin 
hydrazide; Paraquat-exposed fly proteins processed without biotin hydrazide labeling; control fly 
proteins processed as usual with biotin hydrazide; control fly proteins processed without biotin 
hydrazide labeling). Since differences in protein concentration between Paraquat-exposed and 
control samples were expected, comparisons were made between the non-biotinylated and 
biotinylated samples. Most ratios were low, indicating limited non-specific binding, but for some 
proteins higher ratios were obtained. The proteins highlighted in red, which were found to have 
ratios in excess of 0.5 in either comparison, were excluded from further analyses. 
FlyBase Gene 
ID used for 
Construction 
of Protein 
Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Count 
Non-
biotinylated 
versus 
Biotinylated 
Control 
Ratio 
Non-
biotinylated 
versus 
Biotinylated 
Paraquat-
exposed Ratio 
FBgn0033246 ACC 
Acetyl-CoA 
carboxylase 
54 3.36 4.12 
FBgn0027580 CG1516  209 2.12 2.00 
FBgn0032242 CG5355  5 1.03 0.49 
FBgn0261597 RpS26 Ribosomal protein S26 6 0.76 0.34 
FBgn0035978 UGP UGP 5 0.70 0.38 
FBgn0011284 RpS4 Ribosomal protein S4 8 0.59 0.33 
FBgn0017579 RpL14 Ribosomal protein L14 5 0.55 0.37 
FBgn0035032 CG4692  31 0.53 0.47 
FBgn0001091 Gapdh1 
Glyceraldehyde 3 
phosphate 
dehydrogenase 1 
5 0.51 0.32 
FBgn0035600 CG4769  5 0.49 0.33 
FBgn0002719 Men Malic enzyme 10 0.48 0.21 
FBgn0000559 Ef2b Elongation factor 2b 13 0.45 0.57 
FBgn0030239 CG17333  5 0.45 0.37 
FBgn0037351 RpL13A 
Ribosomal protein 
L13A 
11 0.44 0.30 
FBgn0032518 RpL24 Ribosomal protein L24 12 0.43 0.28 
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Symbol 
Associated FlyBase 
Gene Name 
PSM 
Count 
Non-
biotinylated 
versus 
Biotinylated 
Control 
Ratio 
Non-
biotinylated 
versus 
Biotinylated 
Paraquat-
exposed Ratio 
FBgn0000556 Ef1alpha48D 
Elongation factor 
1alpha48D 
5 0.43 0.31 
FBgn0013678 mt:Cyt-b 
mitochondrial 
Cytochrome b 
11 0.43 0.33 
FBgn0010217 ATPsyn-beta ATP synthase-beta 95 0.43 0.46 
FBgn0035753 RpL18 Ribosomal protein L18 6 0.41 0.32 
FBgn0010612 l(2)06225 lethal (2) 06225 16 0.40 0.43 
FBgn0064225 RpL5 Ribosomal protein L5 6 0.39 0.31 
FBgn0002590 RpS5a Ribosomal protein S5a 5 0.39 0.19 
FBgn0028685 Rpt4 Rpt4 5 0.36 0.21 
FBgn0002921 Atpalpha 
Na pump alpha 
subunit 
7 0.35 0.26 
FBgn0010198 RpS15Aa 
Ribosomal protein 
S15Aa 
5 0.35 0.15 
FBgn0038922 CG6439  28 0.33 0.19 
FBgn0020238 
14-3-
3epsilon 
14-3-3epsilon 8 0.32 0.23 
FBgn0010352 Nc73EF 
Neural conserved at 
73EF 
27 0.32 0.19 
FBgn0004047 Yp3 Yolk protein 3 119 0.30 0.26 
FBgn0019644 ATPsyn-b 
ATP synthase, subunit 
b 
9 0.30 0.29 
FBgn0004045 Yp1 Yolk protein 1 5 0.29 0.35 
FBgn0029155 Men-b Malic enzyme b 10 0.29 0.23 
FBgn0029897 RpL17 Ribosomal protein L17 17 0.29 0.19 
FBgn0037001 CG6020  11 0.28 0.17 
FBgn0250906 Pgk 
Phosphoglycerate 
kinase 
17 0.28 0.21 
FBgn0017545 RpS3A 
Ribosomal protein 
S3A 
18 0.27 0.21 
FBgn0250838 CG30415  16 0.27 0.21 
FBgn0039737 CG7920  42 0.27 0.22 
FBgn0027560 Tps1 
Trehalose-6-phosphate 
synthase 1 
12 0.27 0.18 
151 
  
FlyBase Gene 
ID used for 
Construction 
of Protein 
Group 
Associated 
FlyBase 
Gene 
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biotinylated 
versus 
Biotinylated 
Paraquat-
exposed Ratio 
FBgn0028325 l(1)G0334 lethal (1) G0334 8 0.26 0.18 
FBgn0011272 RpL13 Ribosomal protein L13 11 0.26 0.21 
FBgn0034497 CG9090  65 0.26 0.17 
FBgn0024733 RpL10 Ribosomal protein L10 6 0.26 0.18 
FBgn0004507 GlyP 
Glycogen 
phosphorylase 
44 0.25 0.26 
FBgn0019936 RpS20 Ribosomal protein S20 6 0.25 0.18 
FBgn0250814 CG4169  35 0.25 0.17 
FBgn0016120 ATPsyn-d 
ATP synthase, subunit 
d 
6 0.25 0.22 
FBgn0037138 CG7145  6 0.23 0.17 
FBgn0003178 PyK Pyruvate kinase 104 0.23 0.17 
FBgn0020236 ATPCL ATP citrate lyase 8 0.23 0.31 
FBgn0263006 Ca-P60A 
Calcium ATPase at 
60A 
95 0.23 0.19 
FBgn0010100 Acon Aconitase 73 0.23 0.21 
FBgn0000064 Ald Aldolase 121 0.23 0.20 
FBgn0020235 
ATPsyn-
gamma 
ATP synthase-gamma 
chain 
97 0.22 0.18 
FBgn0010226 GstS1 
Glutathione S 
transferase S1 
10 0.22 0.19 
FBgn0039635 CG11876  5 0.21 0.25 
FBgn0261955 kdn knockdown 210 0.21 0.15 
FBgn0038271 CG3731  50 0.21 0.12 
FBgn0085201 CG34172  46 0.20 0.18 
FBgn0020513 ade5 ade5 31 0.20 0.14 
FBgn0026409 Mpcp 
Mitochondrial 
phosphate carrier 
protein 
14 0.19 0.11 
FBgn0000116 Argk Arginine kinase 146 0.19 0.16 
FBgn0000055 Adh 
Alcohol 
dehydrogenase 
195 0.18 0.14 
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versus 
Biotinylated 
Control 
Ratio 
Non-
biotinylated 
versus 
Biotinylated 
Paraquat-
exposed Ratio 
FBgn0001248 Idh 
Isocitrate 
dehydrogenase 
24 0.18 0.15 
FBgn0022160 Gpo-1 
Glycerophosphate 
oxidase-1 
78 0.18 0.14 
FBgn0010078 RpL23 Ribosomal protein L23 7 0.18 0.14 
FBgn0003071 Pfk Phosphofructokinase 57 0.18 0.15 
FBgn0000083 AnnIX Annexin IX 19 0.17 0.11 
FBgn0001128 Gpdh 
Glycerol 3 phosphate 
dehydrogenase 
201 0.17 0.14 
FBgn0031436 CG3214  5 0.17 0.10 
FBgn0027590 CG16936  18 0.17 0.11 
FBgn0015031 cype cyclope 19 0.16 0.18 
FBgn0020618 Rack1 
Receptor of activated 
protein kinase C 1 
10 0.16 0.13 
FBgn0003074 Pgi 
Phosphoglucose 
isomerase 
25 0.16 0.18 
FBgn0003360 sesB stress-sensitive B 388 0.16 0.11 
FBgn0016687 Nurf-38 
Nucleosome 
remodeling factor - 
38kD 
8 0.16 0.17 
FBgn0011211 blw bellwether 262 0.16 0.18 
FBgn0001942 eIF-4a 
Eukaryotic initiation 
factor 4a 
6 0.15 0.12 
FBgn0015324 Vha26 
Vacuolar H[+]-
ATPase 26kD E 
subunit 
25 0.15 0.11 
FBgn0010411 RpS18 Ribosomal protein S18 8 0.15 0.11 
FBgn0038570 Prx5 Peroxiredoxin 5 9 0.15 0.14 
FBgn0029176 Ef1gamma Ef1gamma 5 0.14 0.12 
FBgn0000579 Eno Enolase 131 0.14 0.13 
FBgn0000409 Cyt-c-p 
Cytochrome c 
proximal 
38 0.14 0.18 
FBgn0086783 Mhc Myosin heavy chain 8 0.14 0.18 
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biotinylated 
versus 
Biotinylated 
Paraquat-
exposed Ratio 
FBgn0001145 Gs2 
Glutamine synthetase 
2 
14 0.13 0.12 
FBgn0262782 Mdh1 
Malate dehydrogenase 
1 
12 0.13 0.11 
FBgn0086355 Tpi 
Triose phosphate 
isomerase 
65 0.13 0.10 
FBgn0032833 CG10664  49 0.13 0.09 
FBgn0016691 Oscp 
Oligomycin 
sensitivity-conferring 
protein 
96 0.12 0.13 
FBgn0027291 l(1)G0156 lethal (1) G0156 31 0.12 0.14 
FBgn0031912 CG5261  32 0.12 0.10 
FBgn0034743 RpS16 Ribosomal protein S16 13 0.12 0.12 
FBgn0262559 Mdh2 
Malate dehydrogenase 
2 
147 0.11 0.09 
FBgn0020908 Scp1 
Sarcoplasmic calcium-
binding protein 1 
168 0.11 0.09 
FBgn0001149 GstD1 
Glutathione S 
transferase D1 
7 0.11 0.09 
FBgn0037643 skap 
skpA associated 
protein 
42 0.09 0.11 
FBgn0002772 Mlc1 
Myosin alkali light 
chain 1 
20 0.08 0.12 
FBgn0014869 Pglym78 Phosphoglyceromutase 6 0.07 0.10 
FBgn0030733 CG3560  5 0.06 0.10 
FBgn0004432 Cyp1 Cyclophilin 1 11 0.04 0.11 
 
Table A2 
Observed changes in carbonylated protein relative abundance on exposure to Paraquat in D. 
melanogaster. Whole fly homogenates were analyzed and quantitation was via a mass 
spectrometry-based proteomics approach using the iTRAQ relative quantitation system. 
Carbonylated proteins were organized into groups by parent gene. Measurements were obtained 
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for 249 carbonylated protein groups after requiring at least five PSMs with no missing reporter 
ions and excluding those groups suspected of being prone to non-specific binding. Here, the 
three repeats performed have been combined. 
FlyBase Gene 
ID used for 
Construction 
of Protein 
Group 
Associated 
FlyBase Gene 
Symbol 
Associated FlyBase Gene Name 
PSM 
Count 
Paraquat-exposed 
versus Control 
Carbonylated 
Protein Relative 
Abundance Ratio 
FBgn0010516 wal walrus 16 2.75 
FBgn0010213 Sod2 Superoxide dismutase 2 (Mn) 25 2.73 
FBgn0031801 CG9498  5 2.53 
FBgn0024289 Sodh-1 Sorbitol dehydrogenase 1 6 2.52 
FBgn0003067 Pepck 
Phosphoenolpyruvate 
carboxykinase 
9 2.45 
FBgn0019957 ND42 
NADH:ubiquinone reductase 
42kD subunit precursor 
37 2.42 
FBgn0020653 Trxr-1 Thioredoxin reductase-1 14 2.38 
FBgn0000556 Ef1alpha48D Elongation factor 1alpha48D 42 2.36 
FBgn0029823 CG3011  23 2.30 
FBgn0261014 TER94 TER94 76 2.27 
FBgn0020513 ade5 ade5 86 2.26 
FBgn0010482 l(2)01289 lethal (2) 01289 17 2.25 
FBgn0000052 ade2 adenosine 2 5 2.22 
FBgn0000319 Chc Clathrin heavy chain 17 2.21 
FBgn0036044 CG14168  11 2.20 
FBgn0260439 Pp2A-29B Protein phosphatase 2A at 29B 49 2.16 
FBgn0037607 CG8036  48 2.16 
FBgn0001219 Hsc70-4 Heat shock protein cognate 4 31 2.14 
FBgn0040349 CG3699  28 2.13 
FBgn0003887 betaTub56D beta-Tubulin at 56D 15 2.09 
FBgn0004047 Yp3 Yolk protein 3 842 2.09 
FBgn0004419 me31B maternal expression at 31B 10 2.07 
FBgn0003676 T-cp1 Tcp1-like 17 2.07 
FBgn0000261 Cat Catalase 82 2.06 
FBgn0039737 CG7920  153 2.04 
FBgn0012036 Aldh Aldehyde dehydrogenase 43 2.01 
FBgn0262559 Mdh2 Malate dehydrogenase 2 637 2.01 
FBgn0019830 colt congested-like trachea 9 2.01 
FBgn0037632 Tcp-1eta Tcp-1eta 5 2.00 
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Paraquat-exposed 
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Carbonylated 
Protein Relative 
Abundance Ratio 
FBgn0000579 Eno Enolase 874 1.99 
FBgn0261394 Pros29 Proteasome 29kD subunit 5 1.97 
FBgn0023477 Tal Tal 24 1.94 
FBgn0037891 CG5214  33 1.93 
FBgn0026418 Hsc70Cb Hsc70Cb 45 1.93 
FBgn0086691 UK114 UK114 24 1.91 
FBgn0029155 Men-b Malic enzyme b 42 1.91 
FBgn0261439 SdhA Succinate dehydrogenase A 25 1.91 
FBgn0034138 RpS15 Ribosomal protein S15 7 1.89 
FBgn0003890 betaTub97EF beta-Tubulin at 97EF 8 1.89 
FBgn0002921 Atpalpha Na pump alpha subunit 95 1.88 
FBgn0027291 l(1)G0156 lethal (1) G0156 233 1.87 
FBgn0037138 CG7145  71 1.87 
FBgn0037001 CG6020  60 1.87 
FBgn0001142 Gs1 Glutamine synthetase 1 8 1.87 
FBgn0001149 GstD1 Glutathione S transferase D1 30 1.87 
FBgn0040064 yip2 yippee interacting protein 2 30 1.86 
FBgn0011211 blw bellwether 1159 1.85 
FBgn0250814 CG4169  218 1.85 
FBgn0003076 Pgm Phosphogluconate mutase 18 1.84 
FBgn0005666 bt bent 5 1.84 
FBgn0262782 Mdh1 Malate dehydrogenase 1 38 1.83 
FBgn0011693 Pdh Photoreceptor dehydrogenase 5 1.81 
FBgn0015222 Fer1HCH 
Ferritin 1 heavy chain 
homologue 
7 1.80 
FBgn0032721 CG10602  12 1.79 
FBgn0005671 Vha55 
Vacuolar H[+]-ATPase 55kD B 
subunit 
73 1.78 
FBgn0036762 CG7430  37 1.77 
FBgn0038922 CG6439  183 1.77 
FBgn0027590 CG16936  49 1.76 
FBgn0250906 Pgk Phosphoglycerate kinase 135 1.75 
FBgn0003423 slgA sluggish A 23 1.74 
FBgn0038271 CG3731  252 1.74 
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FBgn0020255 ran ran 6 1.74 
FBgn0004045 Yp1 Yolk protein 1 23 1.73 
FBgn0040309 Jafrac1 thioredoxin peroxidase 1 38 1.73 
FBgn0010100 Acon Aconitase 408 1.72 
FBgn0017566 ND75 
NADH:ubiquinone reductase 
75kD subunit precursor 
23 1.72 
FBgn0030478 CG1640  40 1.71 
FBgn0004867 RpS2 Ribosomal protein S2 18 1.71 
FBgn0022355 Tsf1 Transferrin 1 6 1.70 
FBgn0028336 l(1)G0255 lethal (1) G0255 24 1.70 
FBgn0004654 Pgd 
Phosphogluconate 
dehydrogenase 
29 1.70 
FBgn0003074 Pgi Phosphoglucose isomerase 64 1.70 
FBgn0035811 CG12262  29 1.70 
FBgn0261955 kdn knockdown 779 1.70 
FBgn0005391 Yp2 Yolk protein 2 17 1.68 
FBgn0029687 Vap-33-1 Vap-33-1 26 1.68 
FBgn0036927 CG7433  9 1.67 
FBgn0022160 Gpo-1 Glycerophosphate oxidase-1 404 1.67 
FBgn0039241 CG11089  13 1.67 
FBgn0027560 Tps1 
Trehalose-6-phosphate synthase 
1 
96 1.66 
FBgn0029868 CG3446  12 1.66 
FBgn0024556 EfTuM 
Elongation factor Tu 
mitochondrial 
29 1.66 
FBgn0038293 CG6904  7 1.66 
FBgn0032216 CG5384  10 1.66 
FBgn0004888 Scsalpha 
Succinyl coenzyme A 
synthetase alpha subunit 
28 1.65 
FBgn0035600 CG4769  65 1.65 
FBgn0031830 CG11015  10 1.64 
FBgn0035189 CG9119  13 1.64 
FBgn0001942 eIF-4a Eukaryotic initiation factor 4a 67 1.64 
FBgn0030853 CG5703  15 1.64 
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FBgn0029176 Ef1gamma Ef1gamma 83 1.64 
FBgn0034603 Glycogenin Glycogenin 8 1.64 
FBgn0004636 R Roughened 6 1.63 
FBgn0038946 CG7077  5 1.63 
FBgn0003279 RpL4 Ribosomal protein L4 35 1.62 
FBgn0039358 CG5028  25 1.62 
FBgn0039909 CG1970  7 1.62 
FBgn0020908 Scp1 
Sarcoplasmic calcium-binding 
protein 1 
590 1.60 
FBgn0027571 CG3523  81 1.60 
FBgn0015324 Vha26 
Vacuolar H[+]-ATPase 26kD E 
subunit 
105 1.60 
FBgn0262511 Vha44 
Vacuolar H[+] ATPase 44kD C 
subunit 
6 1.60 
FBgn0003071 Pfk Phosphofructokinase 309 1.59 
FBgn0002719 Men Malic enzyme 87 1.59 
FBgn0001220 Hsc70-5 Heat shock protein cognate 5 16 1.59 
FBgn0024733 RpL10 Ribosomal protein L10 22 1.59 
FBgn0010352 Nc73EF Neural conserved at 73EF 290 1.59 
FBgn0028686 Rpt3 Rpt3 7 1.58 
FBgn0028325 l(1)G0334 lethal (1) G0334 59 1.58 
FBgn0023507 CG3835  55 1.58 
FBgn0028685 Rpt4 Rpt4 33 1.57 
FBgn0028968 gammaCop gamma-coatomer protein 8 1.57 
FBgn0024891 ferrochelatase ferrochelatase 5 1.57 
FBgn0001248 Idh Isocitrate dehydrogenase 194 1.57 
FBgn0021765 scu scully 7 1.57 
FBgn0000064 Ald Aldolase 624 1.57 
FBgn0047038 CG6463  6 1.56 
FBgn0031771 CG9140  30 1.56 
FBgn0039635 CG11876  45 1.56 
FBgn0003178 PyK Pyruvate kinase 511 1.56 
FBgn0039537 CG5590  5 1.55 
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FBgn0020235 
ATPsyn-
gamma 
ATP synthase-gamma chain 363 1.54 
FBgn0011726 tsr twinstar 12 1.54 
FBgn0001125 Got2 
Glutamate oxaloacetate 
transaminase 2 
17 1.54 
FBgn0032833 CG10664  139 1.53 
FBgn0086134 Pros25 Proteasome 25kD subunit 10 1.53 
FBgn0000055 Adh Alcohol dehydrogenase 933 1.52 
FBgn0032518 RpL24 Ribosomal protein L24 31 1.52 
FBgn0016687 Nurf-38 
Nucleosome remodeling factor - 
38kD 
38 1.52 
FBgn0020238 14-3-3epsilon 14-3-3epsilon 66 1.50 
FBgn0001145 Gs2 Glutamine synthetase 2 50 1.49 
FBgn0001098 Gdh Glutamate dehydrogenase 7 1.47 
FBgn0004507 GlyP Glycogen phosphorylase 340 1.47 
FBgn0086254 CG6084  36 1.47 
FBgn0261602 RpL8 Ribosomal protein L8 14 1.46 
FBgn0035404 CG12079  33 1.46 
FBgn0030239 CG17333  17 1.45 
FBgn0023143 Uba1 Ubiquitin activating enzyme 1 17 1.45 
FBgn0027786 Mtch 
Mitochondrial carrier homolog 
1 
7 1.44 
FBgn0000318 cl clot 5 1.44 
FBgn0002938 ninaC 
neither inactivation nor 
afterpotential C 
27 1.44 
FBgn0002590 RpS5a Ribosomal protein S5a 22 1.43 
FBgn0030737 CG9914  33 1.43 
FBgn0002789 Mp20 Muscle protein 20 77 1.43 
FBgn0020368 Vha68-1 
Vacuolar H[+] ATPase subunit 
68-1 
9 1.43 
FBgn0031497 CG17259  5 1.42 
FBgn0028479 CG4389  41 1.42 
FBgn0034618 CG9485  29 1.42 
FBgn0028737 Ef1beta Elongation factor 1 beta 7 1.41 
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FBgn0002607 RpL19 Ribosomal protein L19 9 1.40 
FBgn0037580 DppIII Dipeptidyl aminopeptidase III 5 1.39 
FBgn0020367 Vha68-2 
Vacuolar H[+] ATPase subunit 
68-2 
19 1.39 
FBgn0035753 RpL18 Ribosomal protein L18 12 1.39 
FBgn0039682 Obp99c Odorant-binding protein 99c 5 1.39 
FBgn0034688 CG11474  9 1.38 
FBgn0087013 Karybeta3 Karyopherin beta 3 7 1.38 
FBgn0028693 Rpn12 Rpn12 7 1.38 
FBgn0000100 RpLP0 Ribosomal protein LP0 5 1.38 
FBgn0002622 RpS3 Ribosomal protein S3 48 1.38 
FBgn0003360 sesB stress-sensitive B 1069 1.38 
FBgn0032783 CG10237  5 1.37 
FBgn0037874 Tctp 
Translationally controlled 
tumor protein 
7 1.37 
FBgn0016691 Oscp 
Oligomycin sensitivity-
conferring protein 
314 1.36 
FBgn0038277 RpS5b Ribosomal protein S5b 18 1.36 
FBgn0036928 Tom20 
Translocase of outer membrane 
20 
8 1.36 
FBgn0003149 Prm Paramyosin 29 1.36 
FBgn0010226 GstS1 Glutathione S transferase S1 52 1.36 
FBgn0064225 RpL5 Ribosomal protein L5 29 1.35 
FBgn0004432 Cyp1 Cyclophilin 1 99 1.35 
FBgn0086355 Tpi Triose phosphate isomerase 414 1.35 
FBgn0011227 ox oxen 5 1.35 
FBgn0032076 CG9510  6 1.34 
FBgn0004907 14-3-3zeta 14-3-3zeta 18 1.34 
FBgn0010217 ATPsyn-beta ATP synthase-beta 434 1.34 
FBgn0038570 Prx5 Peroxiredoxin 5 52 1.34 
FBgn0033109 coro coro 8 1.34 
FBgn0261596 RpS24 Ribosomal protein S24 11 1.33 
FBgn0263006 Ca-P60A Calcium ATPase at 60A 508 1.33 
FBgn0019936 RpS20 Ribosomal protein S20 14 1.32 
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Abundance Ratio 
FBgn0031912 CG5261  201 1.32 
FBgn0033663 ERp60 ERp60 15 1.32 
FBgn0011661 Moe Moesin 21 1.32 
FBgn0001128 Gpdh 
Glycerol 3 phosphate 
dehydrogenase 
1088 1.31 
FBgn0261592 RpS6 Ribosomal protein S6 23 1.31 
FBgn0000045 Act79B Actin 79B 5 1.30 
FBgn0001186 Hex-A Hexokinase A 16 1.30 
FBgn0000150 awd abnormal wing discs 15 1.30 
FBgn0261606 RpL27A Ribosomal protein L27A 11 1.30 
FBgn0004066 Pros28.1 Proteasome 28kD subunit 1 8 1.29 
FBgn0001233 Hsp83 Heat shock protein 83 46 1.29 
FBgn0028688 Rpn7 Rpn7 8 1.29 
FBgn0010078 RpL23 Ribosomal protein L23 10 1.29 
FBgn0004117 Tm2 Tropomyosin 2 11 1.28 
FBgn0025814 Mgstl 
Microsomal glutathione S-
transferase-like 
5 1.28 
FBgn0000116 Argk Arginine kinase 559 1.28 
FBgn0017545 RpS3A Ribosomal protein S3A 96 1.27 
FBgn0000083 AnnIX Annexin IX 43 1.26 
FBgn0039713 RpS8 Ribosomal protein S8 13 1.26 
FBgn0053138 CG33138  5 1.26 
FBgn0020236 ATPCL ATP citrate lyase 95 1.26 
FBgn0030733 CG3560  12 1.25 
FBgn0019644 ATPsyn-b ATP synthase, subunit b 71 1.25 
FBgn0033446 CG1648  5 1.25 
FBgn0260441 RpS12 Ribosomal protein S12 9 1.25 
FBgn0020618 Rack1 
Receptor of activated protein 
kinase C 1 
39 1.25 
FBgn0037912 sea scheggia 50 1.25 
FBgn0004580 Cbp53E Calbindin 53E 9 1.24 
FBgn0031436 CG3214  21 1.24 
FBgn0025839 CG3621  8 1.22 
FBgn0000667 Actn alpha actinin 33 1.21 
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FBgn0029897 RpL17 Ribosomal protein L17 43 1.20 
FBgn0032444 CG5525  6 1.20 
FBgn0037245 growl growl 7 1.19 
FBgn0030136 RpS28b Ribosomal protein S28b 31 1.19 
FBgn0010348 Arf79F ADP ribosylation factor 79F 20 1.19 
FBgn0034743 RpS16 Ribosomal protein S16 66 1.19 
FBgn0004363 porin porin 16 1.18 
FBgn0002593 RpLP1 Ribosomal protein LP1 47 1.17 
FBgn0031908 CG5177  9 1.16 
FBgn0034968 RpL12 Ribosomal protein L12 10 1.16 
FBgn0014028 SdhB Succinate dehydrogenase B 10 1.15 
FBgn0037643 skap skpA associated protein 115 1.15 
FBgn0011272 RpL13 Ribosomal protein L13 43 1.14 
FBgn0032511 CG9306  37 1.13 
FBgn0014869 Pglym78 Phosphoglyceromutase 37 1.13 
FBgn0010411 RpS18 Ribosomal protein S18 48 1.12 
FBgn0016120 ATPsyn-d ATP synthase, subunit d 94 1.12 
FBgn0037351 RpL13A Ribosomal protein L13A 14 1.12 
FBgn0026409 Mpcp 
Mitochondrial phosphate carrier 
protein 
74 1.11 
FBgn0027779 VhaSFD 
Vacuolar H[+]-ATPase SFD 
subunit 
36 1.10 
FBgn0086710 RpL30 Ribosomal protein L30 6 1.08 
FBgn0085201 CG34172  108 1.05 
FBgn0034497 CG9090  211 1.05 
FBgn0002772 Mlc1 Myosin alkali light chain 1 129 1.04 
FBgn0000409 Cyt-c-p Cytochrome c proximal 206 1.04 
FBgn0010198 RpS15Aa Ribosomal protein S15Aa 14 1.04 
FBgn0010019 Cyp4g1 Cytochrome P450-4g1 94 1.03 
FBgn0035121 Tudor-SN Tudor-SN 8 1.03 
FBgn0015031 cype cyclope 37 1.02 
FBgn0087002 Rfabg 
Retinoid- and fatty acid-binding 
glycoprotein 
15 1.02 
FBgn0250838 CG30415  30 1.02 
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FBgn0016119 ATPsyn-Cf6 ATPase coupling factor 6 9 1.01 
FBgn0026439 Eaat1 
Excitatory amino acid 
transporter 1 
7 1.01 
FBgn0019624 CoVa 
Cytochrome c oxidase subunit 
Va 
28 1.00 
FBgn0013678 mt:Cyt-b mitochondrial Cytochrome b 33 0.96 
FBgn0010612 l(2)06225 lethal (2) 06225 59 0.96 
FBgn0013672 mt:ATPase6 mitochondrial ATPase subunit 6 10 0.88 
FBgn0000047 Act88F Actin 88F 6 0.87 
FBgn0013675 mt:CoII 
mitochondrial Cytochrome c 
oxidase subunit II 
15 0.86 
FBgn0086783 Mhc Myosin heavy chain 173 0.69 
Table A3 
Observed changes in carbonylated protein relative abundance on exposure to Paraquat in D. 
melanogaster. Whole fly homogenates were analyzed and quantitation was via a mass spectrometry-based 
proteomics approach using the iTRAQ relative quantitation system. Carbonylated proteins were organized 
into groups by parent gene. Measurements were obtained for 249 carbonylated protein groups after 
requiring at least five PSMs with no missing reporter ions and excluding those groups suspected of being 
prone to non-specific binding. Here, information for the three repeats has been provided. *Paraquat-
exposed versus control ratio/PSM count. 
FlyBase Gene 
ID used for 
Construction 
of Protein 
Group 
Associated 
FlyBase Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM Counts 
for Repeat 
1* 
Ratios and 
PSM Counts 
for Repeat 
2* 
Ratios and 
PSM Counts 
for Repeat 
3* 
FBgn0000045 Act79B Actin 79B 1.30/5 Not Detected Not Detected 
FBgn0000047 Act88F Actin 88F 0.85/5 Not Detected 0.96/1 
FBgn0000052 ade2 adenosine 2 2.43/1 2.31/3 1.81/1 
FBgn0000055 Adh 
Alcohol 
dehydrogenase 
1.49/284 1.54/305 1.51/344 
FBgn0000064 Ald Aldolase 1.72/186 1.68/224 1.34/214 
FBgn0000083 AnnIX Annexin IX 1.16/8 1.44/25 0.98/10 
FBgn0000100 RpLP0 
Ribosomal protein 
LP0 
1.62/1 1.53/3 0.87/1 
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FBgn0000116 Argk Arginine kinase 1.29/125 1.41/219 1.15/215 
FBgn0000150 awd abnormal wing discs 1.31/5 1.42/7 1.03/3 
FBgn0000261 Cat Catalase 2.09/18 2.58/33 1.60/31 
FBgn0000318 cl clot 1.39/1 1.63/3 1.04/1 
FBgn0000319 Chc Clathrin heavy chain 1.77/1 2.81/11 1.37/5 
FBgn0000409 Cyt-c-p 
Cytochrome c 
proximal 
1.40/31 1.20/73 0.86/102 
FBgn0000556 Ef1alpha48D 
Elongation factor 
1alpha48D 
2.25/4 3.03/10 2.17/28 
FBgn0000579 Eno Enolase 2.41/149 2.29/356 1.61/369 
FBgn0000667 Actn alpha actinin 0.95/5 1.37/23 0.88/5 
FBgn0001098 Gdh 
Glutamate 
dehydrogenase 
1.37/6 2.23/1 Not Detected 
FBgn0001125 Got2 
Glutamate 
oxaloacetate 
transaminase 2 
1.54/10 1.53/7 Not Detected 
FBgn0001128 Gpdh 
Glycerol 3 phosphate 
dehydrogenase 
1.29/176 1.54/471 1.12/441 
FBgn0001142 Gs1 
Glutamine synthetase 
1 
2.59/3 Not Detected 1.53/5 
FBgn0001145 Gs2 
Glutamine synthetase 
2 
1.79/13 1.45/19 1.35/18 
FBgn0001149 GstD1 
Glutathione S 
transferase D1 
2.12/7 2.01/17 1.32/6 
FBgn0001186 Hex-A Hexokinase A 1.25/3 1.31/9 1.31/4 
FBgn0001219 Hsc70-4 
Heat shock protein 
cognate 4 
2.21/29 1.20/1 1.36/1 
FBgn0001220 Hsc70-5 
Heat shock protein 
cognate 5 
1.45/2 1.70/10 1.42/4 
FBgn0001233 Hsp83 Heat shock protein 83 1.10/4 1.47/28 1.04/14 
FBgn0001248 Idh 
Isocitrate 
dehydrogenase 
1.66/43 1.67/68 1.45/83 
FBgn0001942 eIF-4a 
Eukaryotic initiation 
factor 4a 
1.60/11 1.87/31 1.42/25 
FBgn0002590 RpS5a Ribosomal protein S5a 1.80/5 1.41/10 1.25/7 
FBgn0002593 RpLP1 
Ribosomal protein 
LP1 
1.29/15 1.26/19 0.95/13 
FBgn0002607 RpL19 Ribosomal protein L19 1.79/4 1.20/4 0.93/1 
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FBgn0002622 RpS3 Ribosomal protein S3 1.72/14 1.38/19 1.12/15 
FBgn0002719 Men Malic enzyme 1.72/27 1.64/38 1.38/22 
FBgn0002772 Mlc1 
Myosin alkali light 
chain 1 
0.95/34 1.46/46 0.81/49 
FBgn0002789 Mp20 Muscle protein 20 1.54/19 1.71/34 1.04/24 
FBgn0002921 Atpalpha 
Na pump alpha 
subunit 
1.96/29 1.95/36 1.74/30 
FBgn0002938 ninaC 
neither inactivation 
nor afterpotential C 
1.65/1 1.62/10 1.33/16 
FBgn0003067 Pepck 
Phosphoenolpyruvate 
carboxykinase 
4.16/4 1.61/4 1.58/1 
FBgn0003071 Pfk Phosphofructokinase 1.86/63 1.69/118 1.40/128 
FBgn0003074 Pgi 
Phosphoglucose 
isomerase 
1.81/18 1.63/34 1.76/12 
FBgn0003076 Pgm 
Phosphogluconate 
mutase 
1.98/4 2.04/9 1.43/5 
FBgn0003149 Prm Paramyosin Not Detected 1.65/19 0.94/10 
FBgn0003178 PyK Pyruvate kinase 1.69/96 1.88/184 1.30/231 
FBgn0003279 RpL4 Ribosomal protein L4 1.75/4 1.72/18 1.46/13 
FBgn0003360 sesB stress-sensitive B 1.41/147 1.56/468 1.20/454 
FBgn0003423 slgA sluggish A 1.64/6 1.96/8 1.64/9 
FBgn0003676 T-cp1 Tcp1-like 1.73/2 2.71/9 1.46/6 
FBgn0003887 betaTub56D beta-Tubulin at 56D 2.38/9 1.70/2 1.74/4 
FBgn0003890 betaTub97EF beta-Tubulin at 97EF 2.20/2 2.16/3 1.50/3 
FBgn0004045 Yp1 Yolk protein 1 1.91/20 0.92/3 Not Detected 
FBgn0004047 Yp3 Yolk protein 3 2.14/121 2.74/317 1.67/404 
FBgn0004066 Pros28.1 
Proteasome 28kD 
subunit 1 
1.35/2 1.28/6 Not Detected 
FBgn0004117 Tm2 Tropomyosin 2 1.23/3 1.86/2 1.16/6 
FBgn0004363 porin porin 1.18/15 Not Detected 1.20/1 
FBgn0004419 me31B 
maternal expression at 
31B 
3.69/1 2.08/5 1.78/4 
FBgn0004432 Cyp1 Cyclophilin 1 1.30/20 1.42/53 1.25/26 
FBgn0004507 GlyP 
Glycogen 
phosphorylase 
1.58/85 1.56/141 1.30/114 
FBgn0004580 Cbp53E Calbindin 53E Not Detected 1.36/7 0.90/2 
FBgn0004636 R Roughened 1.47/3 1.82/3 Not Detected 
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FBgn0004654 Pgd 
Phosphogluconate 
dehydrogenase 
1.51/6 1.92/16 1.45/7 
FBgn0004867 RpS2 Ribosomal protein S2 Not Detected 1.88/14 1.23/4 
FBgn0004888 Scsalpha 
Succinyl coenzyme A 
synthetase alpha 
subunit 
1.75/7 1.69/12 1.53/9 
FBgn0004907 14-3-3zeta 14-3-3zeta 1.67/6 1.20/10 1.25/2 
FBgn0005391 Yp2 Yolk protein 2 1.69/16 1.46/1 Not Detected 
FBgn0005666 bt bent 1.73/1 1.87/4 Not Detected 
FBgn0005671 Vha55 
Vacuolar H[+]-
ATPase 55kD B 
subunit 
1.83/22 2.12/23 1.50/28 
FBgn0010019 Cyp4g1 Cytochrome P450-4g1 1.03/20 1.22/40 0.85/34 
FBgn0010078 RpL23 Ribosomal protein L23 1.21/4 1.50/4 1.07/2 
FBgn0010100 Acon Aconitase 1.87/138 1.79/148 1.50/122 
FBgn0010198 RpS15Aa 
Ribosomal protein 
S15Aa 
1.08/5 1.13/3 0.96/6 
FBgn0010213 Sod2 
Superoxide dismutase 
2 (Mn) 
2.14/7 5.79/5 2.33/13 
FBgn0010217 ATPsyn-beta ATP synthase-beta 1.61/184 1.14/115 1.20/135 
FBgn0010226 GstS1 
Glutathione S 
transferase S1 
1.21/19 1.82/19 1.06/14 
FBgn0010348 Arf79F 
ADP ribosylation 
factor 79F 
1.18/1 1.29/13 1.00/6 
FBgn0010352 Nc73EF 
Neural conserved at 
73EF 
1.63/83 1.74/96 1.44/111 
FBgn0010411 RpS18 Ribosomal protein S18 1.09/11 1.19/25 1.03/12 
FBgn0010482 l(2)01289 lethal (2) 01289 1.87/1 2.51/13 1.50/3 
FBgn0010516 wal walrus 1.80/3 3.81/10 1.41/3 
FBgn0010612 l(2)06225 lethal (2) 06225 1.17/24 0.87/18 0.80/17 
FBgn0011211 blw bellwether 2.14/281 2.04/408 1.57/470 
FBgn0011227 ox oxen 1.16/1 1.40/4 Not Detected 
FBgn0011272 RpL13 Ribosomal protein L13 1.40/7 1.23/22 0.90/14 
FBgn0011661 Moe Moesin Not Detected 1.47/13 1.10/8 
FBgn0011693 Pdh 
Photoreceptor 
dehydrogenase 
1.26/1 1.53/1 2.15/3 
FBgn0011726 tsr twinstar 1.52/11 1.81/1 Not Detected 
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FBgn0012036 Aldh 
Aldehyde 
dehydrogenase 
2.07/19 2.17/8 1.88/16 
FBgn0013672 mt:ATPase6 
mitochondrial ATPase 
subunit 6 
0.76/1 0.88/5 0.92/4 
FBgn0013675 mt:CoII 
mitochondrial 
Cytochrome c oxidase 
subunit II 
1.08/1 0.86/9 0.81/5 
FBgn0013678 mt:Cyt-b 
mitochondrial 
Cytochrome b 
0.95/12 1.10/14 0.75/7 
FBgn0014028 SdhB 
Succinate 
dehydrogenase B 
1.12/9 1.47/1 Not Detected 
FBgn0014869 Pglym78 Phosphoglyceromutase 1.08/6 1.21/19 1.05/12 
FBgn0015031 cype cyclope 1.08/6 1.12/17 0.90/14 
FBgn0015222 Fer1HCH 
Ferritin 1 heavy chain 
homologue 
1.80/3 1.80/4 Not Detected 
FBgn0015324 Vha26 
Vacuolar H[+]-
ATPase 26kD E 
subunit 
1.41/28 2.01/41 1.36/36 
FBgn0016119 ATPsyn-Cf6 
ATPase coupling 
factor 6 
1.01/9 Not Detected Not Detected 
FBgn0016120 ATPsyn-d 
ATP synthase, subunit 
d 
1.19/21 1.28/33 0.98/40 
FBgn0016687 Nurf-38 
Nucleosome 
remodeling factor - 
38kD 
1.50/11 1.52/19 1.52/8 
FBgn0016691 Oscp 
Oligomycin 
sensitivity-conferring 
protein 
1.22/68 1.52/126 1.29/120 
FBgn0017545 RpS3A 
Ribosomal protein 
S3A 
1.34/19 1.39/46 1.08/31 
FBgn0017566 ND75 
NADH:ubiquinone 
reductase 75kD 
subunit precursor 
1.66/11 1.95/9 1.34/3 
FBgn0019624 CoVa 
Cytochrome c oxidase 
subunit Va 
1.03/24 0.85/4 Not Detected 
FBgn0019644 ATPsyn-b 
ATP synthase, subunit 
b 
1.08/20 1.42/32 1.19/19 
FBgn0019830 colt congested-like trachea Not Detected 2.05/8 1.68/1 
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FBgn0019936 RpS20 Ribosomal protein S20 1.43/3 1.40/8 1.05/3 
FBgn0019957 ND42 
NADH:ubiquinone 
reductase 42kD 
subunit precursor 
2.92/9 2.62/11 2.09/17 
FBgn0020235 
ATPsyn-
gamma 
ATP synthase-gamma 
chain 
1.42/47 1.83/159 1.34/157 
FBgn0020236 ATPCL ATP citrate lyase 1.74/11 1.28/32 1.16/52 
FBgn0020238 14-3-3epsilon 14-3-3epsilon 1.63/17 1.61/28 1.28/21 
FBgn0020255 ran ran 1.85/3 1.63/3 Not Detected 
FBgn0020367 Vha68-2 
Vacuolar H[+] 
ATPase subunit 68-2 
1.15/4 1.52/12 1.26/3 
FBgn0020368 Vha68-1 
Vacuolar H[+] 
ATPase subunit 68-1 
1.22/6 2.36/2 1.36/1 
FBgn0020513 ade5 ade5 1.96/11 2.39/40 2.21/35 
FBgn0020618 Rack1 
Receptor of activated 
protein kinase C 1 
1.19/8 1.36/20 1.10/11 
FBgn0020653 Trxr-1 
Thioredoxin 
reductase-1 
2.66/7 2.12/7 Not Detected 
FBgn0020908 Scp1 
Sarcoplasmic calcium-
binding protein 1 
1.59/137 1.78/233 1.45/220 
FBgn0021765 scu scully 1.75/6 Not Detected 0.81/1 
FBgn0022160 Gpo-1 
Glycerophosphate 
oxidase-1 
1.42/55 1.86/162 1.60/187 
FBgn0022355 Tsf1 Transferrin 1 Not Detected 2.25/3 1.29/3 
FBgn0023143 Uba1 
Ubiquitin activating 
enzyme 1 
1.23/1 1.48/11 1.43/5 
FBgn0023477 Tal Tal 1.94/2 1.97/13 1.90/9 
FBgn0023507 CG3835  1.23/12 2.07/29 1.11/14 
FBgn0024289 Sodh-1 
Sorbitol 
dehydrogenase 1 
2.17/2 3.83/2 1.93/2 
FBgn0024556 EfTuM 
Elongation factor Tu 
mitochondrial 
1.53/5 1.89/16 1.33/8 
FBgn0024733 RpL10 Ribosomal protein L10 1.98/8 1.69/8 1.09/6 
FBgn0024891 ferrochelatase ferrochelatase 1.70/1 1.74/3 1.07/1 
FBgn0025814 Mgstl 
Microsomal 
glutathione S-
transferase-like 
Not Detected 1.36/4 1.00/1 
FBgn0025839 CG3621  1.23/4 1.26/3 1.10/1 
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FBgn0026409 Mpcp 
Mitochondrial 
phosphate carrier 
protein 
1.38/12 1.22/32 0.92/30 
FBgn0026418 Hsc70Cb Hsc70Cb 2.17/6 2.16/23 1.57/16 
FBgn0026439 Eaat1 
Excitatory amino acid 
transporter 1 
1.11/2 1.05/2 0.92/3 
FBgn0027291 l(1)G0156 lethal (1) G0156 2.33/60 1.95/80 1.57/93 
FBgn0027560 Tps1 
Trehalose-6-phosphate 
synthase 1 
1.72/23 1.95/39 1.36/34 
FBgn0027571 CG3523  1.53/24 1.86/23 1.49/34 
FBgn0027590 CG16936  1.59/8 1.73/20 1.86/21 
FBgn0027779 VhaSFD 
Vacuolar H[+]-
ATPase SFD subunit 
1.23/4 1.07/23 1.14/9 
FBgn0027786 Mtch 
Mitochondrial carrier 
homolog 1 
Not Detected 1.44/7 Not Detected 
FBgn0028325 l(1)G0334 lethal (1) G0334 1.54/19 1.85/26 1.22/14 
FBgn0028336 l(1)G0255 lethal (1) G0255 2.03/9 1.51/8 1.56/7 
FBgn0028479 CG4389  1.60/1 1.75/17 1.21/23 
FBgn0028685 Rpt4 Rpt4 Not Detected 1.68/20 1.42/13 
FBgn0028686 Rpt3 Rpt3 Not Detected 1.66/6 1.18/1 
FBgn0028688 Rpn7 Rpn7 Not Detected 1.33/7 1.04/1 
FBgn0028693 Rpn12 Rpn12 Not Detected 1.43/5 1.28/2 
FBgn0028737 Ef1beta 
Elongation factor 1 
beta 
Not Detected 1.41/7 Not Detected 
FBgn0028968 gammaCop 
gamma-coatomer 
protein 
Not Detected 1.69/6 1.27/2 
FBgn0029155 Men-b Malic enzyme b 2.00/6 2.08/24 1.57/12 
FBgn0029176 Ef1gamma Ef1gamma 1.63/17 1.79/40 1.44/26 
FBgn0029687 Vap-33-1 Vap-33-1 1.40/2 2.30/12 1.26/12 
FBgn0029823 CG3011  2.54/7 3.44/6 1.69/10 
FBgn0029868 CG3446  1.70/10 1.48/2 Not Detected 
FBgn0029897 RpL17 Ribosomal protein L17 Not Detected 1.28/23 1.12/20 
FBgn0030136 RpS28b 
Ribosomal protein 
S28b 
1.25/10 1.28/13 0.99/8 
FBgn0030239 CG17333  1.23/4 1.68/8 1.30/5 
FBgn0030478 CG1640  1.87/16 1.81/9 1.52/15 
FBgn0030733 CG3560  Not Detected 1.31/10 1.02/2 
FBgn0030737 CG9914  1.50/8 1.39/10 1.42/15 
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FBgn0030853 CG5703  1.65/14 1.53/1 Not Detected 
FBgn0031436 CG3214  1.25/19 1.18/2 Not Detected 
FBgn0031497 CG17259  Not Detected 1.57/3 1.23/2 
FBgn0031771 CG9140  1.54/13 1.89/9 1.29/8 
FBgn0031801 CG9498  Not Detected 2.53/5 Not Detected 
FBgn0031830 CG11015  1.71/6 1.54/4 Not Detected 
FBgn0031908 CG5177  1.02/1 1.26/6 0.97/2 
FBgn0031912 CG5261  1.46/38 1.44/83 1.15/80 
FBgn0032076 CG9510  1.48/2 1.28/4 Not Detected 
FBgn0032216 CG5384  Not Detected 1.75/7 1.45/3 
FBgn0032444 CG5525  Not Detected 1.52/2 1.07/4 
FBgn0032511 CG9306  0.89/8 1.43/17 0.96/12 
FBgn0032518 RpL24 Ribosomal protein L24 2.09/5 1.55/17 1.22/9 
FBgn0032721 CG10602  Not Detected 1.82/8 1.72/4 
FBgn0032783 CG10237  Not Detected 1.43/4 1.14/1 
FBgn0032833 CG10664  1.26/38 1.74/50 1.57/51 
FBgn0033109 coro coro Not Detected 1.37/5 1.28/3 
FBgn0033446 CG1648  1.25/5 Not Detected Not Detected 
FBgn0033663 ERp60 ERp60 0.76/2 1.71/4 1.32/9 
FBgn0034138 RpS15 Ribosomal protein S15 Not Detected 2.38/4 1.39/3 
FBgn0034497 CG9090  1.06/32 1.10/101 0.98/78 
FBgn0034603 Glycogenin Glycogenin Not Detected 2.25/2 1.47/6 
FBgn0034618 CG9485  1.48/8 1.56/11 1.23/10 
FBgn0034688 CG11474  1.29/1 1.34/6 1.57/2 
FBgn0034743 RpS16 Ribosomal protein S16 1.32/11 1.30/27 1.04/28 
FBgn0034968 RpL12 Ribosomal protein L12 1.19/1 1.17/8 1.02/1 
FBgn0035121 Tudor-SN Tudor-SN Not Detected 1.01/3 1.04/5 
FBgn0035189 CG9119  1.16/4 1.92/9 Not Detected 
FBgn0035404 CG12079  2.08/9 1.24/14 1.33/10 
FBgn0035600 CG4769  1.79/25 1.85/23 1.25/17 
FBgn0035753 RpL18 Ribosomal protein L18 1.53/3 1.35/9 Not Detected 
FBgn0035811 CG12262  1.94/9 1.81/7 1.50/13 
FBgn0036044 CG14168  2.03/1 2.24/8 2.11/2 
FBgn0036762 CG7430  2.12/16 1.75/10 1.38/11 
FBgn0036927 CG7433  2.14/4 1.17/2 1.53/3 
FBgn0036928 Tom20 
Translocase of outer 
membrane 20 
1.54/1 1.55/3 1.20/4 
FBgn0037001 CG6020  1.63/9 2.12/36 1.51/15 
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FlyBase Gene 
ID used for 
Construction 
of Protein 
Group 
Associated 
FlyBase Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM Counts 
for Repeat 
1* 
Ratios and 
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for Repeat 
2* 
Ratios and 
PSM Counts 
for Repeat 
3* 
FBgn0037138 CG7145  1.62/18 2.25/35 1.51/18 
FBgn0037245 growl growl Not Detected 1.36/4 1.01/3 
FBgn0037351 RpL13A 
Ribosomal protein 
L13A 
1.15/6 1.10/8 Not Detected 
FBgn0037580 DppIII 
Dipeptidyl 
aminopeptidase III 
Not Detected 1.50/2 1.33/3 
FBgn0037607 CG8036  2.12/17 2.33/18 2.00/13 
FBgn0037632 Tcp-1eta Tcp-1eta 1.74/1 2.45/2 1.74/2 
FBgn0037643 skap 
skpA associated 
protein 
1.18/21 1.46/44 0.92/50 
FBgn0037874 Tctp 
Translationally 
controlled tumor 
protein 
1.08/1 1.51/4 1.27/2 
FBgn0037891 CG5214  2.32/7 2.16/14 1.53/12 
FBgn0037912 sea scheggia 1.35/4 1.44/27 1.00/19 
FBgn0038271 CG3731  1.91/65 1.70/78 1.67/109 
FBgn0038277 RpS5b Ribosomal protein S5b 1.27/2 1.48/10 1.22/6 
FBgn0038293 CG6904  1.72/5 1.51/1 1.49/1 
FBgn0038570 Prx5 Peroxiredoxin 5 1.36/22 1.53/19 1.05/11 
FBgn0038922 CG6439  1.78/35 2.12/66 1.52/82 
FBgn0038946 CG7077  1.46/4 2.47/1 Not Detected 
FBgn0039241 CG11089  1.90/5 1.70/5 1.31/3 
FBgn0039358 CG5028  1.75/17 1.71/2 1.28/6 
FBgn0039537 CG5590  Not Detected 1.87/3 1.18/2 
FBgn0039635 CG11876  1.58/21 1.64/12 1.45/12 
FBgn0039682 Obp99c 
Odorant-binding 
protein 99c 
1.70/3 Not Detected 1.02/2 
FBgn0039713 RpS8 Ribosomal protein S8 1.41/5 1.07/3 1.24/5 
FBgn0039737 CG7920  1.88/28 2.20/60 1.96/65 
FBgn0039909 CG1970  Not Detected 1.50/2 1.67/5 
FBgn0040064 yip2 
yippee interacting 
protein 2 
2.24/5 2.00/16 1.49/9 
FBgn0040309 Jafrac1 
thioredoxin peroxidase 
1 
1.93/14 1.80/9 1.52/15 
FBgn0040349 CG3699  2.82/3 2.56/16 1.41/9 
FBgn0047038 CG6463  Not Detected 1.83/5 0.70/1 
FBgn0053138 CG33138  1.11/2 1.37/2 1.34/1 
FBgn0064225 RpL5 Ribosomal protein L5 1.52/5 1.53/12 1.13/12 
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FBgn0085201 CG34172  1.17/17 0.97/40 1.08/51 
FBgn0086134 Pros25 
Proteasome 25kD 
subunit 
Not Detected 1.68/7 1.23/3 
FBgn0086254 CG6084  1.44/21 1.62/11 1.22/4 
FBgn0086355 Tpi 
Triose phosphate 
isomerase 
1.36/96 1.56/150 1.18/168 
FBgn0086691 UK114 UK114 1.50/4 2.31/14 1.44/6 
FBgn0086710 RpL30 Ribosomal protein L30 1.11/3 1.16/2 0.89/1 
FBgn0086783 Mhc Myosin heavy chain 0.76/92 1.31/13 0.55/68 
FBgn0087002 Rfabg 
Retinoid- and fatty 
acid-binding 
glycoprotein 
1.15/2 0.96/10 1.15/3 
FBgn0087013 Karybeta3 Karyopherin beta 3 Not Detected 1.74/2 1.26/5 
FBgn0250814 CG4169  2.23/49 1.91/67 1.66/102 
FBgn0250838 CG30415  1.18/7 1.00/14 0.93/9 
FBgn0250906 Pgk 
Phosphoglycerate 
kinase 
1.79/35 1.86/63 1.52/37 
FBgn0260439 Pp2A-29B 
Protein phosphatase 
2A at 29B 
1.23/1 2.88/25 1.62/23 
FBgn0260441 RpS12 Ribosomal protein S12 Not Detected 1.29/6 1.19/3 
FBgn0261014 TER94 TER94 2.10/4 2.69/40 1.85/32 
FBgn0261394 Pros29 
Proteasome 29kD 
subunit 
2.07/3 1.81/2 Not Detected 
FBgn0261439 SdhA 
Succinate 
dehydrogenase A 
1.48/5 2.68/10 1.54/10 
FBgn0261592 RpS6 Ribosomal protein S6 2.08/4 1.21/7 1.18/12 
FBgn0261596 RpS24 Ribosomal protein S24 Not Detected 1.33/7 1.33/4 
FBgn0261602 RpL8 Ribosomal protein L8 1.36/2 1.63/8 1.22/4 
FBgn0261606 RpL27A 
Ribosomal protein 
L27A 
1.35/1 1.29/10 Not Detected 
FBgn0261955 kdn knockdown 1.70/172 1.86/293 1.56/314 
FBgn0262511 Vha44 
Vacuolar H[+] 
ATPase 44kD C 
subunit 
1.36/2 1.73/4 Not Detected 
FBgn0262559 Mdh2 
Malate dehydrogenase 
2 
1.97/168 2.39/235 1.71/234 
FBgn0262782 Mdh1 
Malate dehydrogenase 
1 
1.45/7 2.35/18 1.46/13 
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FBgn0263006 Ca-P60A 
Calcium ATPase at 
60A 
1.29/108 1.47/188 1.23/212 
 
Table A4 
Observed changes in protein relative abundance on exposure to Paraquat in D. melanogaster. Isolated 
mitochondrial were analyzed and quantitation was via a mass spectrometry-based proteomics approach 
using label free spectral counting method. Relative abundance of batch 1 and batch 2 were given in the 
following table as per section 3.4.2 criteria 
FlyBase protein ID Protein Symbol SpC_Batch_1_Ratio SpC_Batch_2_Ratio 
FBpp0074679 fln-PA 1.07 0.96 
FBpp0078130 CG7470-PA 1.09 0.95 
FBpp0087547 CG1516-PG 0.67 0.96 
FBpp0088252 Rfabg-PA 1.00 0.92 
FBpp0083570 ND42-PA 0.76 0.94 
FBpp0073445 Hsc70-3-PB 1.00 1.16 
FBpp0071970 levy-PA 1.13 1.16 
FBpp0077209 Pdsw-PA 0.93 0.81 
FBpp0081437 skap-PA 0.47 1.03 
FBpp0080835 CG10664-PA 0.58 1.45 
FBpp0081153 αTub84B-PA 1.05 1.30 
FBpp0088250 ATPsyn-β- PA 0.83 1.24 
FBpp0073277 sesB-PA 0.98 1.21 
FBpp0072135 Thiolase-PA 0.84 1.16 
FBpp0082459 CG3731-PA 0.88 1.20 
FBpp0080707 l(2)37Cc-PB 1.00 1.25 
FBpp0084905 ATPsyn-γ-PA 0.82 1.18 
FBpp0071373 l(1)G0230-PA 0.78 1.22 
FBpp0085736 SdhA-PB 0.83 0.93 
FBpp0074584 CG14235-PA 1.00 1.21 
FBpp0083824 ATPsyn-Cf6PA 0.43 1.66 
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FBpp0071794 blw-PA 0.99 1.41 
FBpp0081947 CoVa-PA 0.46 1.84 
FBpp0100045 Adh-PC 0.60 1.33 
FBpp0071128 ND75-PA 0.75 1.11 
FBpp0082139 Vha55-PB 0.86 1.55 
FBpp0081002 Acon-PB 0.54 0.95 
FBpp0086442 Gpo-1-PC 0.80 1.79 
FBpp0078918 CoVb-PA 0.57 0.94 
FBpp0075069 CG4169-PA 0.68 1.68 
FBpp0084275 CG5028-PA 1.00 0.78 
FBpp0100177 mt:CoII-PA 0.67 1.43 
FBpp0085720 betaTub56D-PB 0.60 0.89 
FBpp0087502 14-3-3zeta-PD 1.13 0.77 
FBpp0074549 l(1)G0156-PA 1.43 1.67 
FBpp0088503 Atpα-PB 1.30 1.51 
FBpp0072121 Ca-P60A-PE 0.61 0.76 
FBpp0083141 ATPsyn-d-PB 0.93 2.26 
FBpp0070950 CG3192-PA 0.43 0.79 
FBpp0070039 CG32230-PA 1.00 1.20 
FBpp0079771 porin-PA 0.90 2.80 
FBpp0083610 PyK-PB 1.40 2.83 
FBpp0081370 CG8036-PB 1.25 2.00 
FBpp0077343 CG3523-PA 1.08 1.92 
FBpp0076848 CG4769-PA 1.18 1.35 
FBpp0085107 l(3)03670-PA 0.75 0.92 
FBpp0084774 CG1458-PA 1.00 1.83 
FBpp0074881 Met75Ca-PA 0.55 0.44 
FBpp0083588 CG6439-PA 2.14 1.40 
FBpp0080452 Mhc-PG 0.19 0.14 
FBpp0084630 No data 1.80 1.67 
FBpp0082514 Hsc70-4-PE 0.67 0.80 
FBpp0087164 ERp60-PA 2.75 0.70 
FBpp0071448 Act57B-PA 0.64 0.47 
FBpp0100178 mt:ATPase8-PA 1.13 1.36 
FBpp0072177 βTub60D-PA 1.92 2.08 
FBpp0074298 wupA-PG 0.90 0.357 
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Table A5 
Observed changes in protein relative abundance on exposure to Paraquat in D. melanogaster. Isolated 
mitochondrial were analyzed and quantitation was via a mass spectrometry-based proteomics approach 
the iTRAQ relative quantitation system. Relative abundance of batch 1 and batch 2 were given in the 
following table as per section 3.4.3 criteria 
Flybase Protein Id Protein Symbol iTRAQ_Batch_1_Ratio iTRAQ_Batch_2_Ratio 
FBpp0082535 Tm2-PA 0.57 0.25 
FBpp0291928 Strn-Mlck-PH 0.35 0.31 
FBpp0082489 Mf-PA 0.71 0.33 
FBpp0072687 RpL23A-PA 0.71 0.50 
FBpp0070039 CG32230-PA 0.87 0.57 
FBpp0087577 CG1648-PA 0.66 0.57 
FBpp0082597 Act88F-PA 0.54 0.62 
FBpp0070094 Cyp4g1-PA 0.71 0.66 
FBpp0084367 Ald-PB 0.81 0.66 
FBpp0084275 CG5028-PA 1.15 0.66 
FBpp0072124 Ca-P60A-PA 0.62 0.71 
FBpp0074481 CG12203-PA 0.93 0.71 
FBpp0084905 ATPsyn-γ-PA 0.71 0.76 
FBpp0080835 CG10664-PA 0.62 0.76 
FBpp0083141 ATPsyn-d-PB 1.15 0.76 
FBpp0082390 CG3321-PA 1.62 0.76 
FBpp0087472 CG12140-PA 1.74 0.76 
FBpp0070950 CG3192-PA 0.93 0.76 
FBpp0110421 RpL5-PA 0.66 0.76 
FBpp0078130 CG7470-PA 0.87 0.81 
FBpp0081002 Acon-PB 0.93 0.81 
FBpp0071970 levy-PA 1.00 0.81 
FBpp0081437 skap-PA 1.07 0.81 
FBpp0077581 RFeSP-PB 0.87 0.81 
FBpp0085107 l(3)03670-PA 1.15 0.81 
FBpp0083526 CG31198-PA 1.07 0.81 
FBpp0076848 CG4769-PA 1.00 0.87 
FBpp0078918 CG11015-PA 0.81 0.87 
FBpp0085736 SdhA-PB 1.00 0.87 
FBpp0077209 Pdsw-PA 0.81 0.87 
FBpp0074679 fln-PA 1.00 0.87 
FBpp0077343 CG3523-PA 1.07 0.87 
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FBpp0082514 Hsc70-4-PE 1.23 0.87 
FBpp0073290 Hsp60-PA 1.07 0.87 
FBpp0087502 14-3-3zeta-PD 1.32 0.87 
FBpp0289781 PMCA-PI 1.23 0.87 
FBpp0070871 kdn-PB 0.71 0.87 
FBpp0071373 l(1)G0230-PA 1.00 0.93 
FBpp0071128 ND75-PA 1.00 0.93 
FBpp0087539 CG1516-PI 1.07 0.93 
FBpp0077859 CG6020-PA 0.93 0.93 
FBpp0080707 l(2)37Cc-PB 1.07 0.93 
FBpp0073594 Jafrac1-PB 0.87 0.93 
FBpp0081062 alphaTub84DPA 1.00 1.00 
FBpp0073445 Hsc70-3-PB 1.00 1.00 
FBpp0085720 betaTub56D-PB 1.07 1.00 
FBpp0074584 CG14235-PA 0.87 1.00 
FBpp0087142 Ef1alpha48D-PA 1.15 1.00 
FBpp0071939 CG30415-PA 1.07 1.00 
FBpp0079454 CG4389-PA 1.00 1.00 
FBpp0084774 CG1458-PA 0.87 1.00 
FBpp0087972 cathD-PA 1.07 1.00 
FBpp0100045 Adh-PC 0.87 1.00 
FBpp0075755 l(3)neo18-PA 0.76 1.00 
FBpp0078847 CG9140-PA 1.15 1.00 
FBpp0071794 blw-PA 0.93 1.07 
FBpp0088250 ATPsyn-beta-PA 0.93 1.07 
FBpp0086442 Gpo-1-PC 0.81 1.07 
FBpp0083570 ND42-PA 0.81 1.07 
FBpp0083588 CG6439-PA 1.23 1.07 
FBpp0072975 CG12079-PA 0.87 1.07 
FBpp0072135 Thiolase-PA 1.32 1.07 
FBpp0100178 mt:ATPase8-PA 1.74 1.07 
FBpp0084901 CG7834-PA 1.41 1.07 
FBpp0088252 Rfabg-PA 1.32 1.07 
FBpp0081834 CG5214-PA 0.93 1.07 
FBpp0081074 alpha-Est7-PA 1.23 1.07 
FBpp0081581 Crc-PA 1.07 1.07 
FBpp0083503 Rab1-PA 0.87 1.07 
FBpp0088502 Atpalpha-PA 1.32 1.15 
FBpp0082459 CG3731-PA 1.15 1.15 
176 
  
FBpp0082645 ND23-PA 0.76 1.15 
FBpp0086694 Hsc70-5-PA 1.74 1.15 
FBpp0075069 CG4169-PA 0.87 1.23 
FBpp0083824 ATPsyn-Cf6-PA 0.76 1.23 
FBpp0078707 cype-PA 1.52 1.23 
FBpp0289511 CG7461-PB 1.07 1.23 
FBpp0079771 porin-PA 1.00 1.32 
FBpp0081947 CoVa-PA 0.57 1.32 
FBpp0081370 CG8036-PB 1.23 1.32 
FBpp0072672 alpha-Spec-PA 1.15 1.32 
FBpp0083126 NP15.6-PA 1.07 1.32 
FBpp0085615 CG9090-PA 0.93 1.41 
FBpp0073277 sesB-PA 1.15 1.52 
FBpp0072246 CG4692-PB 1.07 1.52 
FBpp0073950 CG9172-PB 1.00 1.52 
FBpp0082522 Oscp-PA 0.93 1.74 
Table A6 
Observed changes in carbonylated protein relative abundance due to Sod2 knockdown in D. 
melanogaster. Whole fly homogenates were analyzed and quantitation was via a mass 
spectrometry-based proteomics approach using the iTRAQ relative quantitation system. 
Carbonylated proteins were organized into groups by parent gene. Measurements were obtained 
for 276 carbonylated protein groups after requiring at least five PSMs with no missing reporter 
ions and excluding those groups suspected of being prone to non-specific binding. Separate Sod2 
knockdown versus control ratios are presented for the da-Gal4 driver alone and UAS-Sod2-IR24 
transgene alone controls. Here, the three repeats performed have been combined. 
FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Coun
t 
Sod2 
Knockdown 
versus da-
Gal4 Driver 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
Sod2 
Knockdown 
versus UAS-
Sod2-IR24 
Transgene 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
FBgn0011768 Fdh 
Formaldehyde 
dehydrogenase 
5 2.68 1.32 
FBgn0036766 CG5506  11 2.48 2.45 
FBgn0031830 CG11015  35 2.39 2.26 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Coun
t 
Sod2 
Knockdown 
versus da-
Gal4 Driver 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
Sod2 
Knockdown 
versus UAS-
Sod2-IR24 
Transgene 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
FBgn0032350 CG6287  5 1.99 2.39 
FBgn0052230 CG32230  5 1.72 1.21 
FBgn0021906 RFeSP 
Rieske iron-sulfur 
protein 
42 1.67 1.58 
FBgn0000045 Act79B Actin 79B 5 1.66 2.24 
FBgn0004242 Syt1 Synaptotagmin 1 8 1.66 1.61 
FBgn0000150 awd abnormal wing discs 28 1.60 1.41 
FBgn0001098 Gdh 
Glutamate 
dehydrogenase 
29 1.59 1.67 
FBgn0002921 Atpalpha Na pump alpha subunit 158 1.58 1.62 
FBgn0038224 CG3321  12 1.57 1.52 
FBgn0000047 Act88F Actin 88F 5 1.56 1.39 
FBgn0000557 
Ef1alpha10
0E 
Elongation factor 
1alpha100E 
5 1.55 1.74 
FBgn0032946 nrv3 nervana 3 6 1.55 1.62 
FBgn0020908 Scp1 
Sarcoplasmic calcium-
binding protein 1 
672 1.52 1.26 
FBgn0019644 ATPsyn-b ATP synthase, subunit b 200 1.51 1.56 
FBgn0038774 CG5023  5 1.49 1.43 
FBgn0019957 ND42 
NADH:ubiquinone 
reductase 42kD subunit 
precursor 
17 1.48 1.46 
FBgn0038181 CG9297  12 1.48 1.22 
FBgn0033608 CG13220  13 1.47 1.43 
FBgn0053113 Rtnl1 Rtnl1 14 1.45 1.49 
FBgn0000667 Actn alpha actinin 24 1.45 1.29 
FBgn0037580 DppIII 
Dipeptidyl 
aminopeptidase III 
15 1.45 1.51 
FBgn0001092 Gapdh2 
Glyceraldehyde 3 
phosphate 
dehydrogenase 2 
41 1.44 1.41 
FBgn0029823 CG3011  14 1.44 1.13 
FBgn0004419 me31B 
maternal expression at 
31B 
8 1.44 1.00 
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ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Coun
t 
Sod2 
Knockdown 
versus da-
Gal4 Driver 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
Sod2 
Knockdown 
versus UAS-
Sod2-IR24 
Transgene 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
FBgn0010612 l(2)06225 lethal (2) 06225 139 1.43 1.32 
FBgn0036728 CG7580  36 1.42 1.29 
FBgn0250814 CG4169  228 1.41 1.23 
FBgn0001186 Hex-A Hexokinase A 15 1.41 1.26 
FBgn0037891 CG5214  89 1.40 1.42 
FBgn0024238 Fim Fimbrin 24 1.40 1.45 
FBgn0004516 Gad1 
Glutamic acid 
decarboxylase 1 
25 1.40 1.67 
FBgn0005671 Vha55 
Vacuolar H[+]-ATPase 
55kD B subunit 
120 1.40 1.47 
FBgn0087002 Rfabg 
Retinoid- and fatty acid-
binding glycoprotein 
227 1.40 1.27 
FBgn0034497 CG9090  630 1.39 1.25 
FBgn0039909 CG1970  61 1.39 1.27 
FBgn0028325 l(1)G0334 lethal (1) G0334 101 1.39 1.20 
FBgn0263006 Ca-P60A Calcium ATPase at 60A 1024 1.38 1.37 
FBgn0011661 Moe Moesin 57 1.38 1.31 
FBgn0039635 CG11876  69 1.38 1.27 
FBgn0250838 CG30415  102 1.37 1.28 
FBgn0030733 CG3560  11 1.37 1.03 
FBgn0004907 14-3-3zeta 14-3-3zeta 34 1.37 1.22 
FBgn0035404 CG12079  7 1.36 1.31 
FBgn0013678 mt:Cyt-b 
mitochondrial 
Cytochrome b 
74 1.36 1.18 
FBgn0001128 Gpdh 
Glycerol 3 phosphate 
dehydrogenase 
1017 1.36 1.12 
FBgn0261955 kdn knockdown 871 1.35 1.41 
FBgn0023023 CRMP 
Collapsin Response 
Mediator Protein 
6 1.35 1.29 
FBgn0003423 slgA sluggish A 12 1.35 1.70 
FBgn0037001 CG6020  99 1.35 1.23 
FBgn0001149 GstD1 
Glutathione S transferase 
D1 
15 1.34 1.21 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Coun
t 
Sod2 
Knockdown 
versus da-
Gal4 Driver 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
Sod2 
Knockdown 
versus UAS-
Sod2-IR24 
Transgene 
Alone 
Control 
Carbonylate
d Protein 
Relative 
Abundance 
Ratio 
FBgn0029868 CG3446  25 1.34 1.20 
FBgn0010551 l(2)03709 lethal (2) 03709 6 1.33 1.50 
FBgn0038922 CG6439  128 1.33 1.25 
FBgn0259209 Mlp60A 
Muscle LIM protein at 
60A 
13 1.33 1.09 
FBgn0038293 CG6904  19 1.32 1.31 
FBgn0038271 CG3731  213 1.32 1.11 
FBgn0037643 skap skpA associated protein 106 1.32 1.29 
FBgn0004363 porin porin 83 1.32 1.26 
FBgn0010217 
ATPsyn-
beta 
ATP synthase-beta 814 1.32 1.21 
FBgn0027291 l(1)G0156 lethal (1) G0156 177 1.32 1.20 
FBgn0003178 PyK Pyruvate kinase 519 1.31 1.14 
FBgn0031771 CG9140  53 1.31 1.16 
FBgn0035600 CG4769  318 1.31 1.35 
FBgn0038519 Prx3 Peroxiredoxin 3 6 1.31 1.11 
FBgn0011726 tsr twinstar 7 1.31 1.17 
FBgn0002938 ninaC 
neither inactivation nor 
afterpotential C 
29 1.31 1.16 
FBgn0020235 
ATPsyn-
gamma 
ATP synthase-gamma 
chain 
420 1.30 1.21 
FBgn0013673 mt:ATPase8 
mitochondrial ATPase 
subunit 8 
28 1.30 1.29 
FBgn0003360 sesB stress-sensitive B 1308 1.29 1.21 
FBgn0011211 blw bellwether 1241 1.29 1.15 
FBgn0004507 GlyP Glycogen phosphorylase 657 1.29 1.17 
FBgn0002940 ninaE 
neither inactivation nor 
afterpotential E 
5 1.29 1.28 
FBgn0032820 fbp 
fructose-1,6-
bisphosphatase 
12 1.29 1.16 
FBgn0260439 Pp2A-29B 
Protein phosphatase 2A 
at 29B 
19 1.28 0.90 
180 
  
FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
PSM 
Coun
t 
Sod2 
Knockdown 
versus da-
Gal4 Driver 
Alone 
Control 
Carbonylate
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FBgn0038020 GstD9 
Glutathione S transferase 
D9 
13 1.28 0.94 
FBgn0013675 mt:CoII 
mitochondrial 
Cytochrome c oxidase 
subunit II 
185 1.28 1.30 
FBgn0025352 Thiolase Thiolase 5 1.27 1.15 
FBgn0011227 ox oxen 16 1.27 1.14 
FBgn0037715 CG9399  21 1.26 1.22 
FBgn0262559 Mdh2 Malate dehydrogenase 2 448 1.26 1.18 
FBgn0003887 betaTub56D beta-Tubulin at 56D 33 1.26 1.09 
FBgn0027785 NP15.6 NP15.6 9 1.26 1.12 
FBgn0020238 
14-3-
3epsilon 
14-3-3epsilon 51 1.26 1.11 
FBgn0010100 Acon Aconitase 338 1.25 1.22 
FBgn0004868 Gdi 
GDP dissociation 
inhibitor 
5 1.25 1.20 
FBgn0032511 CG9306  46 1.23 1.18 
FBgn0004636 R Roughened 11 1.23 1.07 
FBgn0039737 CG7920  126 1.23 1.29 
FBgn0086783 Mhc Myosin heavy chain 14 1.23 1.32 
FBgn0000319 Chc Clathrin heavy chain 29 1.23 1.06 
FBgn0001989 l(2)35Di lethal (2) 35Di 6 1.22 1.19 
FBgn0039049 CG6726  5 1.22 1.04 
FBgn0031436 CG3214  9 1.22 1.08 
FBgn0036030 CG6767  5 1.22 0.86 
FBgn0000116 Argk Arginine kinase 553 1.22 1.11 
FBgn0037874 Tctp 
Translationally 
controlled tumor protein 
21 1.21 1.00 
FBgn0039674 CG1907  15 1.21 1.27 
FBgn0016120 ATPsyn-d ATP synthase, subunit d 63 1.21 1.07 
FBgn0015031 cype cyclope 94 1.20 1.10 
FBgn0036213 RpL10Ab 
Ribosomal protein 
L10Ab 
12 1.20 1.13 
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FBgn0000406 Cyt-b5-r Cytochrome b5-related 17 1.20 1.12 
FBgn0013684 mt:ND5 
mitochondrial NADH-
ubiquinone 
oxidoreductase chain 5 
6 1.20 0.98 
FBgn0250906 Pgk Phosphoglycerate kinase 49 1.19 1.05 
FBgn0030239 CG17333  15 1.19 0.98 
FBgn0086134 Pros25 
Proteasome 25kD 
subunit 
5 1.19 1.03 
FBgn0037146 CG7470  5 1.19 1.21 
FBgn0034877 levy levy 20 1.19 1.12 
FBgn0000556 
Ef1alpha48
D 
Elongation factor 
1alpha48D 
74 1.19 1.20 
FBgn0004867 RpS2 Ribosomal protein S2 41 1.19 1.17 
FBgn0039358 CG5028  46 1.18 1.15 
FBgn0003074 Pgi 
Phosphoglucose 
isomerase 
56 1.18 1.17 
FBgn0032833 CG10664  195 1.18 1.21 
FBgn0001187 Hex-C Hexokinase C 6 1.18 1.00 
FBgn0031912 CG5261  150 1.17 1.05 
FBgn0086254 CG6084  7 1.17 0.91 
FBgn0036762 CG7430  28 1.17 1.05 
FBgn0020910 RpL3 Ribosomal protein L3 17 1.16 0.99 
FBgn0010352 Nc73EF 
Neural conserved at 
73EF 
177 1.16 0.97 
FBgn0029155 Men-b Malic enzyme b 43 1.16 1.19 
FBgn0026439 Eaat1 
Excitatory amino acid 
transporter 1 
31 1.16 1.20 
FBgn0027779 VhaSFD 
Vacuolar H[+]-ATPase 
SFD subunit 
56 1.16 1.12 
FBgn0040309 Jafrac1 thioredoxin peroxidase 1 16 1.16 0.92 
FBgn0030853 CG5703  20 1.16 0.97 
FBgn0013988 Strn-Mlck Stretchin-Mlck 5 1.16 1.13 
FBgn0001233 Hsp83 Heat shock protein 83 63 1.15 0.94 
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FBgn0013674 mt:CoI 
mitochondrial 
Cytochrome c oxidase 
subunit I 
6 1.14 1.13 
FBgn0023143 Uba1 
Ubiquitin activating 
enzyme 1 
15 1.14 0.96 
FBgn0039359 RpL27 Ribosomal protein L27 5 1.14 1.09 
FBgn0028686 Rpt3 Rpt3 8 1.14 0.81 
FBgn0028685 Rpt4 Rpt4 40 1.14 0.92 
FBgn0036927 CG7433  5 1.14 1.12 
FBgn0085201 CG34172  124 1.13 1.19 
FBgn0004888 Scsalpha 
Succinyl coenzyme A 
synthetase alpha subunit 
16 1.13 0.99 
FBgn0013325 RpL11 Ribosomal protein L11 6 1.13 1.01 
FBgn0020618 Rack1 
Receptor of activated 
protein kinase C 1 
42 1.13 0.91 
FBgn0261596 RpS24 Ribosomal protein S24 57 1.13 1.07 
FBgn0010412 RpS19a Ribosomal protein S19a 7 1.12 1.27 
FBgn0002772 Mlc1 
Myosin alkali light chain 
1 
33 1.12 0.97 
FBgn0010226 GstS1 
Glutathione S transferase 
S1 
78 1.12 1.12 
FBgn0020513 ade5 ade5 118 1.12 0.95 
FBgn0086355 Tpi 
Triose phosphate 
isomerase 
245 1.12 0.96 
FBgn0001220 Hsc70-5 
Heat shock protein 
cognate 5 
5 1.11 1.13 
FBgn0005533 RpS17 Ribosomal protein S17 16 1.11 1.24 
FBgn0019830 colt congested-like trachea 6 1.11 1.08 
FBgn0035422 RpL28 Ribosomal protein L28 18 1.11 1.07 
FBgn0014869 Pglym78 Phosphoglyceromutase 19 1.11 1.03 
FBgn0027657 glob1 globin 1 14 1.11 1.03 
FBgn0002590 RpS5a Ribosomal protein S5a 46 1.11 1.04 
FBgn0028968 gammaCop gamma-coatomer protein 18 1.11 0.93 
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FBgn0015288 RpL22 Ribosomal protein L22 9 1.10 1.03 
FBgn0037138 CG7145  26 1.10 1.17 
FBgn0013679 mt:ND1 
mitochondrial NADH-
ubiquinone 
oxidoreductase chain 1 
16 1.10 0.95 
FBgn0026479 Drp1 
Dynamin related protein 
1 
5 1.10 0.98 
FBgn0016687 Nurf-38 
Nucleosome remodeling 
factor - 38kD 
30 1.09 0.96 
FBgn0000064 Ald Aldolase 629 1.09 1.08 
FBgn0064225 RpL5 Ribosomal protein L5 10 1.09 1.10 
FBgn0000055 Adh Alcohol dehydrogenase 912 1.09 0.92 
FBgn0026409 Mpcp 
Mitochondrial phosphate 
carrier protein 
135 1.09 0.95 
FBgn0013681 mt:ND3 
mitochondrial NADH-
ubiquinone 
oxidoreductase chain 3 
5 1.09 0.91 
FBgn0002773 Mlc2 Myosin light chain 2 18 1.08 1.05 
FBgn0034618 CG9485  9 1.07 0.91 
FBgn0003076 Pgm 
Phosphogluconate 
mutase 
24 1.07 1.05 
FBgn0024556 EfTuM 
Elongation factor Tu 
mitochondrial 
26 1.07 1.01 
FBgn0029176 Ef1gamma Ef1gamma 20 1.07 0.98 
FBgn0010198 RpS15Aa 
Ribosomal protein 
S15Aa 
24 1.07 0.92 
FBgn0038570 Prx5 Peroxiredoxin 5 36 1.06 0.93 
FBgn0053138 CG33138  31 1.06 1.12 
FBgn0001248 Idh Isocitrate dehydrogenase 121 1.06 0.86 
FBgn0000579 Eno Enolase 302 1.06 1.00 
FBgn0027493 CG17273  8 1.06 1.06 
FBgn0029687 Vap-33-1 Vap-33-1 10 1.06 0.95 
FBgn0037245 growl growl 9 1.05 0.99 
FBgn0032783 CG10237  6 1.05 1.00 
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FBgn0001145 Gs2 Glutamine synthetase 2 9 1.05 0.97 
FBgn0010265 RpS13 Ribosomal protein S13 14 1.05 1.05 
FBgn0000083 AnnIX Annexin IX 5 1.05 0.95 
FBgn0261439 SdhA 
Succinate 
dehydrogenase A 
52 1.05 0.91 
FBgn0086372 lap like-AP180 10 1.05 0.89 
FBgn0034259 CG6459  10 1.05 0.98 
FBgn0035753 RpL18 Ribosomal protein L18 27 1.05 0.90 
FBgn0003071 Pfk Phosphofructokinase 228 1.04 1.03 
FBgn0000409 Cyt-c-p Cytochrome c proximal 289 1.04 1.11 
FBgn0014455 Ahcy13 
Adenosylhomocysteinas
e at 13 
6 1.04 0.80 
FBgn0027590 CG16936  25 1.04 1.17 
FBgn0020385 pug pugilist 6 1.04 0.98 
FBgn0002622 RpS3 Ribosomal protein S3 54 1.03 0.92 
FBgn0020236 ATPCL ATP citrate lyase 88 1.03 0.85 
FBgn0022160 Gpo-1 
Glycerophosphate 
oxidase-1 
214 1.03 0.92 
FBgn0033912 RpS23 Ribosomal protein S23 11 1.02 0.92 
FBgn0024733 RpL10 Ribosomal protein L10 45 1.02 0.82 
FBgn0001125 Got2 
Glutamate oxaloacetate 
transaminase 2 
19 1.02 0.87 
FBgn0015623 Cpr 
Cytochrome P450 
reductase 
6 1.02 0.95 
FBgn0029897 RpL17 Ribosomal protein L17 62 1.02 0.88 
FBgn0039830 CG1746  14 1.02 1.15 
FBgn0033699 RpS11 Ribosomal protein S11 14 1.01 0.94 
FBgn0002593 RpLP1 Ribosomal protein LP1 12 1.01 0.85 
FBgn0027560 Tps1 
Trehalose-6-phosphate 
synthase 1 
218 1.01 0.84 
FBgn0005593 RpL7 Ribosomal protein L7 42 1.01 0.91 
FBgn0037913 CG6783  19 1.01 0.80 
FBgn0034743 RpS16 Ribosomal protein S16 24 1.00 0.86 
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FBgn0010078 RpL23 Ribosomal protein L23 8 1.00 1.02 
FBgn0028697 RpL15 Ribosomal protein L15 10 1.00 0.85 
FBgn0004066 Pros28.1 
Proteasome 28kD 
subunit 1 
7 1.00 0.81 
FBgn0001219 Hsc70-4 
Heat shock protein 
cognate 4 
14 1.00 1.05 
FBgn0039757 RpS7 Ribosomal protein S7 9 1.00 0.96 
FBgn0001942 eIF-4a 
Eukaryotic initiation 
factor 4a 
25 1.00 0.83 
FBgn0000261 Cat Catalase 72 1.00 1.04 
FBgn0020367 Vha68-2 
Vacuolar H[+] ATPase 
subunit 68-2 
70 1.00 1.02 
FBgn0261014 TER94 TER94 44 0.99 0.80 
FBgn0037607 CG8036  69 0.99 0.92 
FBgn0003256 rl rolled 6 0.99 1.13 
FBgn0028479 CG4389  29 0.99 0.88 
FBgn0004654 Pgd 
Phosphogluconate 
dehydrogenase 
38 0.98 0.93 
FBgn0036044 CG14168  5 0.98 0.94 
FBgn0034138 RpS15 Ribosomal protein S15 16 0.98 1.19 
FBgn0260441 RpS12 Ribosomal protein S12 14 0.98 0.83 
FBgn0052549 CG32549  8 0.97 0.82 
FBgn0003676 T-cp1 Tcp1-like 25 0.97 0.78 
FBgn0037547 CG7910  6 0.97 1.07 
FBgn0017545 RpS3A Ribosomal protein S3A 39 0.97 0.87 
FBgn0019624 CoVa 
Cytochrome c oxidase 
subunit Va 
20 0.96 0.81 
FBgn0032987 RpL21 Ribosomal protein L21 14 0.96 0.93 
FBgn0010408 RpS9 Ribosomal protein S9 15 0.96 0.90 
FBgn0010409 RpL18A Ribosomal protein L18A 15 0.95 0.85 
FBgn0002607 RpL19 Ribosomal protein L19 31 0.95 0.81 
FBgn0011272 RpL13 Ribosomal protein L13 37 0.95 0.78 
FBgn0002789 Mp20 Muscle protein 20 20 0.95 0.94 
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FBgn0002579 RpL36 Ribosomal protein L36 12 0.95 0.94 
FBgn0037912 sea scheggia 17 0.94 0.82 
FBgn0002719 Men Malic enzyme 76 0.94 0.85 
FBgn0038277 RpS5b Ribosomal protein S5b 14 0.94 0.76 
FBgn0027571 CG3523  143 0.94 0.84 
FBgn0016691 Oscp 
Oligomycin sensitivity-
conferring protein 
181 0.93 1.00 
FBgn0039857 RpL6 Ribosomal protein L6 35 0.93 0.86 
FBgn0037328 RpL35A Ribosomal protein L35A 15 0.93 0.89 
FBgn0261592 RpS6 Ribosomal protein S6 44 0.93 0.83 
FBgn0040349 CG3699  18 0.92 0.72 
FBgn0003149 Prm Paramyosin 22 0.91 1.17 
FBgn0017567 ND23 
NADH:ubiquinone 
reductase 23kD subunit 
precursor 
12 0.91 0.73 
FBgn0015324 Vha26 
Vacuolar H[+]-ATPase 
26kD E subunit 
23 0.90 0.87 
FBgn0261602 RpL8 Ribosomal protein L8 17 0.90 0.89 
FBgn0028688 Rpn7 Rpn7 5 0.89 0.80 
FBgn0030136 RpS28b Ribosomal protein S28b 33 0.89 0.77 
FBgn0037351 RpL13A Ribosomal protein L13A 19 0.89 0.84 
FBgn0004432 Cyp1 Cyclophilin 1 19 0.89 0.80 
FBgn0004045 Yp1 Yolk protein 1 27 0.88 0.69 
FBgn0035811 CG12262  10 0.88 0.86 
FBgn0039713 RpS8 Ribosomal protein S8 50 0.87 0.81 
FBgn0032518 RpL24 Ribosomal protein L24 20 0.87 0.79 
FBgn0047038 CG6463  6 0.86 0.76 
FBgn0010411 RpS18 Ribosomal protein S18 29 0.86 0.74 
FBgn0262782 Mdh1 Malate dehydrogenase 1 9 0.85 0.76 
FBgn0012036 Aldh 
Aldehyde 
dehydrogenase 
20 0.85 0.90 
FBgn0029785 RpL35 Ribosomal protein L35 11 0.85 0.78 
FBgn0010019 Cyp4g1 Cytochrome P450-4g1 147 0.85 0.87 
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FBgn0030737 CG9914  11 0.84 0.68 
FBgn0031913 CG5958  9 0.83 0.79 
FBgn0023477 Tal Tal 5 0.82 0.78 
FBgn0005391 Yp2 Yolk protein 2 12 0.82 0.66 
FBgn0035189 CG9119  6 0.82 0.75 
FBgn0003279 RpL4 Ribosomal protein L4 73 0.81 0.77 
FBgn0002626 RpL32 Ribosomal protein L32 8 0.81 0.80 
FBgn0004047 Yp3 Yolk protein 3 431 0.77 0.60 
FBgn0261606 RpL27A Ribosomal protein L27A 8 0.75 0.67 
FBgn0033663 ERp60 ERp60 11 0.70 0.61 
FBgn0034152 Acp53C14a Acp53C14a 7 0.69 0.75 
FBgn0026372 RpL23A Ribosomal protein L23A 5 0.66 0.56 
FBgn0023507 CG3835  22 0.63 0.74 
FBgn0038834 RpS30 Ribosomal protein S30 5 0.61 0.56 
FBgn0086691 UK114 UK114 12 0.60 0.56 
FBgn0033978 Cyp6a23 Cyp6a23 10 0.58 0.95 
FBgn0040074 retinin retinin 7 0.42 0.43 
FBgn0031159 CG11566  9 0.21 1.43 
 
Table A7 
Observed changes in carbonylated protein relative abundance due to Sod2 knockdown in D. 
melanogaster. Whole fly homogenates were analyzed and quantitation was via a mass 
spectrometry-based proteomics approach using the iTRAQ relative quantitation system. 
Carbonylated proteins were organized into groups by parent gene. Measurements were obtained 
for 276 carbonylated protein groups after requiring at least five PSMs with no missing reporter 
ions and excluding those groups suspected of being prone to non-specific binding. Separate Sod2 
knockdown versus control ratios are presented for the da-Gal4 driver alone and UAS-Sod2-IR24 
transgene alone controls. Here, information for the three repeats has been provided. *Sod2 
knockdown versus da-Gal4 driver alone control ratio/Sod2 knockdown versus UAS-Sod2-IR24 
transgene alone control ratio/PSM count. 
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FBgn0000045 Act79B Actin 79B 
Not 
Detected 
Not 
Detected 
1.66/2.24/5 
FBgn0000047 Act88F Actin 88F 1.40/1.23/3 1.72/1.48/1 1.95/1.87/1 
FBgn0000055 Adh 
Alcohol 
dehydrogenase 
0.92/0.74/2
36 
1.04/0.82/2
66 
1.24/1.13/4
10 
FBgn0000064 Ald Aldolase 
0.85/0.79/1
98 
0.98/0.94/1
93 
1.47/1.56/2
38 
FBgn0000083 AnnIX Annexin IX 1.05/0.95/5 
Not 
Detected 
Not 
Detected 
FBgn0000116 Argk Arginine kinase 
1.05/0.93/2
30 
1.29/1.16/2
15 
1.51/1.50/1
08 
FBgn0000150 awd abnormal wing discs 1.19/0.93/2 1.63/1.19/9 
1.63/1.62/1
7 
FBgn0000261 Cat Catalase 
0.78/0.81/1
2 
0.92/0.97/1
7 
1.10/1.14/4
3 
FBgn0000319 Chc Clathrin heavy chain 
1.18/0.98/1
1 
1.23/1.06/1
6 
1.51/1.64/2 
FBgn0000406 Cyt-b5-r 
Cytochrome b5-
related 
Not 
Detected 
Not 
Detected 
1.20/1.12/1
7 
FBgn0000409 Cyt-c-p 
Cytochrome c 
proximal 
0.77/0.80/8
3 
1.04/1.15/1
40 
1.52/1.53/6
6 
FBgn0000556 
Ef1alpha48
D 
Elongation factor 
1alpha48D 
1.12/0.77/8 
1.18/1.12/2
0 
1.20/1.33/4
6 
FBgn0000557 
Ef1alpha10
0E 
Elongation factor 
1alpha100E 
Not 
Detected 
Not 
Detected 
1.55/1.74/5 
FBgn0000579 Eno Enolase 
0.93/0.82/1
11 
0.96/0.92/1
12 
1.45/1.52/7
9 
FBgn0000667 Actn alpha actinin 
1.45/1.13/1
2 
1.47/1.43/8 1.40/1.56/4 
FBgn0001092 Gapdh2 
Glyceraldehyde 3 
phosphate 
dehydrogenase 2 
1.96/1.92/2 1.15/1.93/2 
1.44/1.37/3
7 
FBgn0001098 Gdh 
Glutamate 
dehydrogenase 
1.15/1.01/1 1.67/1.40/5 
1.59/1.77/2
3 
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FBgn0001125 Got2 
Glutamate 
oxaloacetate 
transaminase 2 
0.96/0.80/1
2 
1.10/0.94/6 1.36/1.32/1 
FBgn0001128 Gpdh 
Glycerol 3 
phosphate 
dehydrogenase 
1.12/0.91/3
07 
1.37/1.09/4
76 
1.72/1.56/2
34 
FBgn0001145 Gs2 
Glutamine 
synthetase 2 
0.86/0.79/5 1.25/1.27/1 1.39/1.25/3 
FBgn0001149 GstD1 
Glutathione S 
transferase D1 
1.25/0.96/4 1.42/1.22/5 1.33/1.38/6 
FBgn0001186 Hex-A Hexokinase A 1.33/1.05/3 1.39/1.18/7 1.51/1.55/5 
FBgn0001187 Hex-C Hexokinase C 
Not 
Detected 
1.18/0.77/1 1.18/1.06/5 
FBgn0001219 Hsc70-4 
Heat shock protein 
cognate 4 
0.64/0.66/4 
Not 
Detected 
1.19/1.26/1
0 
FBgn0001220 Hsc70-5 
Heat shock protein 
cognate 5 
1.22/1.22/4 0.78/0.85/1 
Not 
Detected 
FBgn0001233 Hsp83 
Heat shock protein 
83 
0.97/0.78/2
2 
1.03/0.85/1
7 
1.44/1.19/2
4 
FBgn0001248 Idh 
Isocitrate 
dehydrogenase 
0.91/0.71/5
6 
1.17/0.88/4
0 
1.28/1.25/2
5 
FBgn0001942 eIF-4a 
Eukaryotic initiation 
factor 4a 
0.98/0.81/1
9 
1.02/0.88/5 1.36/0.86/1 
FBgn0001989 l(2)35Di lethal (2) 35Di 1.11/0.90/2 1.22/1.03/1 1.31/1.51/3 
FBgn0002579 RpL36 
Ribosomal protein 
L36 
0.88/0.67/1 1.00/1.00/1 
0.95/0.97/1
0 
FBgn0002590 RpS5a 
Ribosomal protein 
S5a 
0.98/0.96/1
7 
1.19/0.99/1
9 
1.19/1.32/1
0 
FBgn0002593 RpLP1 
Ribosomal protein 
LP1 
0.97/0.83/7 1.07/0.88/5 
Not 
Detected 
FBgn0002607 RpL19 
Ribosomal protein 
L19 
0.97/0.80/1
1 
1.14/0.98/8 
0.83/0.74/1
2 
FBgn0002622 RpS3 
Ribosomal protein 
S3 
0.93/0.77/2
5 
1.03/0.91/1
1 
1.20/1.17/1
8 
FBgn0002626 RpL32 
Ribosomal protein 
L32 
0.88/0.76/2 
Not 
Detected 
0.78/0.81/6 
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FBgn0002719 Men Malic enzyme 
0.78/0.69/1
7 
0.82/0.68/3
0 
1.23/1.20/2
9 
FBgn0002772 Mlc1 
Myosin alkali light 
chain 1 
1.07/0.93/2
2 
1.25/1.05/1
1 
Not 
Detected 
FBgn0002773 Mlc2 Myosin light chain 2 1.20/1.10/5 
1.03/1.04/1
3 
Not 
Detected 
FBgn0002789 Mp20 Muscle protein 20 
0.95/0.94/1
2 
0.84/0.86/6 1.30/1.30/2 
FBgn0002921 Atpalpha 
Na pump alpha 
subunit 
1.36/1.04/1
5 
1.41/1.40/4
1 
1.69/1.84/1
02 
FBgn0002938 ninaC 
neither inactivation 
nor afterpotential C 
1.11/0.93/7 1.39/1.20/9 
1.36/1.28/1
3 
FBgn0002940 ninaE 
neither inactivation 
nor afterpotential E 
1.23/1.25/4 
Not 
Detected 
1.54/1.40/1 
FBgn0003071 Pfk Phosphofructokinase 
0.94/0.88/8
1 
1.04/1.01/1
00 
1.26/1.37/4
7 
FBgn0003074 Pgi 
Phosphoglucose 
isomerase 
1.23/0.93/5 0.84/0.72/6 
1.23/1.29/4
5 
FBgn0003076 Pgm 
Phosphogluconate 
mutase 
0.87/0.90/1
0 
1.11/0.96/6 1.35/1.36/8 
FBgn0003149 Prm Paramyosin 0.82/1.07/7 0.85/1.02/8 1.10/1.50/7 
FBgn0003178 PyK Pyruvate kinase 
1.07/0.83/1
37 
1.25/1.02/1
66 
1.55/1.51/2
16 
FBgn0003256 rl rolled 0.96/1.08/2 1.00/1.15/4 
Not 
Detected 
FBgn0003279 RpL4 
Ribosomal protein 
L4 
0.87/0.75/1
1 
1.18/0.95/9 
0.75/0.75/5
3 
FBgn0003360 sesB stress-sensitive B 
1.14/0.99/3
11 
1.40/1.21/3
37 
1.32/1.33/6
60 
FBgn0003423 slgA sluggish A 
Not 
Detected 
1.06/1.17/1 
1.38/1.76/1
1 
FBgn0003676 T-cp1 Tcp1-like 0.84/0.60/8 0.98/0.77/9 1.11/1.04/8 
FBgn0003887 
betaTub56
D 
beta-Tubulin at 56D 1.15/0.90/7 1.26/1.03/6 
1.30/1.18/2
0 
FBgn0004045 Yp1 Yolk protein 1 
0.74/0.59/1
1 
0.99/0.76/1
6 
Not 
Detected 
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FBgn0004047 Yp3 Yolk protein 3 
0.63/0.51/1
56 
0.74/0.50/1
55 
1.06/0.93/1
20 
FBgn0004066 Pros28.1 
Proteasome 28kD 
subunit 1 
0.95/0.83/2 1.02/0.80/5 
Not 
Detected 
FBgn0004242 Syt1 Synaptotagmin 1 1.29/1.16/3 
Not 
Detected 
1.93/1.96/5 
FBgn0004363 porin porin 
Not 
Detected 
Not 
Detected 
1.32/1.26/8
3 
FBgn0004419 me31B 
maternal expression 
at 31B 
Not 
Detected 
Not 
Detected 
1.44/1.00/8 
FBgn0004432 Cyp1 Cyclophilin 1 
0.88/0.79/1
7 
0.99/0.88/2 
Not 
Detected 
FBgn0004507 GlyP 
Glycogen 
phosphorylase 
1.16/0.90/1
17 
1.14/1.02/1
15 
1.38/1.31/4
25 
FBgn0004516 Gad1 
Glutamic acid 
decarboxylase 1 
1.37/1.26/4 1.25/1.31/6 
1.47/1.99/1
5 
FBgn0004636 R Roughened 1.14/0.99/3 1.27/1.11/8 
Not 
Detected 
FBgn0004654 Pgd 
Phosphogluconate 
dehydrogenase 
0.87/0.76/1
2 
0.82/0.90/1
5 
1.44/1.21/1
1 
FBgn0004867 RpS2 
Ribosomal protein 
S2 
0.72/0.66/1 
Not 
Detected 
1.20/1.19/4
0 
FBgn0004868 Gdi 
GDP dissociation 
inhibitor 
1.05/0.95/3 
Not 
Detected 
1.60/1.71/2 
FBgn0004888 Scsalpha 
Succinyl coenzyme 
A synthetase alpha 
subunit 
0.96/0.85/6 1.14/0.91/5 1.37/1.30/5 
FBgn0004907 14-3-3zeta 14-3-3zeta 1.09/0.91/7 
1.39/1.26/1
7 
1.56/1.42/1
0 
FBgn0005391 Yp2 Yolk protein 2 0.66/0.54/4 0.96/0.67/6 0.78/0.94/2 
FBgn0005533 RpS17 
Ribosomal protein 
S17 
0.82/0.89/3 
Not 
Detected 
1.19/1.34/1
3 
FBgn0005593 RpL7 
Ribosomal protein 
L7 
Not 
Detected 
1.37/0.97/9 
0.93/0.89/3
3 
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FBgn0005671 Vha55 
Vacuolar H[+]-
ATPase 55kD B 
subunit 
1.09/0.92/1
6 
1.26/1.11/2
2 
1.51/1.73/8
2 
FBgn0010019 Cyp4g1 
Cytochrome P450-
4g1 
0.82/0.78/3
3 
0.86/0.91/5
8 
0.85/0.90/5
6 
FBgn0010078 RpL23 
Ribosomal protein 
L23 
0.85/0.83/2 
Not 
Detected 
1.06/1.09/6 
FBgn0010100 Acon Aconitase 
0.96/0.83/5
7 
1.12/0.99/1
13 
1.47/1.61/1
68 
FBgn0010198 RpS15Aa 
Ribosomal protein 
S15Aa 
0.90/0.75/7 1.06/0.88/9 1.24/1.16/8 
FBgn0010217 
ATPsyn-
beta 
ATP synthase-beta 
1.11/0.89/1
73 
1.09/0.90/2
01 
1.53/1.56/4
40 
FBgn0010226 GstS1 
Glutathione S 
transferase S1 
0.98/0.94/3
9 
1.07/1.11/1
9 
1.52/1.60/2
0 
FBgn0010265 RpS13 
Ribosomal protein 
S13 
Not 
Detected 
Not 
Detected 
1.05/1.05/1
4 
FBgn0010352 Nc73EF 
Neural conserved at 
73EF 
0.97/0.78/4
7 
1.09/0.90/5
3 
1.35/1.17/7
7 
FBgn0010408 RpS9 
Ribosomal protein 
S9 
0.91/0.74/3 
Not 
Detected 
0.97/0.95/1
2 
FBgn0010409 RpL18A 
Ribosomal protein 
L18A 
Not 
Detected 
Not 
Detected 
0.95/0.85/1
5 
FBgn0010411 RpS18 
Ribosomal protein 
S18 
0.89/0.73/1
6 
1.03/0.87/1 
0.81/0.75/1
2 
FBgn0010412 RpS19a 
Ribosomal protein 
S19a 
Not 
Detected 
Not 
Detected 
1.12/1.27/7 
FBgn0010551 l(2)03709 lethal (2) 03709 
Not 
Detected 
Not 
Detected 
1.33/1.50/6 
FBgn0010612 l(2)06225 lethal (2) 06225 
1.34/1.04/4
4 
1.39/1.39/4
5 
1.56/1.55/5
0 
FBgn0011211 blw bellwether 
1.09/0.91/3
41 
1.11/0.96/3
66 
1.60/1.51/5
34 
FBgn0011227 ox oxen 
1.20/1.02/1
0 
1.19/1.05/1 1.43/1.43/5 
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FBgn0011272 RpL13 
Ribosomal protein 
L13 
0.92/0.80/1
2 
1.18/0.92/1
5 
0.71/0.60/1
0 
FBgn0011661 Moe Moesin 
1.31/1.03/1
8 
1.19/1.20/1
9 
1.65/1.77/2
0 
FBgn0011726 tsr twinstar 1.18/1.03/2 1.36/1.23/5 
Not 
Detected 
FBgn0011768 Fdh 
Formaldehyde 
dehydrogenase 
Not 
Detected 
2.14/1.11/3 3.74/1.73/2 
FBgn0012036 Aldh 
Aldehyde 
dehydrogenase 
0.73/0.74/8 0.93/0.92/7 0.93/1.18/5 
FBgn0013325 RpL11 
Ribosomal protein 
L11 
1.04/0.83/2 
Not 
Detected 
1.18/1.11/4 
FBgn0013673 
mt:ATPase
8 
mitochondrial 
ATPase subunit 8 
1.11/0.84/5 1.14/1.30/4 
1.40/1.44/1
9 
FBgn0013674 mt:CoI 
mitochondrial 
Cytochrome c 
oxidase subunit I 
Not 
Detected 
Not 
Detected 
1.14/1.13/6 
FBgn0013675 mt:CoII 
mitochondrial 
Cytochrome c 
oxidase subunit II 
1.17/1.22/2
2 
1.20/1.29/2
3 
1.31/1.32/1
40 
FBgn0013678 mt:Cyt-b 
mitochondrial 
Cytochrome b 
1.21/0.98/1
9 
1.34/1.21/3
3 
1.54/1.33/2
2 
FBgn0013679 mt:ND1 
mitochondrial 
NADH-ubiquinone 
oxidoreductase chain 
1 
0.98/0.82/5 1.12/1.03/5 1.19/1.01/6 
FBgn0013681 mt:ND3 
mitochondrial 
NADH-ubiquinone 
oxidoreductase chain 
3 
0.97/0.80/2 
Not 
Detected 
1.17/1.00/3 
FBgn0013684 mt:ND5 
mitochondrial 
NADH-ubiquinone 
oxidoreductase chain 
5 
1.16/0.92/4 1.52/1.19/1 1.10/1.04/1 
FBgn0013988 Strn-Mlck Stretchin-Mlck 1.00/0.90/1 1.20/1.20/4 
Not 
Detected 
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FBgn0014455 Ahcy13 
Adenosylhomocystei
nase at 13 
0.96/0.73/4 1.22/0.95/2 
Not 
Detected 
FBgn0014869 Pglym78 
Phosphoglyceromuta
se 
0.94/0.86/9 1.35/1.06/5 1.23/1.37/5 
FBgn0015031 cype cyclope 
0.96/0.85/3
3 
1.22/1.09/3
4 
1.55/1.50/2
7 
FBgn0015288 RpL22 
Ribosomal protein 
L22 
0.88/0.73/3 1.15/1.04/1 1.26/1.26/5 
FBgn0015324 Vha26 
Vacuolar H[+]-
ATPase 26kD E 
subunit 
0.92/0.85/1
5 
0.87/0.91/8 
Not 
Detected 
FBgn0015623 Cpr 
Cytochrome P450 
reductase 
0.85/0.91/1 1.05/0.96/5 
Not 
Detected 
FBgn0016120 ATPsyn-d 
ATP synthase, 
subunit d 
1.16/1.01/2
5 
1.22/1.08/3
5 
1.43/1.52/3 
FBgn0016687 Nurf-38 
Nucleosome 
remodeling factor - 
38kD 
0.97/0.80/1
7 
1.05/0.99/6 1.52/1.45/7 
FBgn0016691 Oscp 
Oligomycin 
sensitivity-
conferring protein 
0.84/0.87/9
1 
0.91/0.99/5
7 
1.33/1.45/3
3 
FBgn0017545 RpS3A 
Ribosomal protein 
S3A 
0.94/0.80/2
0 
1.01/0.95/8 
0.99/0.97/1
1 
FBgn0017567 ND23 
NADH:ubiquinone 
reductase 23kD 
subunit precursor 
0.88/0.70/9 0.99/0.85/3 
Not 
Detected 
FBgn0019624 CoVa 
Cytochrome c 
oxidase subunit Va 
0.79/0.74/1
0 
0.99/0.68/5 1.40/1.18/5 
FBgn0019644 ATPsyn-b 
ATP synthase, 
subunit b 
1.21/0.95/4
0 
1.38/1.32/3
8 
1.67/1.93/1
22 
FBgn0019830 colt 
congested-like 
trachea 
1.01/0.87/2 
Not 
Detected 
1.16/1.20/4 
FBgn0019957 ND42 
NADH:ubiquinone 
reductase 42kD 
subunit precursor 
Not 
Detected 
Not 
Detected 
1.48/1.46/1
7 
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FBgn0020235 
ATPsyn-
gamma 
ATP synthase-
gamma chain 
1.05/0.87/9
6 
1.20/1.04/1
04 
1.49/1.50/2
20 
FBgn0020236 ATPCL ATP citrate lyase 
0.82/0.67/2
2 
0.95/0.76/3
4 
1.30/1.14/3
2 
FBgn0020238 
14-3-
3epsilon 
14-3-3epsilon 1.12/0.98/9 
1.30/1.16/3
0 
1.27/1.10/1
2 
FBgn0020367 Vha68-2 
Vacuolar H[+] 
ATPase subunit 68-2 
0.88/0.85/1
9 
0.94/0.96/3
4 
1.28/1.40/1
7 
FBgn0020385 pug pugilist 0.86/0.80/2 1.23/1.10/3 0.90/1.04/1 
FBgn0020513 ade5 ade5 
0.93/0.75/3
6 
1.04/0.88/3
4 
1.34/1.20/4
8 
FBgn0020618 Rack1 
Receptor of 
activated protein 
kinase C 1 
0.97/0.79/1
6 
1.20/0.91/1
8 
1.30/1.19/8 
FBgn0020908 Scp1 
Sarcoplasmic 
calcium-binding 
protein 1 
1.11/0.95/1
89 
1.67/1.29/3
71 
1.90/1.86/1
12 
FBgn0020910 RpL3 
Ribosomal protein 
L3 
1.01/0.89/4 1.51/1.11/6 1.01/0.95/7 
FBgn0021906 RFeSP 
Rieske iron-sulfur 
protein 
Not 
Detected 
Not 
Detected 
1.67/1.58/4
2 
FBgn0022160 Gpo-1 
Glycerophosphate 
oxidase-1 
0.97/0.79/8
6 
1.02/0.95/8
0 
1.14/1.13/4
8 
FBgn0023023 CRMP 
Collapsin Response 
Mediator Protein 
1.09/1.08/2 1.23/1.15/1 1.60/1.51/3 
FBgn0023143 Uba1 
Ubiquitin activating 
enzyme 1 
1.06/0.85/7 1.10/0.97/7 2.56/2.21/1 
FBgn0023477 Tal Tal 0.82/0.81/2 0.82/0.76/3 
Not 
Detected 
FBgn0023507 CG3835  
0.63/0.71/1
0 
0.54/0.64/9 1.01/1.28/3 
FBgn0024238 Fim Fimbrin 1.31/1.21/9 1.35/1.49/9 1.65/1.82/6 
FBgn0024556 EfTuM 
Elongation factor Tu 
mitochondrial 
0.98/0.95/1
3 
1.12/1.06/1
2 
1.98/1.26/1 
FBgn0024733 RpL10 
Ribosomal protein 
L10 
0.90/0.66/1
5 
1.21/0.86/1
1 
1.02/0.96/1
9 
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FBgn0025352 Thiolase Thiolase 
Not 
Detected 
Not 
Detected 
1.27/1.15/5 
FBgn0026372 RpL23A 
Ribosomal protein 
L23A 
Not 
Detected 
Not 
Detected 
0.66/0.56/5 
FBgn0026409 Mpcp 
Mitochondrial 
phosphate carrier 
protein 
0.98/0.85/3
0 
1.14/0.98/2
9 
1.12/0.97/7
6 
FBgn0026439 Eaat1 
Excitatory amino 
acid transporter 1 
0.98/0.98/9 
1.19/1.33/1
1 
1.30/1.28/1
1 
FBgn0026479 Drp1 
Dynamin related 
protein 1 
1.10/0.95/2 1.11/1.06/2 1.09/0.88/1 
FBgn0027291 l(1)G0156 lethal (1) G0156 
1.04/0.87/5
3 
1.24/1.05/4
3 
1.58/1.58/8
1 
FBgn0027493 CG17273  1.06/1.09/5 1.06/1.02/3 
Not 
Detected 
FBgn0027560 Tps1 
Trehalose-6-
phosphate synthase 
1 
0.85/0.67/6
5 
1.01/0.82/5
8 
1.14/0.99/9
5 
FBgn0027571 CG3523  
0.78/0.72/2
7 
0.93/0.80/3
8 
1.01/0.92/7
8 
FBgn0027590 CG16936  0.87/0.89/8 0.81/0.81/3 
1.21/1.48/1
4 
FBgn0027657 glob1 globin 1 1.16/0.92/5 1.06/0.93/6 1.13/1.49/3 
FBgn0027779 VhaSFD 
Vacuolar H[+]-
ATPase SFD subunit 
1.03/1.04/2
3 
1.21/1.12/2
2 
1.34/1.30/1
1 
FBgn0027785 NP15.6 NP15.6 1.05/0.88/3 1.18/1.01/1 1.42/1.33/5 
FBgn0028325 l(1)G0334 lethal (1) G0334 
1.17/0.97/3
5 
1.37/1.06/3
1 
1.67/1.65/3
5 
FBgn0028479 CG4389  0.80/0.84/3 
0.97/0.76/1
0 
1.04/0.98/1
6 
FBgn0028685 Rpt4 Rpt4 
0.99/0.77/1
4 
1.17/0.90/2
0 
1.42/1.52/6 
FBgn0028686 Rpt3 Rpt3 1.18/0.73/2 1.12/0.85/6 
Not 
Detected 
FBgn0028688 Rpn7 Rpn7 0.89/0.80/5 
Not 
Detected 
Not 
Detected 
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FBgn0028697 RpL15 
Ribosomal protein 
L15 
0.83/0.69/2 
Not 
Detected 
1.05/0.89/8 
FBgn0028968 gammaCop 
gamma-coatomer 
protein 
1.00/0.84/6 1.06/0.94/9 1.54/1.11/3 
FBgn0029155 Men-b Malic enzyme b 
1.04/1.00/1
7 
1.03/0.93/1
3 
1.49/1.90/1
3 
FBgn0029176 Ef1gamma Ef1gamma 0.98/0.81/5 1.04/0.93/8 1.16/1.21/7 
FBgn0029687 Vap-33-1 Vap-33-1 0.91/0.82/8 
Not 
Detected 
1.89/1.74/2 
FBgn0029785 RpL35 
Ribosomal protein 
L35 
0.88/0.78/4 1.08/0.97/1 0.79/0.74/6 
FBgn0029823 CG3011  1.30/0.91/4 1.14/0.72/2 1.60/1.42/8 
FBgn0029868 CG3446  1.19/0.88/5 1.18/1.00/4 
1.43/1.39/1
6 
FBgn0029897 RpL17 
Ribosomal protein 
L17 
1.11/0.90/1
4 
1.06/0.74/1
2 
0.97/0.92/3
6 
FBgn0030136 RpS28b 
Ribosomal protein 
S28b 
0.85/0.75/1
8 
0.95/0.79/1
5 
Not 
Detected 
FBgn0030239 CG17333  1.32/0.99/7 1.06/0.97/7 1.30/1.01/1 
FBgn0030733 CG3560  1.11/0.86/3 1.51/1.06/7 1.31/1.44/1 
FBgn0030737 CG9914  0.81/0.66/9 0.96/0.76/2 
Not 
Detected 
FBgn0030853 CG5703  1.11/0.88/7 
1.17/1.01/1
2 
1.39/1.16/1 
FBgn0031159 CG11566  0.21/1.43/9 
Not 
Detected 
Not 
Detected 
FBgn0031436 CG3214  1.13/0.92/4 1.23/1.04/2 1.36/1.36/3 
FBgn0031771 CG9140  1.00/0.77/8 
1.23/0.98/1
4 
1.45/1.38/3
1 
FBgn0031830 CG11015  
2.30/2.19/1
1 
2.64/2.39/1
6 
2.07/2.10/8 
FBgn0031912 CG5261  
1.06/0.90/6
1 
1.04/0.96/4
1 
1.47/1.37/4
8 
FBgn0031913 CG5958  0.76/0.73/6 1.02/0.86/2 0.97/1.06/1 
FBgn0032350 CG6287  
Not 
Detected 
Not 
Detected 
1.99/2.39/5 
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Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0032511 CG9306  
1.18/0.81/1
3 
1.10/0.85/6 
1.29/1.52/2
7 
FBgn0032518 RpL24 
Ribosomal protein 
L24 
0.83/0.75/7 0.90/0.81/8 0.87/0.80/5 
FBgn0032783 CG10237  1.01/0.92/2 1.05/0.98/3 1.15/1.25/1 
FBgn0032820 fbp 
fructose-1,6-
bisphosphatase 
0.96/0.89/3 0.93/0.78/1 1.50/1.34/8 
FBgn0032833 CG10664  
1.04/0.92/4
9 
0.97/1.01/5
5 
1.41/1.56/9
1 
FBgn0032946 nrv3 nervana 3 
Not 
Detected 
Not 
Detected 
1.55/1.62/6 
FBgn0032987 RpL21 
Ribosomal protein 
L21 
0.90/0.83/4 1.19/1.00/1 0.97/0.97/9 
FBgn0033608 CG13220  1.15/0.93/1 1.03/0.99/1 
1.55/1.54/1
1 
FBgn0033663 ERp60 ERp60 0.68/0.60/8 0.75/0.64/3 
Not 
Detected 
FBgn0033699 RpS11 
Ribosomal protein 
S11 
Not 
Detected 
1.12/1.01/4 
0.97/0.91/1
0 
FBgn0033912 RpS23 
Ribosomal protein 
S23 
0.91/0.86/1 
Not 
Detected 
1.04/0.92/1
0 
FBgn0033978 Cyp6a23 Cyp6a23 0.46/0.75/2 
Not 
Detected 
0.62/1.01/8 
FBgn0034138 RpS15 
Ribosomal protein 
S15 
0.89/1.12/1 
Not 
Detected 
0.98/1.20/1
5 
FBgn0034152 
Acp53C14
a 
Acp53C14a 
Not 
Detected 
0.66/0.72/6 0.95/0.99/1 
FBgn0034259 CG6459  1.02/0.91/1 1.05/0.98/9 
Not 
Detected 
FBgn0034497 CG9090  
1.25/1.05/1
69 
1.51/1.28/1
64 
1.41/1.36/2
97 
FBgn0034618 CG9485  1.06/0.82/4 1.03/0.97/4 1.34/1.02/1 
FBgn0034743 RpS16 
Ribosomal protein 
S16 
0.92/0.79/1
1 
1.03/0.81/8 1.17/1.16/5 
FBgn0034877 levy levy 1.03/0.92/8 1.19/1.09/6 1.42/1.51/6 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM 
Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0035189 CG9119  0.73/0.69/4 1.03/0.89/2 
Not 
Detected 
FBgn0035404 CG12079  1.08/0.82/1 1.40/0.97/1 1.42/1.53/5 
FBgn0035422 RpL28 
Ribosomal protein 
L28 
Not 
Detected 
Not 
Detected 
1.11/1.07/1
8 
FBgn0035600 CG4769  
1.00/0.86/6
3 
1.00/1.02/1
03 
1.77/1.99/1
52 
FBgn0035753 RpL18 
Ribosomal protein 
L18 
0.99/0.83/1
3 
1.33/1.08/1 
1.09/0.97/1
3 
FBgn0035811 CG12262  0.76/0.78/6 0.94/0.85/2 1.26/1.19/2 
FBgn0036030 CG6767  1.08/0.73/2 1.33/0.95/3 
Not 
Detected 
FBgn0036044 CG14168  0.97/1.31/1 0.98/0.87/4 
Not 
Detected 
FBgn0036213 RpL10Ab 
Ribosomal protein 
L10Ab 
1.05/0.86/2 1.47/1.26/3 1.15/1.16/7 
FBgn0036728 CG7580  0.99/0.80/3 1.28/1.11/3 
1.48/1.37/3
0 
FBgn0036762 CG7430  0.95/0.76/3 
1.07/0.89/1
3 
1.34/1.35/1
2 
FBgn0036766 CG5506  1.91/2.19/5 3.08/2.69/6 
Not 
Detected 
FBgn0036927 CG7433  0.89/0.93/1 1.18/1.10/3 1.31/1.41/1 
FBgn0037001 CG6020  
1.11/0.83/2
4 
1.11/0.86/1
1 
1.50/1.52/6
4 
FBgn0037138 CG7145  0.96/0.93/8 1.03/1.00/6 
1.25/1.49/1
2 
FBgn0037146 CG7470  
Not 
Detected 
0.96/1.01/1 1.25/1.27/4 
FBgn0037245 growl growl 0.90/0.80/1 0.96/0.90/1 1.09/1.04/7 
FBgn0037328 RpL35A 
Ribosomal protein 
L35A 
0.79/0.73/5 0.98/0.96/3 1.02/0.99/7 
FBgn0037351 RpL13A 
Ribosomal protein 
L13A 
0.77/0.73/1
0 
1.06/1.00/8 0.93/0.87/1 
FBgn0037547 CG7910  0.86/0.83/2 0.99/1.08/1 1.04/1.27/3 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM 
Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0037580 DppIII 
Dipeptidyl 
aminopeptidase III 
Not 
Detected 
1.30/1.21/7 1.59/1.83/8 
FBgn0037607 CG8036  
0.95/0.70/1
1 
0.97/0.89/1
8 
1.02/1.01/4
0 
FBgn0037643 skap 
skpA associated 
protein 
1.04/0.98/3
2 
1.34/1.21/2
6 
1.54/1.60/4
8 
FBgn0037715 CG9399  1.09/1.02/3 1.24/1.19/8 
1.34/1.30/1
0 
FBgn0037874 Tctp 
Translationally 
controlled tumor 
protein 
1.06/1.02/4 
1.25/0.99/1
7 
Not 
Detected 
FBgn0037891 CG5214  
1.07/0.95/1
0 
1.52/1.24/2 
1.45/1.51/7
7 
FBgn0037912 sea scheggia 0.82/0.73/6 1.02/0.83/8 1.02/0.99/3 
FBgn0037913 CG6783  
0.86/0.73/1
0 
1.19/0.89/9 
Not 
Detected 
FBgn0038020 GstD9 
Glutathione S 
transferase D9 
1.27/0.92/1
0 
1.48/1.08/2 1.08/0.93/1 
FBgn0038181 CG9297  1.03/0.92/2 1.75/1.34/7 1.26/1.20/3 
FBgn0038224 CG3321  
Not 
Detected 
Not 
Detected 
1.57/1.52/1
2 
FBgn0038271 CG3731  
1.09/0.91/7
6 
1.41/1.10/7
5 
1.57/1.43/6
2 
FBgn0038277 RpS5b 
Ribosomal protein 
S5b 
0.86/0.72/6 1.01/0.80/8 
Not 
Detected 
FBgn0038293 CG6904  1.21/0.98/3 1.16/1.07/5 
1.44/1.56/1
1 
FBgn0038519 Prx3 Peroxiredoxin 3 1.05/0.96/1 1.36/1.14/5 
Not 
Detected 
FBgn0038570 Prx5 Peroxiredoxin 5 
0.90/0.84/1
7 
1.23/1.03/1
9 
Not 
Detected 
FBgn0038774 CG5023  1.70/1.34/3 1.22/1.59/2 
Not 
Detected 
FBgn0038834 RpS30 
Ribosomal protein 
S30 
0.98/0.88/1 
Not 
Detected 
0.54/0.50/4 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM 
Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0038922 CG6439  
1.15/0.94/2
9 
1.07/0.92/3
6 
1.61/1.69/6
3 
FBgn0039049 CG6726  
Not 
Detected 
0.81/1.11/1 1.36/1.02/4 
FBgn0039358 CG5028  
1.02/0.91/1
3 
1.29/1.08/1
6 
1.23/1.45/1
7 
FBgn0039359 RpL27 
Ribosomal protein 
L27 
Not 
Detected 
Not 
Detected 
1.14/1.09/5 
FBgn0039635 CG11876  0.95/0.83/6 
1.37/1.13/3
2 
1.48/1.54/3
1 
FBgn0039674 CG1907  1.24/1.10/1 1.76/1.25/1 
1.17/1.29/1
3 
FBgn0039713 RpS8 
Ribosomal protein 
S8 
0.81/0.71/1
3 
Not 
Detected 
0.90/0.84/3
7 
FBgn0039737 CG7920  
1.03/0.93/2
8 
1.11/1.03/3
5 
1.41/1.68/6
3 
FBgn0039757 RpS7 
Ribosomal protein 
S7 
Not 
Detected 
Not 
Detected 
1.00/0.96/9 
FBgn0039830 CG1746  
Not 
Detected 
1.02/1.15/1
4 
Not 
Detected 
FBgn0039857 RpL6 
Ribosomal protein 
L6 
0.91/0.84/8 1.12/1.08/2 
0.93/0.86/2
5 
FBgn0039909 CG1970  
1.21/0.96/1
0 
1.42/1.12/1
0 
1.43/1.40/4
1 
FBgn0040074 retinin retinin 0.54/0.49/5 0.23/0.30/2 
Not 
Detected 
FBgn0040309 Jafrac1 
thioredoxin 
peroxidase 1 
1.02/0.80/8 1.33/1.01/6 1.25/1.20/2 
FBgn0040349 CG3699  
0.93/0.75/1
3 
0.90/0.66/5 
Not 
Detected 
FBgn0047038 CG6463  0.94/0.77/3 0.59/0.49/2 1.41/1.85/1 
FBgn0052230 CG32230  1.18/0.81/2 
Not 
Detected 
2.22/1.58/3 
FBgn0052549 CG32549  0.88/0.76/5 1.16/0.93/3 
Not 
Detected 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM 
Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0053113 Rtnl1 Rtnl1 
Not 
Detected 
Not 
Detected 
1.45/1.49/1
4 
FBgn0053138 CG33138  0.93/0.95/8 1.18/1.20/9 
1.07/1.17/1
4 
FBgn0064225 RpL5 
Ribosomal protein 
L5 
0.89/0.78/2 1.02/0.97/3 1.23/1.37/5 
FBgn0085201 CG34172  
0.99/0.98/3
7 
1.07/1.17/4
2 
1.34/1.43/4
5 
FBgn0086134 Pros25 
Proteasome 25kD 
subunit 
0.87/0.75/2 1.06/1.19/1 1.72/1.31/2 
FBgn0086254 CG6084  1.12/0.91/1 1.18/0.91/6 
Not 
Detected 
FBgn0086355 Tpi 
Triose phosphate 
isomerase 
1.05/0.91/1
31 
1.15/0.97/8
6 
1.32/1.22/2
8 
FBgn0086372 lap like-AP180 1.19/0.99/8 0.64/0.59/2 
Not 
Detected 
FBgn0086691 UK114 UK114 
0.58/0.55/1
1 
0.79/0.62/1 
Not 
Detected 
FBgn0086783 Mhc Myosin heavy chain 0.98/1.12/5 1.14/1.07/5 1.81/2.10/4 
FBgn0087002 Rfabg 
Retinoid- and fatty 
acid-binding 
glycoprotein 
1.24/1.07/1
5 
1.14/1.15/2
1 
1.44/1.30/1
91 
FBgn0250814 CG4169  
1.15/0.90/6
2 
1.23/0.97/5
1 
1.68/1.61/1
15 
FBgn0250838 CG30415  
1.18/0.98/2
2 
1.21/1.24/1
9 
1.51/1.43/6
1 
FBgn0250906 Pgk 
Phosphoglycerate 
kinase 
1.05/0.88/1
9 
1.28/1.10/2
5 
1.37/1.60/5 
FBgn0259209 Mlp60A 
Muscle LIM protein 
at 60A 
1.16/0.90/3 1.48/1.15/8 1.06/1.19/2 
FBgn0260439 Pp2A-29B 
Protein phosphatase 
2A at 29B 
1.35/0.89/1
1 
0.90/0.75/5 1.91/1.31/3 
FBgn0260441 RpS12 
Ribosomal protein 
S12 
0.84/0.76/7 1.13/0.91/7 
Not 
Detected 
FBgn0261014 TER94 TER94 
0.90/0.72/1
7 
1.04/0.84/2
6 
1.78/1.45/1 
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FlyBase Gene 
ID used for 
Construction of 
Protein Group 
Associated 
FlyBase 
Gene 
Symbol 
Associated FlyBase 
Gene Name 
Ratios and 
PSM 
Counts for 
Repeat 1* 
Ratios and 
PSM 
Counts for 
Repeat 2* 
Ratios and 
PSM 
Counts for 
Repeat 3* 
FBgn0261439 SdhA 
Succinate 
dehydrogenase A 
1.03/0.66/8 0.90/0.83/7 
1.08/1.00/3
7 
FBgn0261592 RpS6 
Ribosomal protein 
S6 
0.85/0.76/1
7 
1.10/0.97/1
1 
0.89/0.81/1
6 
FBgn0261596 RpS24 
Ribosomal protein 
S24 
1.05/0.93/1
6 
1.25/1.21/1
3 
1.12/1.10/2
8 
FBgn0261602 RpL8 
Ribosomal protein 
L8 
Not 
Detected 
Not 
Detected 
0.90/0.89/1
7 
FBgn0261606 RpL27A 
Ribosomal protein 
L27A 
0.75/0.67/8 
Not 
Detected 
Not 
Detected 
FBgn0261955 kdn knockdown 
1.16/0.98/2
24 
1.17/1.11/2
15 
1.57/1.93/4
32 
FBgn0262559 Mdh2 
Malate 
dehydrogenase 2 
1.06/0.88/1
50 
1.15/1.05/1
27 
1.57/1.68/1
71 
FBgn0262782 Mdh1 
Malate 
dehydrogenase 1 
0.80/0.71/8 
Not 
Detected 
1.38/1.31/1 
FBgn0263006 Ca-P60A 
Calcium ATPase at 
60A 
1.12/1.00/2
04 
1.36/1.37/2
40 
1.49/1.54/5
80 
 
 Table A8 
Uncorrected change in carbonylated protein relative abundance over eight days immediately 
following traumatic injury observed in serum obtained from Patient A. Relative abundances were 
calculated by dividing the measured intensity for each reporter ion by the summed intensity for 
all eight reporter ions for each PSM followed by averaging for all PSMs supporting each protein 
group. A PeptideProphet score ≥ 0.9 was required for PSM acceptance. ProteinProphet was used 
for construction of protein groups, all of which were composed of related proteins except the 
alpha-2-macroglobulin and pregnancy zone protein group. 
Protein Group 
Description 
Associated 
Gene 
Supportin
g PSM 
Count 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day7 
Day 
8 
Streptavidin not available 940 
21.3
% 
14.6
% 
9.5% 9.9% 
13.6
% 
10.3
% 
10.1
% 
10.7
% 
Serum albumin ALB 461 
21.5
% 
20.5
% 
8.9% 
12.0
% 
12.2
% 
9.6% 7.5% 7.8% 
Trypsin (Pig) not available 84 15.8 14.5 8.0% 13.0 13.3 12.4 11.2 11.8
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Protein Group 
Description 
Associated 
Gene 
Supportin
g PSM 
Count 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day7 
Day 
8 
% % % % % % % 
Ig gamma chain 
C region 
IGHG 61 
18.7
% 
16.6
% 
6.6% 9.0% 
12.9
% 
11.9
% 
11.2
% 
13.0
% 
Fibrinogen alpha 
chain 
FGA 57 
12.4
% 
4.2% 
12.6
% 
20.8
% 
3.3% 
20.6
% 
12.8
% 
13.4
% 
Complement C3 C3 33 
12.9
% 
13.0
% 
7.4% 9.0% 
14.9
% 
17.6
% 
12.1
% 
13.1
% 
Alpha-1-
antitrypsin 
SERPINA1 31 7.7% 
11.7
% 
8.7% 
13.5
% 
18.5
% 
15.1
% 
12.0
% 
12.8
% 
Ig kappa chain C 
region 
IGKC 28 
18.4
% 
12.8
% 
9.0% 
11.0
% 
13.0
% 
11.3
% 
11.3
% 
13.2
% 
Decoy not available 16 
10.7
% 
8.6% 9.9% 
15.1
% 
16.9
% 
11.3
% 
13.2
% 
14.4
% 
Vitronectin VTN 12 
14.5
% 
15.8
% 
9.9% 
12.5
% 
16.4
% 
13.1
% 
8.2% 9.6% 
Fibrinogen beta 
chain 
FGB 11 
10.6
% 
3.1% 
13.8
% 
21.4
% 
3.0% 
21.1
% 
13.6
% 
13.5
% 
Complement 
C4-A & B 
C4A & C4B 10 
16.0
% 
12.0
% 
9.7% 
13.0
% 
17.2
% 
11.0
% 
9.4% 
11.6
% 
Ig alpha chain C 
region 
IGHA 10 
13.9
% 
14.6
% 
9.8% 9.5% 
12.6
% 
13.1
% 
12.6
% 
13.9
% 
Fibrinogen 
gamma chain 
FGG 7 
19.9
% 
8.8% 
10.3
% 
14.2
% 
9.0% 
14.0
% 
11.4
% 
12.5
% 
Serotransferrin TF 6 
30.0
% 
26.1
% 
5.5% 7.6% 8.1% 7.7% 7.6% 7.3% 
Hemoglobin 
subunit beta 
HBB 5 
18.4
% 
26.7
% 
5.6% 
14.1
% 
7.7% 
13.1
% 
6.3% 8.1% 
Keratin, type II 
cytoskeletal 1 
KRT1 4 
22.5
% 
16.7
% 
6.7% 9.5% 
12.4
% 
10.6
% 
8.3% 
13.4
% 
Trypsin-1 & 2 
PRSS1 & 
PRSS2 
4 
19.2
% 
17.2
% 
7.9% 
11.3
% 
11.3
% 
11.5
% 
10.0
% 
11.7
% 
Alpha-2-
macroglobulin & 
Pregnancy zone 
protein 
A2M & PZP 2 
15.9
% 
14.2
% 
9.3% 
10.9
% 
11.8
% 
15.1
% 
10.4
% 
12.4
% 
Apolipoprotein 
A-I 
APOA1 2 
24.6
% 
17.6
% 
8.3% 
11.0
% 
9.2% 
11.8
% 
7.6% 9.8% 
Hemoglobin 
subunit alpha 
HBA 2 
19.3
% 
27.0
% 
3.9% 
17.3
% 
6.5% 
12.5
% 
5.9% 7.6% 
Keratin, type I 
cytoskeletal (9, 
10, 12, 14-17, 
19) 
KRT9, 10, 12, 
14-17, 19 
2 
21.9
% 
14.5
% 
7.4% 
10.2
% 
13.1
% 
11.8
% 
8.3% 
12.6
% 
Apolipoprotein APOB 1 13.4 6.5% 6.7% 13.1 17.3 14.7 14.3 13.9
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Protein Group 
Description 
Associated 
Gene 
Supportin
g PSM 
Count 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day7 
Day 
8 
B-100 % % % % % % 
Decoy not available 1 
16.7
% 
10.0
% 
7.9% 
10.5
% 
9.8% 8.2% 
17.1
% 
19.8
% 
Protein FAM98B FAM98B 1 
11.9
% 
16.9
% 
9.5% 
11.3
% 
20.4
% 
8.5% 
10.6
% 
10.9
% 
Serum amyloid 
A-1 & 2 protein 
SAA1 & SAA2 1 3.1% 
11.6
% 
11.7
% 
23.1
% 
22.5
% 
10.9
% 
6.0% 
11.1
% 
T-cell receptor 
alpha chain V 
region PY14 
not available 1 
22.7
% 
2.5% 
14.7
% 
1.3% 
49.7
% 
1.5% 3.6% 4.0% 
 
Table A9 
Uncorrected change in carbonylated protein relative abundance over five days immediately following 
traumatic injury observed in serum obtained from Patient B. Relative abundances were calculated by 
dividing the measured intensity for each reporter ion by the summed intensity for all six reporter ions for 
each PSM followed by averaging for all PSMs supporting each protein group. A PeptideProphet score ≥ 
0.9 was required for PSM acceptance. ProteinProphet was used for construction of protein groups, all of 
which were composed of related proteins except the alpha-2-macroglobulin and pregnancy zone protein 
group. 
Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM 
Count 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Streptavidin 
not 
available 
1661 20.1% 16.4% 15.6% 10.2% 18.8% 18.9% 
Serum albumin ALB 908 13.4% 12.0% 19.3% 23.4% 17.1% 14.7% 
Ig gamma chain 
C region 
IGHG 214 15.7% 13.3% 18.2% 20.6% 16.7% 15.4% 
Fibrinogen alpha 
chain 
FGA 199 5.4% 8.1% 13.5% 17.6% 24.8% 30.7% 
Alpha-1-
antitrypsin 
SERPINA1 143 8.0% 5.7% 12.8% 22.2% 26.1% 25.2% 
Trypsin (Pig) 
not 
available 
106 18.3% 15.2% 12.7% 17.7% 18.1% 17.9% 
Complement C3 C3 100 15.2% 8.4% 17.8% 16.0% 21.0% 21.6% 
Fibrinogen beta 
chain 
FGB 95 5.0% 7.3% 14.2% 20.9% 24.6% 28.0% 
Serotransferrin TF 83 12.2% 10.3% 25.4% 18.3% 17.0% 16.9% 
Fibrinogen 
gamma chain 
FGG 78 6.9% 8.6% 14.9% 18.2% 24.6% 26.9% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM 
Count 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Ig kappa chain C 
region 
IGKC 67 17.4% 10.9% 19.6% 19.3% 16.4% 16.4% 
Alpha-2-
macroglobulin & 
Pregnancy zone 
protein 
A2M & 
PZP 
46 8.4% 6.3% 22.2% 23.8% 20.3% 19.1% 
Haptoglobin HP 40 5.1% 4.6% 14.1% 7.9% 27.2% 41.1% 
Complement C4-
A & B 
C4A & C4B 39 12.6% 6.2% 17.6% 22.5% 20.2% 20.9% 
Alpha-1-
antichymotrypsin 
SERPINA3 37 3.9% 2.9% 14.3% 26.7% 27.4% 24.7% 
Apolipoprotein 
A-I 
APOA1 35 10.5% 8.2% 26.9% 29.7% 12.0% 12.7% 
Vitronectin VTN 29 13.0% 11.2% 16.9% 17.1% 20.9% 20.9% 
Decoy 
not 
available 
27 17.2% 17.2% 13.7% 18.6% 16.9% 16.3% 
Ceruloplasmin CP 25 9.3% 6.4% 15.6% 19.8% 23.6% 25.3% 
Ig alpha chain C 
region 
IGHA 24 14.2% 10.6% 22.8% 19.6% 16.0% 16.8% 
Serum amyloid 
A-1 & 2 protein 
SAA1 & 
SAA2 
21 3.9% 3.3% 18.9% 25.9% 18.5% 29.5% 
Hemopexin HPX 16 11.7% 9.8% 43.2% 12.0% 10.6% 12.6% 
Ig heavy chain V-
III regions 
not 
available 
12 13.8% 10.9% 23.7% 21.9% 15.1% 14.5% 
Trypsin-1 & 2 
PRSS1 & 
PRSS2 
10 19.5% 16.1% 10.3% 19.4% 17.9% 16.8% 
Plasma protease 
C1 inhibitor 
SERPING1 5 7.5% 6.0% 15.1% 28.5% 20.8% 22.1% 
Apolipoprotein 
B-100 
APOB 4 13.6% 9.5% 14.5% 24.9% 19.4% 18.1% 
Ig lambda chain 
C region 
IGLC 4 15.9% 13.8% 15.8% 21.4% 17.0% 16.0% 
Alkaline 
ceramidase 1 
ACER1 3 12.5% 11.6% 22.2% 24.4% 15.6% 13.6% 
Keratin, type I 
cytoskeletal (9, 
10, 12, 14-17, 19) 
KRT9, 10, 
12, 14-17, 
19 
3 25.4% 12.2% 13.7% 15.5% 18.8% 14.5% 
Keratin, type II 
cytoskeletal 1 
KRT1 3 21.0% 11.4% 14.2% 15.3% 19.4% 18.7% 
Ig heavy chain V-
III regions 
not 
available 
2 18.7% 12.2% 22.5% 20.6% 13.4% 12.8% 
Protein AMBP AMBP 2 19.8% 7.0% 11.6% 19.1% 20.2% 22.2% 
Angiotensinogen AGT 1 10.3% 6.3% 14.0% 15.5% 28.9% 25.0% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM 
Count 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
C-reactive 
protein 
CRP 1 5.1% 5.6% 16.2% 30.5% 24.6% 18.0% 
Decoy 
not 
available 
1 16.2% 10.6% 16.0% 24.6% 15.9% 16.7% 
Decoy 
not 
available 
1 5.1% 5.4% 41.6% 14.8% 20.6% 12.6% 
Hemoglobin 
subunit beta 
HBB 1 12.6% 7.5% 12.5% 25.5% 18.7% 23.1% 
Ig kappa chain V-
III regions 
not 
available 
1 15.5% 11.4% 19.9% 21.1% 14.4% 17.7% 
Ig mu chain C 
region 
IGHM 1 12.8% 10.1% 24.4% 21.1% 16.0% 15.6% 
Kininogen-1 KNG1 1 11.7% 12.8% 24.2% 21.6% 14.2% 15.6% 
Protein FAM98B FAM98B 1 11.7% 11.7% 13.6% 12.0% 24.5% 26.4% 
 
Table A10 
Uncorrected change in carbonylated protein relative abundance over four days immediately 
following traumatic injury observed in ProteoMiner high-abundance protein-depleted plasma 
obtained from Patient C. Relative abundances were calculated by dividing the measured intensity 
for each reporter ion by the summed intensity for all four reporter ions for each PSM followed by 
averaging for all PSMs supporting each protein group. A PeptideProphet score ≥ 0.9 was 
required for PSM acceptance. ProteinProphet was used for construction of protein groups, all of 
which were composed of related proteins except the alpha-2-macroglobulin and pregnancy zone 
protein group. 
Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
Complement C4-A & B C4A & C4B 589 36.8% 24.8% 15.6% 22.8% 
Fibrinogen alpha chain FGA 402 32.3% 21.9% 19.1% 26.7% 
Complement C3 C3 279 36.5% 23.8% 17.1% 22.6% 
Fibrinogen beta chain FGB 249 31.9% 22.3% 19.8% 26.0% 
Serum albumin ALB 226 31.0% 25.5% 18.1% 25.3% 
Ceruloplasmin CP 209 29.1% 28.9% 16.9% 25.1% 
Vitronectin VTN 199 32.8% 19.5% 16.9% 30.7% 
Fibrinogen gamma chain FGG 192 33.4% 21.4% 18.7% 26.4% 
Thrombin F2 186 31.4% 25.0% 18.2% 25.5% 
Apolipoprotein A-I APOA1 164 34.3% 27.7% 17.6% 20.4% 
Serum amyloid A-1 & 2 
protein 
SAA1 & 
SAA2 
144 15.9% 11.8% 18.9% 53.4% 
Apolipoprotein B-100 APOB 114 33.1% 20.8% 17.9% 28.2% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
Ig gamma chain C region IGHG 110 36.0% 27.5% 14.8% 21.7% 
Clusterin CLU 100 28.8% 24.8% 19.6% 26.8% 
Apolipoprotein E APOE 97 28.4% 19.7% 20.4% 31.5% 
Alpha-1-antitrypsin SERPINA1 86 27.9% 27.0% 15.3% 29.8% 
C-reactive protein CRP 77 15.4% 11.5% 15.2% 57.9% 
Lipopolysaccharide-
binding protein 
LBP 71 20.2% 17.2% 17.2% 45.4% 
Ig mu chain C region IGHM 65 34.1% 25.7% 17.0% 23.1% 
Serum 
paraoxonase/arylesterase 
1 
PON1 62 36.2% 25.8% 14.8% 23.3% 
Apolipoprotein A-IV APOA4 59 28.2% 19.9% 22.5% 29.5% 
Ig kappa chain C region IGKC 59 34.2% 23.6% 20.8% 21.4% 
Alpha-1-
antichymotrypsin 
SERPINA3 43 28.4% 20.4% 17.9% 33.3% 
Alpha-2-macroglobulin & 
Pregnancy zone protein 
A2M & PZP 32 34.2% 27.1% 16.4% 22.4% 
Complement C1q 
subcomponent subunit C 
C1QC 31 38.7% 21.7% 18.2% 21.3% 
C4b-binding protein 
alpha chain 
C4BPA 24 28.1% 33.6% 15.7% 22.6% 
Galectin-3-binding 
protein 
LGALS3BP 24 28.7% 23.1% 25.0% 23.2% 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
ITIH4 24 27.2% 27.7% 19.7% 25.4% 
Streptavidin 
not 
available 
23 34.2% 24.9% 18.5% 22.4% 
Complement C1s 
subcomponent 
C1S 20 31.7% 22.9% 16.1% 29.3% 
Trypsin (Pig) 
not 
available 
16 29.5% 27.0% 17.3% 26.2% 
Angiotensinogen AGT 15 25.9% 18.7% 23.0% 32.5% 
Decoy 
not 
available 
15 29.3% 19.6% 24.0% 27.1% 
Complement C1q 
subcomponent subunit B 
C1QB 14 33.3% 28.3% 14.3% 24.1% 
Decoy 
not 
available 
11 29.6% 25.6% 19.3% 25.6% 
Ig alpha chain C region IGHA 9 32.0% 26.4% 17.4% 24.2% 
Carboxypeptidase N 
catalytic chain 
CPN1 8 24.0% 18.3% 26.1% 31.6% 
Haptoglobin HP 6 37.3% 33.8% 13.7% 15.1% 
Vitamin K-dependent 
protein S 
PROS1 6 33.9% 22.7% 19.1% 24.2% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
C4b-binding protein beta 
chain 
C4BPB 5 32.8% 32.0% 15.1% 20.1% 
Complement component 
C9 
C9 4 30.2% 27.4% 15.1% 27.3% 
Ig lambda chain C region IGLC 4 39.9% 27.9% 13.8% 18.4% 
Phospholipid transfer 
protein 
PLTP 4 25.3% 23.1% 23.4% 28.2% 
Serum amyloid A-4 
protein 
SAA4 4 30.1% 26.7% 17.2% 26.0% 
Apolipoprotein A-II APOA2 3 32.8% 17.4% 17.9% 31.9% 
Apolipoprotein C-III APOC3 3 33.7% 29.7% 17.1% 19.4% 
Apolipoprotein M APOM 3 29.1% 25.1% 20.6% 25.1% 
Coiled-coil domain-
containing protein 40 
CCDC40 3 29.1% 18.0% 24.0% 28.9% 
Complement C1q 
subcomponent subunit A 
C1QA 3 36.4% 23.4% 13.7% 26.5% 
Decoy 
not 
available 
3 32.5% 23.1% 20.2% 24.2% 
Serum amyloid P-
component 
APCS 3 31.7% 26.9% 14.5% 26.9% 
Collectin-10 COLEC10 2 31.5% 20.7% 20.8% 27.0% 
Decoy 
not 
available 
2 29.9% 31.9% 14.4% 23.8% 
Fibulin-1 FBLN1 2 30.6% 24.2% 19.1% 26.1% 
Hemoglobin subunit beta HBB 2 28.7% 32.9% 15.8% 22.6% 
Ig kappa chain V-IV 
regions 
not 
available 
2 33.0% 25.0% 19.6% 22.3% 
Complement C1r 
subcomponent 
C1R 1 29.8% 21.2% 23.5% 25.6% 
Complement C5 C5 1 32.2% 29.1% 18.6% 20.0% 
Complement factor H CFH 1 32.3% 28.4% 19.0% 20.3% 
Decoy 
not 
available 
1 28.7% 29.4% 17.2% 24.7% 
Hemopexin HPX 1 20.2% 25.5% 26.9% 27.4% 
Inter-alpha-trypsin 
inhibitor heavy chain H3 
ITIH3 1 26.3% 9.0% 21.8% 42.9% 
Leucine-rich alpha-2-
glycoprotein 
LRG1 1 23.9% 14.8% 17.8% 43.6% 
Microtubule cross-linking 
factor 1 
MTCL1 1 31.5% 20.1% 17.1% 31.3% 
Steryl-sulfatase STS 1 36.6% 24.4% 15.2% 23.8% 
WD repeat domain 
phosphoinositide-
interacting protein 1 
WIPI1 1 28.2% 23.4% 24.9% 23.5% 
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Table A11  
Uncorrected change in carbonylated protein relative abundance over four days immediately 
following traumatic injury observed in ProteoMiner high-abundance protein-depleted plasma 
obtained from Patient D. Relative abundances were calculated by dividing the measured intensity 
for each reporter ion by the summed intensity for all four reporter ions for each PSM followed by 
averaging for all PSMs supporting each protein group. A PeptideProphet score ≥ 0.9 was 
required for PSM acceptance. ProteinProphet was used for construction of protein groups, all of 
which were composed of related proteins except the alpha-2-macroglobulin and pregnancy zone 
protein group. 
Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
Complement C4-A & B C4A & C4B 634 25.8% 24.1% 24.8% 25.3% 
Fibrinogen alpha chain FGA 293 26.8% 24.6% 25.4% 23.3% 
Fibrinogen beta chain FGB 279 27.2% 26.0% 23.9% 23.0% 
Complement C3 C3 278 26.2% 25.9% 24.1% 23.8% 
Fibrinogen gamma chain FGG 193 26.1% 25.3% 24.2% 24.4% 
Vitronectin VTN 179 26.7% 21.9% 20.4% 31.0% 
Thrombin F2 165 26.0% 24.3% 23.4% 26.2% 
Ceruloplasmin CP 162 26.7% 25.5% 23.8% 23.9% 
Apolipoprotein A-I APOA1 143 29.7% 25.6% 24.2% 20.5% 
Serum amyloid A-1 & 2 
protein 
SAA1 & 
SAA2 
139 5.0% 3.7% 30.5% 60.8% 
Serum albumin ALB 124 25.8% 18.7% 34.9% 20.6% 
Apolipoprotein B-100 APOB 110 31.1% 22.9% 21.4% 24.6% 
Serum 
paraoxonase/arylesterase 
1 
PON1 95 27.7% 26.1% 25.0% 21.2% 
Ig gamma chain C region IGHG 81 33.1% 24.0% 23.3% 19.6% 
Clusterin CLU 75 28.3% 28.0% 19.7% 24.1% 
C-reactive protein CRP 72 8.2% 6.5% 44.1% 41.2% 
Ig kappa chain C region IGKC 61 27.9% 24.6% 23.0% 24.6% 
Ig mu chain C region IGHM 52 30.3% 25.6% 23.0% 21.0% 
Apolipoprotein A-IV APOA4 48 31.2% 29.2% 20.7% 18.9% 
Lipopolysaccharide-
binding protein 
LBP 43 18.4% 16.7% 36.6% 28.3% 
Complement C1q 
subcomponent subunit C 
C1QC 32 21.8% 20.6% 29.9% 27.6% 
Alpha-1-antitrypsin SERPINA1 31 26.0% 23.2% 24.1% 26.7% 
Apolipoprotein E APOE 30 25.2% 21.2% 25.3% 28.3% 
Galectin-3-binding 
protein 
LGALS3BP 25 26.3% 24.0% 23.6% 26.1% 
Alpha-1-
antichymotrypsin 
SERPINA3 24 19.0% 16.5% 25.8% 38.7% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
C4b-binding protein 
alpha chain 
C4BPA 14 26.2% 23.1% 24.6% 26.1% 
Ig kappa chain V-I regions 
not 
available 
14 35.0% 24.0% 22.2% 18.8% 
Trypsin (Pig) 
not 
available 
11 26.3% 24.3% 25.7% 23.7% 
Streptavidin 
not 
available 
10 28.0% 23.1% 26.5% 22.4% 
Decoy 
not 
available 
7 6.5% 40.8% 26.4% 26.3% 
Alpha-2-macroglobulin & 
Pregnancy zone protein 
A2M & PZP 6 28.3% 23.1% 25.0% 23.6% 
Phosphatidylinositol-
glycan-specific 
phospholipase D 
GPLD1 6 30.6% 27.1% 24.8% 17.6% 
Complement C1s 
subcomponent 
C1S 4 26.0% 21.7% 24.5% 27.8% 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
ITIH4 4 26.2% 19.8% 26.3% 27.7% 
Apolipoprotein C-III APOC3 3 25.9% 25.8% 22.0% 26.3% 
Carboxypeptidase N 
catalytic chain 
CPN1 3 17.3% 18.0% 36.2% 28.5% 
Complement C1q 
subcomponent subunit B 
C1QB 3 26.0% 23.7% 24.1% 26.2% 
Decoy 
not 
available 
3 24.2% 25.2% 25.7% 24.9% 
Decoy 
not 
available 
3 25.3% 29.0% 24.3% 21.4% 
Haptoglobin HP 3 25.1% 18.4% 34.3% 22.2% 
Apolipoprotein A-II APOA2 2 34.1% 20.3% 31.6% 14.0% 
Complement C1q 
subcomponent subunit A 
C1QA 2 25.2% 30.1% 24.7% 20.0% 
Complement C1r 
subcomponent 
C1R 2 28.5% 23.5% 25.4% 22.7% 
Fibronectin FN1 2 20.7% 26.1% 29.2% 24.0% 
Vitamin K-dependent 
protein S 
PROS1 2 27.0% 22.8% 24.9% 25.4% 
Apolipoprotein M APOM 1 25.9% 26.0% 27.4% 20.7% 
C4b-binding protein beta 
chain 
C4BPB 1 31.6% 24.6% 21.5% 22.3% 
Coiled-coil domain-
containing protein 40 
CCDC40 1 23.2% 23.2% 25.2% 28.3% 
Decoy 
not 
available 
1 28.9% 25.4% 21.6% 24.1% 
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Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM Count 
Day 1 Day 2 Day 3 Day 4 
E3 ubiquitin-protein 
ligase 
HUWE1 1 28.9% 23.2% 16.9% 31.0% 
Serum amyloid P-
component 
APCS 1 32.2% 30.0% 17.8% 20.0% 
 
